Abstract is: Chlamydia pneumoniae is a species of Chlamydia, an obligate intracellular bacterium that infects humans and is a major cause of pneumonia. It was known as the Taiwan acute respiratory agent (TWAR) from the names of the two original isolates – Taiwan (TW-183) and an acute respiratory isolate designated AR-39. Briefly, it was known as Chlamydophila pneumoniae, and that name is used as an alternate in some sources. In some cases, to avoid confusion, both names are given. Chlamydia pneumoniae has a complex life cycle and must infect another cell to reproduce; thus, it is classified as an obligate intracellular pathogen. The full genome sequence for C. pneumoniae was published in 1999. It also infects and causes disease in koalas, emerald tree boas (Corallus caninus), iguanas, chameleons, frogs, and turtles. The first known case of infection with C. pneumoniae was a case of conjunctivitis in Taiwan in 1950. There are no known cases of C. pneumoniae in human history before 1950. This atypical bacterium commonly causes pharyngitis, bronchitis, coronary artery disease and atypical pneumonia in addition to several other possible diseases.
taxon | Q16521 |
P1542 | has effect | Chlamydia pneumoniae infection | Q11299062 |
P171 | parent taxon | Chlamydia | Q846309 |
P1813 | short name | C. pneumoniae | |
P225 | taxon name | Chlamydia pneumoniae | |
P105 | taxon rank | species | Q7432 |
P10 | video | 3D model of EGFR-YFP surrounding internalized C. pneumoniae EBs (Related to Figure 3D). Images taken from the boxed area of Figure 3D were imported into ImageJ software to calculate a 3D model of all focal planes based on a maximal intensity projection. The movie was generated by 360° rotation of the model. License: CC BY 2.5 Artists: Molleken K, Becker E, Hegemann J This work is copyrighted. Attribution is required. |
Q61822843 | 1103-197 Chlamydia pneumoniae-heat shock protein 60 induces a highly specific persistent immune response in patients with unstable angina independently from IgG and IgA seropositivity |
Q115437325 | 1271 Chronic chlamydia pneumoniae infection and stroke in Cameroon: a case-control study |
Q94134595 | 2221. Chlamydia pneumoniae (Cpn) Induces IFN-γ Responses in Peripheral Blood Mononuclear Cells (PBMC) from Pediatric and Adult Asthma Patients: Effects of Age and Inhaled Corticosteroid Use |
Q37862565 | 60-kDa heat shock protein of Chlamydia pneumoniae is a target of T-cell immune response |
Q37862985 | 60-kDa heat shock protein of Chlamydia pneumoniae promotes a T helper type 1 immune response through IL-12/IL-23 production in monocyte-derived dendritic cells. |
Q37887420 | : Risk factors for seropositivity and association with coronary heart disease |
Q37871114 | A 22-year-old woman with fulminant Chlamydia pneumoniae pneumonia. |
Q37865011 | A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae |
Q37865026 | A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae |
Q90662703 | A Chlamydia pneumoniae adhesin induces phosphatidylserine exposure on host cells |
Q37879971 | A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide |
Q37870819 | A Chlamydia pneumoniae infection model using established human lymphocyte cell lines |
Q37873820 | A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats |
Q37868503 | A Prospective Study of Chlamydia pneumoniae Antibodies in Children Between 7 months and 8 years of Age |
Q37889220 | A case of adult Chlamydia pneumoniae pneumonia diagnosed from a culture method |
Q37839216 | A case of interstitial pneumonia, myocarditis and severe sepsis caused by Chlamydia pneumoniae. |
Q37888216 | A case of pediatric Chlamydia pneumoniae infection and properties of the isolate |
Q37896796 | A case of pneumonia caused by Chlamydia pneumoniae, strain TWAR |
Q37869652 | A case of pneumonia due to coinfection by Mycoplasma pneumoniae and Chlamydia pneumoniae |
Q37868076 | A case of severe Chlamydia pneumoniae pneumonia requiring mechanical ventilation and complicated with disseminated intravascular coagulation |
Q37890219 | A case of severe interstitial pneumonia probably due to Chlamydia pneumoniae |
Q37874025 | A case of splenic abscess due to Chlamydia pneumoniae |
Q37873704 | A case presenting severe respiratory failure with high antibody titers to Chlamydia pneumoniae |
Q37887958 | A child with iritis due to Chlamydia pneumoniae infection |
Q37899165 | A clinical and epidemiological study of "ornithosis" caused by Chlamydia psittaci and Chlamydia pneumoniae (strain TWAR). |
Q37849190 | A combination of secondhand cigarette smoke and Chlamydia pneumoniae accelerates atherosclerosis |
Q37853972 | A comparative study of RNA and DNA as internal gene expression controls early in the developmental cycle of Chlamydia pneumoniae |
Q37892824 | A family outbreak of Chlamydia pneumoniae infection |
Q37869625 | A lack of serologic evidence of transmission of Chlamydia pneumoniae by transfusion of buffy coat‐depleted RBCs |
Q37838093 | A meta-analysis of the association between Chlamydia pneumoniae infection and lung cancer risk |
Q37858418 | A method for HLA genotyping using the specific cleavage of DNA-rN1-DNA/DNA with RNase HII from Chlamydia pneumoniae |
Q37884466 | A microcarrier culture method for the production of large quantities of viable Chlamydia pneumoniae |
Q33596734 | A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis |
Q37875196 | A new DIG-PCR-EIA method for the detection of Chlamydia pneumoniae DNA in clinical samples |
Q37866736 | A new microimmunofluorescence test for the detection of Chlamydia pneumoniae specific antibodies |
Q37885832 | A new primer pair for detection of Chlamydia pneumoniae by polymerase chain reaction |
Q37896793 | A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. |
Q37882795 | A novel method for isolation of Chlamydia pneumoniae by treatment with trypsin or EDTA. |
Q33889181 | A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae |
Q37871087 | A patient with adult Still's disease with an increased Chlamydia pneumoniae antibody titer |
Q37850074 | A pilot study on the association between double positive Chlamydia pneumoniae serology and serum lipid indices alterations in obese adult females |
Q89478117 | A platform for studying the transfer of Chlamydia pneumoniae infection between respiratory epithelium and phagocytes |
Q35588641 | A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren |
Q37882360 | A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. |
Q37852005 | A potential role of Chlamydia pneumoniae in the pathogenesis of periodontal disease in adolescents and adults |
Q37866674 | A prediction model for community-acquired Chlamydia pneumoniae pneumonia in hospitalized patients |
Q37875154 | A preliminary evaluation of a new enzyme immunoassay to detect Chlamydia pneumoniae-specific antibodies |
Q37867101 | A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts |
Q34082096 | A protein secreted by the respiratory pathogen Chlamydia pneumoniae impairs IL-17 signalling via interaction with human Act1 |
Q37863557 | A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae |
Q37890925 | A report of 4 cases from whom Chlamydia pneumoniae was isolated |
Q58601477 | A retrospective seroepidemiologic survey of Chlamydia pneumoniae infection in patients in Beijing between 2008 and 2017 |
Q101049331 | A retrospective survey of Chlamydia pneumoniae infection rates in paediatric patients from a single centre in Wuxi, China |
Q37885237 | A reverse transcriptase-PCR based assay for in-vitro antibiotic susceptibility testing of Chlamydia pneumoniae |
Q33594484 | A review of Chlamydia pneumoniae and atherosclerosis. |
Q37896100 | A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. |
Q37890729 | A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity |
Q37885733 | A seroepidemiologic study of Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci in different populations on the mainland of China |
Q37868210 | A severe case of Chlamydia pneumoniae pneumonia |
Q37858539 | A simultaneous detection of Chlamydia pneumoniae and Chlamydia trachomatis DNA by real-time PCR |
Q35341808 | A single infection with Chlamydia pneumoniae is sufficient to exacerbate atherosclerosis in ApoE deficient mice |
Q33264901 | A study on immunopathogenetic mechanisms of atherosclerotic process caused by chronic infection of Chlamydia pneumoniae in rats (Ratus novergicus). |
Q37853444 | A systemic network for Chlamydia pneumoniae entry into human cells |
Q37867499 | A thermostable manganese-containing superoxide dismutase from pathogen Chlamydia pneumoniae |
Q37846516 | ABC-cassette transporter 1 (ABCA1) expression in epithelial cells in Chlamydia pneumoniae infection |
Q37840971 | AP-1 Transcription Factor Serves as a Molecular Switch between Chlamydia pneumoniae Replication and Persistence |
Q115335507 | ASSOCIATION OF CHLAMYDIA PNEUMONIAE INFECTION WITH OTITIS MEDIA WITH EFFUSION |
Q37858489 | Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus |
Q37868777 | Absence of Chlamydia pneumoniae in brain of vascular dementia patients |
Q37871487 | Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction |
Q37881116 | Absence of Porphyromonas asaccharolytica, Bacteroides fragilis and Chlamydia pneumoniae in human subgingival plaque |
Q37877073 | Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells |
Q37873346 | Acepromazine modulates cell differentiation: in vitro experiments on monocytes stimulated by Chlamydia pneumoniae toxins |
Q34003385 | Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge |
Q37833680 | Acquisition of Rab11 and Rab11-Fip2-A novel strategy for Chlamydia pneumoniae early survival. |
Q33925828 | Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review |
Q37878072 | Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae |
Q33770135 | Activity of quinolones against Chlamydia pneumoniae |
Q37867383 | Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations. |
Q37869181 | Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs |
Q37855741 | Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases |
Q37863763 | Acute Chlamydia pneumoniae infection with heat-shock-protein-60-related response in patients with acute coronary syndrome |
Q37858533 | Acute Chlamydia pneumoniae infections in asthmatic and non-asthmatic military conscripts during a non-epidemic period |
Q37854858 | Acute Chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice |
Q128476111 | Acute Fulminant Chlamydia pneumoniae Myocarditis Treated with Mechanical Circulatory Support in a Female Adult: A Case Report |
Q37067678 | Acute Glomerulonephritis in a Child with Chlamydia pneumoniae Infection: A Case Report |
Q37894266 | Acute Upper Resiratory Tract Infections Associated with Chlamydia pneumoniae |
Q37850407 | Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients. |
Q37852371 | Acute and chronic Chlamydia pneumoniae infection in pregnancy complicated with preeclampsia. |
Q37875794 | Acute coronary syndrome associated with Chlamydia pneumoniae pneumonia in two cases |
Q37888018 | Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection |
Q37861627 | Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection |
Q73319382 | Acute glomerulonephritis associated with pneumonia: a possible Chlamydia pneumoniae etiology? |
Q37891752 | Acute lower respiratory tract infection associated with Chlamydia pneumoniae in Germany |
Q37856423 | Acute pericarditis as an organic manifestation of the acute infection Chlamydia pneumoniae |
Q37872068 | Acute polyradiculoneuropathy after Chlamydia pneumoniae infection |
Q37878175 | Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection |
Q37852889 | Acute renal failure following Chlamydia pneumoniae pneumonia in a child |
Q37877187 | Acute respiratory Chlamydia pneumoniae infections in adults. Value of direct gene amplification diagnosis |
Q36715394 | Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods |
Q37893849 | Acute respiratory infections by Chlamydia pneumoniae |
Q33360207 | Acute thrombotic thrombocytopenic purpura following doxycycline treatment of Chlamydia pneumoniae infection in a patient with dermatomyositis |
Q37873236 | Acute-phase proteins and Chlamydia pneumoniae infection: which one is more important in acute coronary syndrome? |
Q37869013 | Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus. |
Q37870760 | Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae |
Q37861716 | Adult calcific aortic stenosis and Chlamydia pneumoniae: the role of Chlamydia infection in valvular calcification. |
Q37885000 | Adult respiratory distress syndrome due to Chlamydia pneumoniae in a young adult. |
Q37888887 | Advance in the study of Chlamydia pneumoniae |
Q35917262 | Advances in the management of Chlamydia pneumoniae infections |
Q37889685 | Age specific prevalence of antibodies against Chlamydia pneumoniae in Iceland |
Q37120590 | Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor |
Q37855855 | Airflow limitation, asthma, and Chlamydia pneumoniae-specific heat shock protein 60. |
Q37857345 | Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque |
Q30582874 | AmiA is a penicillin target enzyme with dual activity in the intracellular pathogen Chlamydia pneumoniae |
Q37183656 | Amino acid requirements for growth of Chlamydia pneumoniae in cell cultures: growth enhancement by lysine or methionine depletion |
Q36046741 | Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae |
Q36402455 | Amphiphysin IIm is required for survival of Chlamydia pneumoniae in macrophages |
Q37868355 | An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. |
Q37874374 | An association between an antibody against Chlamydia pneumoniae and common carotid atherosclerosis. |
Q37868954 | An association between an antibody against Chlamydia pneumoniae and ischemic stroke in elderly Japanese |
Q37872408 | An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study |
Q43429551 | An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan |
Q36328854 | An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice |
Q37878794 | An epidemic of a pertussis-like illness caused by Chlamydia pneumoniae |
Q37890430 | An epidemic of infections due to Chlamydia pneumoniae in military conscripts |
Q37862349 | An epidemic outbreak of respiratory infection caused by Chlamydia pneumoniae in medical workers |
Q37848175 | An experimental model for induction of lung cancer in rats by Chlamydia pneumoniae |
Q37886904 | An immunofluorescence assay in microwell plate (IFA) for detecting serum antibodies to Chlamydia pneumoniae |
Q32041459 | An immunogenic epitope of Chlamydia pneumoniae from a random phage display peptide library is reactive with both monoclonal antibody and patients sera. |
Q37845555 | An improved method on isolation and serial passage of Chlamydia pneumoniae from human peripheral blood mononuclear cells. |
Q43422119 | An increased rate of seropositivity for immunoglobulin G antibodies to Chlamydia pneumoniae |
Q34299315 | An infectious basis for multiple sclerosis: perspectives on the role of Chlamydia pneumoniae and other agents |
Q37893837 | An isolation procedure of Chlamydia pneumoniae and Chlamydia trachomatis |
Q37871587 | An open, comparative pilot study of thiamphenicol glycinate hydrochloride vs clarithromycin in the treatment of acute lower respiratory tract infections due to Chlamydia pneumoniae |
Q37891729 | An unusual manifestation of Chlamydia pneumoniae infection: meningitis, hepatitis, iritis and atypical erythema nodosum |
Q37872423 | Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts |
Q37851467 | Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts |
Q37863995 | Analysis of Chlamydia pneumoniae-specific oligoclonal bands in multiple sclerosis and other neurologic diseases |
Q37866515 | Analysis of altered protein expression patterns of Chlamydia pneumoniae by an integrated proteome-works system |
Q37848394 | Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae |
Q92007945 | Analysis of humoral immune responses to recombinant Chlamydia pneumoniae antigens |
Q33997961 | Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation. |
Q37872721 | Analysis of the serological response to Chlamydia pneumoniae in patients with ischemic heart disease by recombinant MOMP-ELISA. |
Q33968165 | Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells |
Q37879491 | Animal models for Chlamydia pneumoniae infection |
Q41564445 | Animal models for Chlamydia pneumoniae infection |
Q37882844 | Anti-Chlamydia pneumoniae antibodies and production of interleukin 6 in acute myocardial infarct |
Q37869913 | Anti-Chlamydia pneumoniae heat shock protein 10 antibodies in asthmatic adults |
Q37855789 | Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients ( |
Q37876362 | Antibiotic susceptibility of Chlamydia pneumoniae |
Q37865020 | Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome |
Q43429735 | Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events |
Q37872609 | Antibiotics against Chlamydia pneumoniae and prognosis after acute myocardial infarction |
Q33935083 | Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis |
Q43423795 | Antibodies against Chlamydia pneumoniae and their relation to lymphocyte population levels |
Q43422473 | Antibodies against Chlamydia pneumoniae in stable angina and interleukin-6 levels |
Q37873783 | Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms |
Q37882900 | Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica. |
Q37872816 | Antibodies anti-Chlamydia pneumoniae and anti-Mycoplasma pneumoniae in patients with negative serology for hantavirus. Retrospective study |
Q33941659 | Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease |
Q37874993 | Antibodies to Chlamydia pneumoniae and clinical course in patients with unstable angina pectoris |
Q37868802 | Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation. |
Q37855045 | Antibodies to Chlamydia pneumoniae are associated with increased intima media thickness in asymptomatic Indian individuals |
Q127098084 | Antibodies to Chlamydia pneumoniae are related to the intima-media thickness in the carotid artery and to an atherogenetic fatty acid profile |
Q37862917 | Antibodies to Chlamydia pneumoniae in blood serum of patients with ischemic heart disease and presence of complicated lesions in coronary arteries |
Q37880449 | Antibodies to Chlamydia pneumoniae in healthy children from Bari, south Italy |
Q37873576 | Antibodies to Chlamydia pneumoniae in young Swedish orienteers |
Q43430065 | Antibodies to cytomegalovirus or Chlamydia pneumoniae and coronary heart disease |
Q44025823 | Antibodies to cytomegalovirus or Chlamydia pneumoniae and coronary heart disease. |
Q37871483 | Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. |
Q37866484 | Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial |
Q37881439 | Antibody response to Chlamydia pneumoniae infection in children with respiratory illness |
Q37876498 | Antibody response to the 60-kDa heat-shock protein of Chlamydia pneumoniae in patients with coronary artery disease |
Q37892043 | Antigenic Characterization of Chlamydia pneumoniae Isolated in Hiroshima, Japan |
Q37883393 | Antigenic and molecular analyses of different Chlamydia pneumoniae strains. |
Q37894749 | Antigenic variation among strains of Chlamydia pneumoniae. |
Q37849908 | Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation |
Q37874398 | Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae |
Q37846046 | Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. |
Q37888465 | Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae |
Q33726287 | Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma |
Q43419753 | Antiphospholipid antibodies induced by Chlamydia pneumoniae infections |
Q37544269 | Application of DNA chip scanning technology for automatic detection of Chlamydia trachomatis and Chlamydia pneumoniae inclusions. |
Q37889844 | Application of PCR for isolation of Chlamydia pneumoniae |
Q37873191 | Application of blood-based polymerase chain reaction for detection of Chlamydia pneumoniae in acute respiratory tract infections |
Q37859290 | Application of the recombinant protein MOMP(VD2-VD3) from Chlamydia pneumoniae in sero diagnosis |
Q37869358 | Are anti-Chlamydia pneumoniae antibodies prognosis indicators for peripartum cardiomyopathy? |
Q37875724 | Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? |
Q37861345 | Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link? |
Q37880719 | Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection |
Q37880818 | Arteriosclerosis caused by infection? A possible link between Chlamydia pneumoniae and atherosclerosis |
Q37882091 | Arteriosclerosis--a Chlamydia pneumoniae infection |
Q43429963 | Arteriosclerosis--a Chlamydia pneumoniae infection? |
Q28195798 | Aspirin inhibits Chlamydia pneumoniae-induced NF-κB activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth |
Q28193411 | Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells |
Q37854565 | Assay of Chlamydia pneumoniae-specific IgM antibodies by ELISA method--reduction of non-specific reaction and resetting of serological criteria by measuring IgM antibodies--. |
Q37883761 | Assay of antibiotic susceptibility of Chlamydia pneumoniae. |
Q37884610 | Assay of specific anti-Chlamydia pneumoniae antibodies by ELISA method. 1. Evaluation of ELISA kit using outer membrane complex |
Q37884606 | Assay of specific anti-Chlamydia pneumoniae antibodies by ELISA method. 2. studies on clinical usefulness and serological diagnostic standards |
Q37878182 | Assay of specific anti-Chlamydia pneumoniae antibodies by ELISA method. 3. Setting of serological criteria |
Q92661162 | Assaying Chlamydia pneumoniae Persistence in Monocyte-Derived Macrophages Identifies Dibenzocyclooctadiene Lignans as Phenotypic Switchers |
Q90799663 | Assessment of evidence for or against contributions of Chlamydia pneumoniae infections to Alzheimer's disease etiology |
Q37872175 | Assessment of polymerase chain reaction and serology for detection of chlamydia pneumoniae in patients with acute respiratory tract infection. |
Q37883028 | Assessment of sputum culture and serology for detection of chlamydia pneumoniae in patients with symptomatic acute respiratory tract infection |
Q62865992 | Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis |
Q37836568 | Association Between Chlamydia pneumoniae and Migraine: A Study from a Tertiary Center in India |
Q37875109 | Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults |
Q36259587 | Association between Chlamydia pneumoniae IgG antibodies and migraine |
Q34406483 | Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement |
Q74181404 | Association between Chlamydia pneumoniae and atherosclerotic lesions |
Q37872430 | Association between Chlamydia pneumoniae antibodies and intimal calcification in femoral arteries of nondiabetic patients |
Q36225330 | Association between Chlamydia pneumoniae antibodies and wheezing in young children and the influence of sex. |
Q30732782 | Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma |
Q37864810 | Association between angiographic evidence of coronary artery disease and seropositivity for Helicobacter pylori and Chlamydia pneumoniae infection. |
Q33183960 | Association between cardiovascular disease and anti-Chlamydia pneumoniae antibodies |
Q37864201 | Association between carotid atherosclerosis, inflammatory markers and Chlamydia pneumoniae infection |
Q37873296 | Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: Results from a population-based case-control study |
Q74329563 | Association between past infection with Chlamydia pneumoniae and body mass index, low-density lipoprotein particle size and fasting insulin |
Q37872032 | Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke |
Q37869140 | Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection |
Q34121913 | Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma |
Q60395859 | Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma |
Q36504586 | Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma |
Q28833753 | Association of Chlamydia pneumoniae Infection With Atherosclerotic Plaque Formation |
Q43418518 | Association of Chlamydia pneumoniae and Helicobacter pylori infection with angiographically demonstrated coronary artery disease |
Q37885075 | Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland |
Q43425344 | Association of Chlamydia pneumoniae and multiple sclerosis: stage two? |
Q37868121 | Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins |
Q37875232 | Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. |
Q40041033 | Association of Chlamydia pneumoniae immunoglobulin G antibodies with the risk of lung cancer among non-smoking women in Liaoning, China |
Q37861976 | Association of Chlamydia pneumoniae infection and carotid intima-media wall thickness in Japanese Americans |
Q36422568 | Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease |
Q37877118 | Association of Chlamydia pneumoniae infection with diabetic nephropathy |
Q37891758 | Association of Chlamydia pneumoniae infection with otitis media with effusion |
Q37850845 | Association of Chlamydia pneumoniae serology and ischemic stroke |
Q35586480 | Association of Chlamydia pneumoniae with central nervous system disease |
Q127475183 | Association of Chlamydia pneumoniae with chronic human diseases |
Q43429503 | Association of Chlamydia pneumoniae with chronic juvenile arthritis |
Q37871349 | Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. |
Q37879810 | Association of Chlamydia pneumoniae with otitis media in children |
Q34420129 | Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain). |
Q37886448 | Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors |
Q37884580 | Association of Positive Chlamydia trachomatis and Chlamydia pneumoniae Immunoglobulin G Titers with Increasing Age |
Q37892814 | Association of Prior Infection With Chlamydia pneumoniae and Angiographically Demonstrated Coronary Artery Disease |
Q33602983 | Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke |
Q126553522 | Association of chlamydia pneumoniae infection with diabetes mellitus in patients with coronary artery disease |
Q37879436 | Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. |
Q24791856 | Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review |
Q37857193 | Association of hyperhomocysteinemia and Chlamydia pneumoniae infection with carotid atherosclerosis and coronary artery disease in Japanese patients |
Q37866640 | Association of peripheral mononuclear cells containing Chlamydia pneumoniae DNA with acute coronary syndrome and stable coronary artery disease in Japanese subjects |
Q37150725 | Association of plasma circulatory markers, Chlamydia pneumoniae, and high sensitive C-reactive protein in coronary artery disease patients of India |
Q37882038 | Association of positive Chlamydia trachomatis and Chlamydia pneumoniae immunoglobulin-gamma titers with increasing age. |
Q37865490 | Association of raised titres of antibodies to Chlamydia pneumoniae with a history of pre-eclampsia |
Q37874837 | Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease |
Q37877190 | Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease |
Q43428213 | Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia |
Q37883320 | Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular? |
Q37878633 | Asthma, atopy and Chlamydia pneumoniae antibodies in adults |
Q37859589 | Asthmatic persons are prone to the persistence of Chlamydia pneumoniae antibodies |
Q64264567 | Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of β-amyloid found in Alzheimer disease |
Q37866051 | Asymptomatic carotid atherosclerosis is associated with circulating chlamydia pneumoniae DNA in younger normotensive subjects in a general population survey |
Q43425332 | Asymptomatic respiratory infection with Chlamydia pneumoniae : what does it mean? |
Q37243062 | Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR |
Q37876467 | Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae |
Q37868568 | Atherogenic effects of chlamydia pneumoniae: refuting the innocent bystander hypothesis |
Q37870277 | Atherosclerosis and Chlamydia pneumoniae |
Q33926255 | Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence |
Q37866637 | Atherosclerosis and inflammation--role of chlamydia pneumoniae infection what do we know to date? |
Q37882083 | Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis |
Q34766537 | Atherosclerosis in dialysis patients: does Chlamydia pneumoniae infection contribute to cardiovascular damage? |
Q33772514 | Atherosclerosis, inflammation and Chlamydia pneumoniae |
Q37878654 | Atherosclerosis--a chronic infectious disease caused by Chlamydia pneumoniae |
Q43423054 | Atherosclerosis: lipid infiltration or Chlamydia pneumoniae infection? |
Q37890581 | Atypical pneumonia due to Chlamydia pneumoniae: a case report. |
Q37871369 | Autoantibodies and anti-factor VIII and Chlamydia pneumoniae infection |
Q37872383 | Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk |
Q96223012 | Azithromycin decreases Chlamydia pneumoniae-mediated Interleukin-4 responses but not Immunoglobulin E responses |
Q37888769 | Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae: report of a case |
Q37866763 | Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae. |
Q37864081 | Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells. |
Q37867723 | Azithromycin therapy in patients with chronic Chlamydia pneumoniae infection and coronary heart disease: immediate and long-term effects on inflammation, coagulation, and lipid status in a double-blind, placebo-controlled study |
Q43429072 | Azithromycin, Chlamydia pneumoniae, and intimal thickening |
Q33935003 | Background and current knowledge of Chlamydia pneumoniae and atherosclerosis |
Q37869893 | Bacterial flora from bronchoalveolar lavage and occurrence of class IgG and IgA antibodies to Chlamydia pneumoniae in patients with chronic obstructive pulmonary disease (COPD) |
Q37877649 | Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women |
Q37879261 | Basic and clinical study of Chlamydia pneumoniae infections |
Q37841601 | Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K. |
Q37850932 | Bilateral hilar lymphadenopathy due to Chlamydia pneumoniae infection |
Q37873741 | Bilateral pleural effusion and a subsegmental infiltrate due to Chlamydia pneumoniae in a mechanically ventilated patient |
Q27684803 | Biochemical and Structural Insights into Microtubule Perturbation by CopN from Chlamydia pneumoniae |
Q37835765 | Biophysical and Biochemical Outcomes of Chlamydia pneumoniae Infection Promotes Pro-atherogenic Matrix Microenvironment |
Q27302171 | Biophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci |
Q37877796 | Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children |
Q37860951 | Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy. |
Q34104428 | Bronchial Chlamydia pneumoniae infection, markers of allergic inflammation and lung function in children |
Q37862568 | Bronchial asthma and Chlamydia pneumoniae antibodies in children aged 4-8 years in Olomouc district |
Q37881156 | Bronchial asthma from Chlamydia pneumoniae? Epidemiology, risk factors and practical consequence for therapy |
Q37881607 | Bronchitis and alveolitis in the course of Chlamydia pneumoniae infection |
Q35113951 | C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. |
Q37874536 | C-reactive protein and chronic Chlamydia pneumoniae infection--long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis |
Q37872961 | C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis |
Q37870054 | C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction |
Q37867040 | CD14 promoter polymorphism -159C>T is associated with susceptibility to chronic Chlamydia pneumoniae infection in peripheral blood monocytes |
Q37859108 | CD8+ T cell protective immunity against Chlamydia pneumoniae includes an H2-M3-restricted response that is largely CD4+ T cell-independent |
Q36794140 | CD8+ T cells mediate Chlamydia pneumoniae-induced atherosclerosis in mice |
Q115380914 | CHLAMYDIA PNEUMONIAE IN ACUTE OTITIS MEDIA. † 988 |
Q43423185 | CNS infection with Chlamydia pneumoniae complicated by multiple strokes |
Q35198182 | Calcium, ARMS2 genotype, and Chlamydia pneumoniae infection in early age-related macular degeneration: a multivariate analysis from the Nagahama study |
Q34479396 | Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? |
Q37877470 | Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? |
Q37879600 | Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? |
Q37874641 | Cardiac allograft vasculopathy in heart transplant recipients: a bacteriosclerosis by chlamydia pneumoniae? |
Q37867726 | Cardiac heart disease in the era of sucrose polyester, Helicobacter pylori and Chlamydia pneumoniae |
Q37881987 | Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile |
Q37875238 | Cardiovascular infection by Chlamydia pneumoniae is not related to apolipoprotein E genotype |
Q104745927 | Case Report: Refractory Acute Respiratory Distress Syndrome Supported by Extracorporeal Membrane Oxygenation due to Coinfection with Chlamydia pneumoniae and Leptospirosis in Reunion Island |
Q37894490 | Case report: Chlamydia pneumoniae pneumonia in an HIV-infected man. |
Q37890811 | Case report: acute postoperative respiratory failure caused by Chlamydia pneumoniae and diagnosed by bronchoalveolar lavage. |
Q33952490 | Caspase-1 dependent IL-1β secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection |
Q37883753 | Cell mediated immunity to Chlamydia pneumoniae. |
Q91210836 | Cell-mediated immune response associated with Chlamydia pneumoniae infection in atherosclerotic patients |
Q34005391 | Cell-mediated immune response during primary Chlamydia pneumoniae infection |
Q33597752 | Cell-mediated immunity to Chlamydia pneumoniae measured as lymphocyte blast transformation in vitro. |
Q37870284 | Cell-to-cell contact of human monocytes with infected arterial smooth-muscle cells enhances growth of Chlamydia pneumoniae |
Q37878008 | Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae |
Q37866587 | Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis |
Q37866972 | Changes in antibody titers against Chlamydia pneumoniae after coronary angioplasty |
Q125998213 | Changing of infectious disease.4.Changing of chlamydia respiratory tract infection.Especially on actual conditions of Chlamydia pneumoniae respiratory tract infection in Japapn. |
Q37872211 | Characterisation of 20-kDa lectin-spermagglutinin from Arum maculatum that prevents Chlamydia pneumoniae infection of L-929 fibroblast cells. |
Q37840790 | Characterisation of Chlamydia pneumoniae and other novel chlamydial infections in captive snakes |
Q37857565 | Characterization and intracellular localization of putative Chlamydia pneumoniae effector proteins |
Q37874935 | Characterization and intracellular trafficking pattern of vacuoles containing Chlamydia pneumoniae in human epithelial cells |
Q37883175 | Characterization of Chlamydia pneumoniae antigens using human T cell clones |
Q37873100 | Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon. |
Q37072769 | Characterization of Chlamydia pneumoniae species-specific proteins immunodominant in humans |
Q37889709 | Characterization of a Chlamydia pneumoniae strain isolated from a 57-year-old man. |
Q33758389 | Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae. |
Q37881299 | Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells |
Q37873267 | Characterization of antiapoptotic activities of Chlamydia pneumoniae in human cells |
Q35700382 | Characterization of antiapoptotic activities of Chlamydia pneumoniae in infected cells |
Q33284727 | Characterization of hypothetical proteins Cpn0146, 0147, 0284 & 0285 that are predicted to be in the Chlamydia pneumoniae inclusion membrane |
Q37877285 | Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae |
Q37844761 | Characterization of serine hydroxymethyltransferase GlyA as a potential source of D-alanine in Chlamydia pneumoniae. |
Q37869147 | Characterization of the first Korean isolate of a Chlamydia pneumoniae strain. |
Q37860360 | Characterization of the hypothetical protein Cpn1027, a newly identified inclusion membrane protein unique to Chlamydia pneumoniae |
Q37878729 | Characterization of the koala biovar of Chlamydia pneumoniae at four gene loci--ompAVD4, ompB, 16S rRNA, groESL spacer region |
Q35513577 | Characterization of the murine antibody response to peptides representing the variable domains of the major outer membrane protein of Chlamydia pneumoniae |
Q37875097 | Chest radiograph of atypical pneumonia: comparison among Chlamydia pneumoniae. Pneumonia, ornithosis, and Mycoplasma pneumoniae pneumonia |
Q35954456 | Chlamydia Outer Protein (Cop) B from Chlamydia pneumoniae possesses characteristic features of a type III secretion (T3S) translocator protein |
Q37850728 | Chlamydia Pneumoniae CdsL Regulates CdsN ATPase Activity, and Disruption with a Peptide Mimetic Prevents Bacterial Invasion |
Q37840244 | Chlamydia Pneumoniae and Immunoinflammatory Reactions in an Unstable Atherosclerotic Plaque in Humans |
Q36272565 | Chlamydia pneumoniae |
Q72190879 | Chlamydia pneumoniae |
Q72523970 | Chlamydia pneumoniae |
Q74649305 | Chlamydia pneumoniae |
Q78554678 | Chlamydia pneumoniae |
Q37866118 | Chlamydia pneumoniae (C. pneumoniae) infection upregulates atherosclerosis-related gene expression in human umbilical vein endothelial cells (HUVECs). |
Q37886058 | Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery |
Q34086738 | Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old) |
Q43435592 | Chlamydia pneumoniae (TWAR) in neonates |
Q37885974 | Chlamydia pneumoniae (TWAR) infection in Tanzanian children |
Q37888569 | Chlamydia pneumoniae (TWAR) infections in children. |
Q37894824 | Chlamydia pneumoniae (TWAR)--a common cause of respiratory tract infections |
Q35367697 | Chlamydia pneumoniae (TWAR). |
Q37889646 | Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis |
Q43433683 | Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis |
Q37894361 | Chlamydia pneumoniae (strain TWAR) isolated from two symptom-free children during evaluation for possible sexual assault |
Q43413871 | Chlamydia pneumoniae - causal pathogen or fortuitous witness of atherosclerosis progression? |
Q37863667 | Chlamydia pneumoniae AP endonuclease IV could cleave AP sites of double- and single-stranded DNA. |
Q37835726 | Chlamydia pneumoniae CPj0783 interaction with Huntingtin-protein14. |
Q37838361 | Chlamydia pneumoniae Clinical Isolate from Gingival Crevicular Fluid: A Potential Atherogenic Strain |
Q35193819 | Chlamydia pneumoniae CopD translocator protein plays a critical role in type III secretion (T3S) and infection |
Q37877400 | Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection |
Q37875681 | Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes |
Q37869411 | Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease |
Q37870489 | Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls |
Q28182623 | Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in healthy control subjects and patients with diabetes mellitus, acute coronary syndrome, stroke, and arterial hypertension |
Q37874784 | Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in peritoneal dialysis patients. |
Q37872267 | Chlamydia pneumoniae DNA in peripheral venous blood samples from patients with carotid artery stenosis |
Q28215623 | Chlamydia pneumoniae DNA in the arterial wall of patients with peripheral vascular disease |
Q37867438 | Chlamydia pneumoniae DNA is more frequent in advanced than in mild atherosclerosis lesions |
Q37880091 | Chlamydia pneumoniae DNA is not detectable within sarcoidosis tissue |
Q37855685 | Chlamydia pneumoniae DNA is present in peripheral blood mononuclear cells during acute coronary syndrome and correlates with chlamydial lipopolysaccharide levels in serum |
Q37857945 | Chlamydia pneumoniae GroEL1 protein is cell surface associated and required for infection of HEp-2 cells |
Q89224116 | Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis |
Q37856431 | Chlamydia pneumoniae IgA and elevated level of IL-6 may synergize to accelerate coronary artery disease |
Q37866621 | Chlamydia pneumoniae IgA seropositivity and sudden sensorineural hearing loss. |
Q37869611 | Chlamydia pneumoniae IgA seropositivity is associated with increased risk for atherosclerotic vascular disease, myocardial infarction and stroke in dialysis patients |
Q43422316 | Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis |
Q37872578 | Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis |
Q37872308 | Chlamydia pneumoniae IgA- and IgG antibodies in young survivors of myocardial infarction. A comparison of antibody detection by a microimmunofluorescence test and an enzyme immunoassay |
Q37853478 | Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial |
Q37865674 | Chlamydia pneumoniae IgG and the severity of coronary atherosclerosis |
Q37889391 | Chlamydia pneumoniae IgG antibody prevalence in south-western and eastern Finland in 1982 and 1987. |
Q37865887 | Chlamydia pneumoniae IgG serological status and venous thromboembolism: a cross-sectional hospital based study |
Q37868358 | Chlamydia pneumoniae IgG seropositivity and clinical history of ischemic heart disease in Singapore |
Q43426762 | Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. |
Q43426220 | Chlamydia pneumoniae IgG seropositivity in deep-vein thrombosis |
Q37346172 | Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis |
Q37834265 | Chlamydia pneumoniae Induces Interferon Gamma Responses in Peripheral Blood Mononuclear Cells in Children with Allergic Asthma. |
Q55038629 | Chlamydia pneumoniae Infection Exacerbates Atherosclerosis in ApoB100only/LDLR-/- Mouse Strain. |
Q91243909 | Chlamydia pneumoniae Infection and Inflammatory Diseases |
Q55503472 | Chlamydia pneumoniae Infection in Human Monocytes. |
Q126784098 | Chlamydia pneumoniae Infections in an Immunocompetent Patient Compared With a Neutropenic Cancer Patient |
Q89697993 | Chlamydia pneumoniae Influence on Cytokine Production in Steroid-Resistant and Steroid-Sensitive Asthmatics |
Q92910713 | Chlamydia pneumoniae Polioencephalomyelitis and Ganglionitis in Captive Houston Toads (Anaxyrus houstonensis) |
Q37868385 | Chlamydia pneumoniae accelerates coronary artery disease progression in transgenic hyperlipidemia-genetic hypertension rat model |
Q37858896 | Chlamydia pneumoniae accompanied by inflammation is associated with the progression of atherosclerosis in CAPD patients: a prospective study for 3 years |
Q37871324 | Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure |
Q37868580 | Chlamydia pneumoniae activates epithelial cell proliferation via NF-kappaB and the glucocorticoid receptor |
Q37876664 | Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation |
Q37840234 | Chlamydia pneumoniae acute liver infection affects hepatic cholesterol and triglyceride metabolism in mice. |
Q50284454 | Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signalling cascades. |
Q37869704 | Chlamydia pneumoniae affect surfactant trafficking and secretion due to changes of type II cell cytoskeleton |
Q33308923 | Chlamydia pneumoniae aggravates vein graft intimal hyperplasia in a rat model |
Q37863456 | Chlamydia pneumoniae alters mildly oxidized low-density lipoprotein-induced cell death in human endothelial cells, leading to necrosis rather than apoptosis. |
Q42718306 | Chlamydia pneumoniae and COPD exacerbation. |
Q51726841 | Chlamydia pneumoniae and Cardiovascular Disease. |
Q37841290 | Chlamydia pneumoniae and Chlamydia Trachomatis Infection Differentially Modulates Human Dendritic Cell Line (MUTZ) Differentiation and Activation. |
Q37887835 | Chlamydia pneumoniae and Chronic Pharyngitis |
Q37868723 | Chlamydia pneumoniae and Epstein-Barr antibodies are not associated with carotid thickness: the effect of hypertension |
Q37840324 | Chlamydia pneumoniae and Helicobacter pylori IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study |
Q37882487 | Chlamydia pneumoniae and Helicobacter pylori infections in Sámi and Finnish reindeer herders. |
Q37874751 | Chlamydia pneumoniae and Helicobacter pylori infections in acute myocardial infarction |
Q36358387 | Chlamydia pneumoniae and Mycoplasma pneumoniae |
Q37864424 | Chlamydia pneumoniae and Mycoplasma pneumoniae in calcified nodes of stenosed aortic valves |
Q103034936 | Chlamydia pneumoniae and Mycoplasma pneumoniae in children with Cystic Fibrosis: impact on bacterial respiratory microbiota diversity |
Q37876913 | Chlamydia pneumoniae and Mycoplasma pneumoniae in children with acute respiratory infection in general practices in The Netherlands |
Q37864930 | Chlamydia pneumoniae and Mycoplasma pneumoniae in young children from China with community-acquired pneumonia |
Q37878540 | Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia in children |
Q37863465 | Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles |
Q43421736 | Chlamydia pneumoniae and NAION |
Q37856717 | Chlamydia pneumoniae and acute aortic syndrome: a call for a multi-institutional study. |
Q43432114 | Chlamydia pneumoniae and acute arterial thrombotic disease |
Q37870319 | Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease |
Q43419334 | Chlamydia pneumoniae and acute coronary syndrome |
Q60178617 | Chlamydia pneumoniae and acute coronary syndrome |
Q37882349 | Chlamydia pneumoniae and acute myocardial infarction in Jerusalem |
Q37871351 | Chlamydia pneumoniae and acute respiratory tract infections in breast-feeding infants: simultaneous mother-child serological study in Niamey (Niger) |
Q36735756 | Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association? |
Q43418238 | Chlamydia pneumoniae and airway remodeling |
Q33732232 | Chlamydia pneumoniae and anti-infective therapy: their role in the pathogenesis and treatment of coronary artery disease |
Q37869933 | Chlamydia pneumoniae and aortic aneurysms |
Q37876934 | Chlamydia pneumoniae and arteriosclerosis |
Q43428028 | Chlamydia pneumoniae and arteriosclerosis: an innocent onlooker? |
Q35532326 | Chlamydia pneumoniae and asthma |
Q37877265 | Chlamydia pneumoniae and asthma |
Q42998006 | Chlamydia pneumoniae and asthma |
Q43420431 | Chlamydia pneumoniae and asthma in children: diagnostic issues |
Q43061266 | Chlamydia pneumoniae and asthma. |
Q43421264 | Chlamydia pneumoniae and asthma: more than just exacerbations |
Q37883619 | Chlamydia pneumoniae and asthmatic disease in adults: relations to be clarified |
Q28237111 | Chlamydia pneumoniae and atherosclerosis |
Q37877184 | Chlamydia pneumoniae and atherosclerosis |
Q43430276 | Chlamydia pneumoniae and atherosclerosis |
Q56829181 | Chlamydia pneumoniae and atherosclerosis |
Q71406522 | Chlamydia pneumoniae and atherosclerosis |
Q73161965 | Chlamydia pneumoniae and atherosclerosis |
Q73178879 | Chlamydia pneumoniae and atherosclerosis |
Q73256770 | Chlamydia pneumoniae and atherosclerosis |
Q73311061 | Chlamydia pneumoniae and atherosclerosis |
Q74181270 | Chlamydia pneumoniae and atherosclerosis |
Q77552594 | Chlamydia pneumoniae and atherosclerosis |
Q78627684 | Chlamydia pneumoniae and atherosclerosis |
Q81576764 | Chlamydia pneumoniae and atherosclerosis |
Q93931450 | Chlamydia pneumoniae and atherosclerosis |
Q34572654 | Chlamydia pneumoniae and atherosclerosis -- what we know and what we don't |
Q37868049 | Chlamydia pneumoniae and atherosclerosis following carotid endarterectomy. |
Q37883725 | Chlamydia pneumoniae and atherosclerosis--an update. |
Q37877643 | Chlamydia pneumoniae and atherosclerosis--the hen, the egg or five feathers? |
Q33534714 | Chlamydia pneumoniae and atherosclerosis. |
Q37876031 | Chlamydia pneumoniae and atherosclerosis. Identification of bacterial DNA in the arterial wall |
Q37858402 | Chlamydia pneumoniae and atherosclerosis: The end? |
Q33905858 | Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies |
Q43414627 | Chlamydia pneumoniae and atherosclerosis: current state and future prospectives |
Q34208034 | Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? |
Q36180789 | Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials |
Q37877547 | Chlamydia pneumoniae and atherosclerosis: links to the disease process |
Q35758705 | Chlamydia pneumoniae and atherosclerosis: no way-out or long way? What about renal failure patients? |
Q43414252 | Chlamydia pneumoniae and atherosclerosis: the role of mast cells. |
Q33822287 | Chlamydia pneumoniae and atherosclerosis: what we know and what we don't know |
Q62279926 | Chlamydia pneumoniae and atherosclerotic cardiovascular disease |
Q43431575 | Chlamydia pneumoniae and atherosclerotic plaque |
Q33935019 | Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology |
Q74420646 | Chlamydia pneumoniae and cardiovascular disease |
Q77729398 | Chlamydia pneumoniae and cardiovascular disease |
Q34995266 | Chlamydia pneumoniae and cardiovascular disease. |
Q33934999 | Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment |
Q35584450 | Chlamydia pneumoniae and cardiovascular disease: current status. |
Q37866157 | Chlamydia pneumoniae and cardiovascular diseases |
Q37885330 | Chlamydia pneumoniae and cardiovascular diseases |
Q37874379 | Chlamydia pneumoniae and cerebrovascular disease |
Q37873723 | Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation |
Q35535328 | Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment |
Q43414895 | Chlamydia pneumoniae and chronic diseases with a great impact on public health |
Q37883738 | Chlamydia pneumoniae and chronic lung diseases |
Q37876229 | Chlamydia pneumoniae and chronic obstructive pulmonary disease: bronchial biopsies (PCR and culture) and specific serum antibodies in patients and controls |
Q34582500 | Chlamydia pneumoniae and chronic skin wounds: a focused review |
Q43417953 | Chlamydia pneumoniae and coronary artery disease: controversial results of serological studies |
Q35696285 | Chlamydia pneumoniae and coronary artery disease: legitimized linkages? |
Q35083268 | Chlamydia pneumoniae and coronary artery disease: the antibiotic trials |
Q33659387 | Chlamydia pneumoniae and coronary heart disease |
Q57953474 | Chlamydia pneumoniae and coronary heart disease |
Q37871787 | Chlamydia pneumoniae and cytomegalovirus in degenerative aortic valve stenoses |
Q37873342 | Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. |
Q37880928 | Chlamydia pneumoniae and exacerbations of asthma in adults |
Q37867881 | Chlamydia pneumoniae and future risk in patients with coronary heart disease |
Q43426806 | Chlamydia pneumoniae and heart |
Q37849596 | Chlamydia pneumoniae and helicobacter pylori serology - importance in patients with coronary heart disease |
Q34130686 | Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice |
Q43425347 | Chlamydia pneumoniae and its proposed link to multiple sclerosis: to be or not to be? |
Q43425888 | Chlamydia pneumoniae and its relation with human atherosclerosis |
Q37881193 | Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease |
Q43427310 | Chlamydia pneumoniae and lipoprotein(a): the right combination for atherosclerosis? |
Q37873867 | Chlamydia pneumoniae and luminal narrowing after coronary angioplasty |
Q34410654 | Chlamydia pneumoniae and lung cancer: epidemiologic evidence |
Q43413271 | Chlamydia pneumoniae and metabolic syndrome |
Q37870129 | Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis |
Q43425292 | Chlamydia pneumoniae and multiple sclerosis: innocent bystander or culprit? |
Q37874491 | Chlamydia pneumoniae and multiple sclerosis: no significant association |
Q37870043 | Chlamydia pneumoniae and multiple sclerosis: the latest etiologic candidate |
Q37872646 | Chlamydia pneumoniae and myocardial infarct? (Serologic study) |
Q37874627 | Chlamydia pneumoniae and myocardial infarction (CLINF). Preliminary randomized controlled study with clarithromycin. CLAINF protocol |
Q37883727 | Chlamydia pneumoniae and myocarditis. |
Q37867013 | Chlamydia pneumoniae and newly diagnosed asthma: a case-control study in 1 to 6-year-old children |
Q37880994 | Chlamydia pneumoniae and occlusive vascular disease: identification and characterization |
Q37847655 | Chlamydia pneumoniae and osteoporosis-associated bone loss: a new risk factor? |
Q37879665 | Chlamydia pneumoniae and other Chlamydia species in community-acquired pneumonia |
Q33935014 | Chlamydia pneumoniae and other risk factors for atherosclerosis |
Q27009367 | Chlamydia pneumoniae and oxidative stress in cardiovascular disease: state of the art and prevention strategies |
Q37879684 | Chlamydia pneumoniae and possible relationship to asthma. Serum immunoglobulins and histamine release in patients and controls. |
Q37847433 | Chlamydia pneumoniae and progression of subclinical atherosclerosis |
Q32061763 | Chlamydia pneumoniae and respiratory pathology. Epidemiological data |
Q37874740 | Chlamydia pneumoniae and screening for tubal factor subfertility |
Q34116681 | Chlamydia pneumoniae and severity of asthma |
Q37854372 | Chlamydia pneumoniae and stroke: is there a direct relationship? |
Q37859300 | Chlamydia pneumoniae and symptomatic carotid atherosclerotic plaque: a prospective study |
Q43422992 | Chlamydia pneumoniae and the "Dutch Hypothesis". |
Q35042320 | Chlamydia pneumoniae and the heart: impact of diagnostic methods. |
Q34128399 | Chlamydia pneumoniae and the lung |
Q37868000 | Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients |
Q37876105 | Chlamydia pneumoniae and the risk of first ischemic stroke : The Northern Manhattan Stroke Study |
Q37865774 | Chlamydia pneumoniae and the risk of ischaemic heart disease. Prevalence in a group of hospitalized elderly men |
Q37844710 | Chlamydia pneumoniae and typical bacteria occurrence in adenoid in children qualified for adenoidectomy |
Q37880177 | Chlamydia pneumoniae and vascular disease |
Q34536607 | Chlamydia pneumoniae and vascular disease: an update |
Q43425842 | Chlamydia pneumoniae and vascular pathology |
Q55311657 | Chlamydia pneumoniae antibodies and C-reactive protein levels in patients with abdominal aortic aneurysms. |
Q43426672 | Chlamydia pneumoniae antibodies and adult-onset asthma |
Q37875315 | Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in Thailand |
Q37878044 | Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy. |
Q37869682 | Chlamydia pneumoniae antibodies and endothelial function as assessed by flow-mediated dilation in patients with chest pain with and without ischemic heart disease |
Q37877684 | Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden |
Q37866124 | Chlamydia pneumoniae antibodies and inflammatory reaction in patients with ischemic heart disease. |
Q37862706 | Chlamydia pneumoniae antibodies and markers of inflammation in patients with cardiovascular diseases |
Q37869958 | Chlamydia pneumoniae antibodies and other atherosclerosis risk factors in haemodialysed patients. Preliminary report |
Q36244426 | Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study |
Q35370873 | Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile |
Q37878800 | Chlamydia pneumoniae antibodies associated with altered serum lipid profile |
Q37884929 | Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease |
Q43430166 | Chlamydia pneumoniae antibodies in myalgia of unknown cause (including fibromyalgia) |
Q37881616 | Chlamydia pneumoniae antibodies in severe essential hypertension |
Q37857236 | Chlamydia pneumoniae antibodies in various subtypes of ischemic stroke in Indian patients |
Q77330455 | Chlamydia pneumoniae antibodies may predict fatal heart disease |
Q37862130 | Chlamydia pneumoniae antibody levels before coronary events in the Helsinki Heart Study as measured by different methods |
Q37881662 | Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up |
Q37859213 | Chlamydia pneumoniae antibody titers and cardiac calcifications: a cross-sectional serological-echocardiographic correlative study. |
Q34457169 | Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project |
Q37874292 | Chlamydia pneumoniae antibody titers in patients with acute ischemic stroke |
Q37870864 | Chlamydia pneumoniae antigens facilitate experimental aortic dilatation: prevention with azithromycin |
Q35395485 | Chlamydia pneumoniae antigens, rather than viable bacteria, persist in atherosclerotic lesions |
Q37864940 | Chlamydia pneumoniae arthritis in a patient with common variable immunodeficiency. |
Q31153517 | Chlamydia pneumoniae as a biological factor contributing to pathological changes of arterial walls in patients with atherosclerosis |
Q37878569 | Chlamydia pneumoniae as a causative agent in atherosclerosis |
Q37884890 | Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin |
Q43433738 | Chlamydia pneumoniae as a cause of reactive arthritis |
Q37882995 | Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes |
Q43420946 | Chlamydia pneumoniae as a pathogenetic risk factor in the development of arteriosclerosis and its complications |
Q34542090 | Chlamydia pneumoniae as a respiratory pathogen |
Q43428017 | Chlamydia pneumoniae as a trigger of reactive arthritis |
Q37878245 | Chlamydia pneumoniae as a triggering infection in reactive arthritis |
Q35013298 | Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease |
Q37883696 | Chlamydia pneumoniae as an etiologic agent in severe pneumonias |
Q37881602 | Chlamydia pneumoniae as an etiologic factor in disease of the respiratory tract |
Q43419946 | Chlamydia pneumoniae as risk factor of cardiovascular disease in dialysis patients. |
Q37885952 | Chlamydia pneumoniae associated with central nervous system infections |
Q33883485 | Chlamydia pneumoniae augments the oxidized low-density lipoprotein-induced death of mouse macrophages by a caspase-independent pathway |
Q37869092 | Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease? |
Q37850239 | Chlamydia pneumoniae binds to the lectin-like oxidized LDL receptor for infection of endothelial cells |
Q37863789 | Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum |
Q37879204 | Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension |
Q37867858 | Chlamydia pneumoniae carriage and infection in hospitalized children with respiratory tract diseases |
Q37879761 | Chlamydia pneumoniae chronic infection in the development of arteriosclerosis |
Q37885417 | Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients |
Q37866728 | Chlamydia pneumoniae decreases smooth muscle cell proliferation through induction of prostaglandin E2 synthesis |
Q37876375 | Chlamydia pneumoniae detection in atherosclerotic plaques in Italy |
Q37859832 | Chlamydia pneumoniae directly interferes with HIF-1alpha stabilization in human host cells. |
Q37844231 | Chlamydia pneumoniae disrupts lipid metabolism in human umbilical vein endothelial cells |
Q37852303 | Chlamydia pneumoniae disturbs cholesterol homeostasis in human THP-1 macrophages via JNK-PPARγ dependent signal transduction pathways |
Q37874405 | Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice |
Q37877209 | Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis |
Q30389751 | Chlamydia pneumoniae effector chlamydial outer protein N sequesters fructose bisphosphate aldolase A, providing a benefit to bacterial growth |
Q37240380 | Chlamydia pneumoniae elementary body antigenic reactivity with fluorescent antibody is destroyed by methanol |
Q34066394 | Chlamydia pneumoniae encodes a functional aromatic amino acid hydroxylase |
Q91474035 | Chlamydia pneumoniae enhances Interleukin 8 (IL-8) production with reduced azithromycin sensitivity under hypoxia |
Q33556766 | Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E2-dependent mechanism |
Q37837295 | Chlamydia pneumoniae enhances the Th2 profile of stimulated peripheral blood mononuclear cells from asthmatic patients |
Q37849602 | Chlamydia pneumoniae entry into epithelial cells by clathrin-independent endocytosis |
Q37877463 | Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study |
Q28362988 | Chlamydia pneumoniae exacerbates aortic inflammatory foci caused by murine cytomegalovirus infection in normocholesterolemic mice |
Q44059235 | Chlamydia pneumoniae exploits adipocyte lipid chaperone FABP4 to facilitate fat mobilization and intracellular growth in murine adipocytes. |
Q37873779 | Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). |
Q34008875 | Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells |
Q37874547 | Chlamydia pneumoniae facilitates monocyte adhesion to endothelial and smooth muscle cells |
Q37864525 | Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells. |
Q36703071 | Chlamydia pneumoniae growth inhibition in cells by the steroid receptor antagonist RU486 (mifepristone). |
Q37863610 | Chlamydia pneumoniae growth inhibition in human monocytic THP-1 cells and human epithelial HEp-2 cells by a novel phenoxazine derivative |
Q37843635 | Chlamydia pneumoniae harness host NLRP3 inflammasome-mediated caspase-1 activation for optimal intracellular growth in murine macrophages |
Q37851643 | Chlamydia pneumoniae heat shock protein 60 enhances expression of ERK, TLR-4 and IL-8 in atheromatous plaques of coronary artery disease patients |
Q37850283 | Chlamydia pneumoniae heat shock protein 60 is associated with apoptotic signaling pathway in human atheromatous plaques of coronary artery disease patients |
Q33472674 | Chlamydia pneumoniae hides inside apoptotic neutrophils to silently infect and propagate in macrophages |
Q37870908 | Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma |
Q90095318 | Chlamydia pneumoniae immunoglobulin E antibody levels in patients with asthma compared with non-asthma |
Q37863793 | Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology |
Q36585704 | Chlamydia pneumoniae impairs the innate immune response in infected epithelial cells by targeting TRAF3 |
Q37866528 | Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-gamma assay, serology and PCR. |
Q37865541 | Chlamydia pneumoniae in PBMC: reproducibility of the OMPA nested touchdown PCR. |
Q37891935 | Chlamydia pneumoniae in Swedish patients |
Q37878264 | Chlamydia pneumoniae in a free-ranging giant barred frog (Mixophyes iteratus) from Australia. |
Q37877432 | Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA. |
Q37882035 | Chlamydia pneumoniae in acute otitis media |
Q37863827 | Chlamydia pneumoniae in an ex vivo human artery culture model |
Q37881991 | Chlamydia pneumoniae in arteries: a tale of the unexpected |
Q33588103 | Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies |
Q37862638 | Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. |
Q37228857 | Chlamydia pneumoniae in atheroma: consideration of criteria for causality |
Q33890410 | Chlamydia pneumoniae in atherosclerosis |
Q37876378 | Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic tissue |
Q37874015 | Chlamydia pneumoniae in atherosclerotic carotid artery plaques: high prevalence among heavy smokers. |
Q37871650 | Chlamydia pneumoniae in atherosclerotic lesions of patients undergoing vascular surgery |
Q37873484 | Chlamydia pneumoniae in atherosclerotic middle cerebral artery |
Q33935024 | Chlamydia pneumoniae in atherosclerotic tissue |
Q37870664 | Chlamydia pneumoniae in carotid artery atherosclerosis: a comparison of its presence in atherosclerotic plaque, healthy vessels, and circulating leukocytes from the same individuals. |
Q37870574 | Chlamydia pneumoniae in central retinal artery occlusion |
Q37880658 | Chlamydia pneumoniae in children attending day-care centers in Gävle, Sweden |
Q37874692 | Chlamydia pneumoniae in children undergoing adenoidectomy. |
Q37869076 | Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies |
Q37881390 | Chlamydia pneumoniae in children with acute respiratory tract infections |
Q37881894 | Chlamydia pneumoniae in children with otitis media. |
Q37874519 | Chlamydia pneumoniae in community-acquired pneumonia. |
Q37871021 | Chlamydia pneumoniae in community-acquired pneumonia: seven years of experience. |
Q37879945 | Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases |
Q43427298 | Chlamydia pneumoniae in coronary artery disease |
Q44028702 | Chlamydia pneumoniae in coronary artery disease |
Q43412635 | Chlamydia pneumoniae in coronary atherosclerotic plaques and coronary instability |
Q37866240 | Chlamydia pneumoniae in coronary bypass grafts of redo patients. The concept of the 'adventitial baseline infection'. |
Q37878503 | Chlamydia pneumoniae in coronary plaques: Increased detection with acute coronary syndrome |
Q37872492 | Chlamydia pneumoniae in different coronary artery segments in the young |
Q37870539 | Chlamydia pneumoniae in elderly patients with stroke (C-PEPS): a case-control study on the seroprevalence of Chlamydia pneumoniae in elderly patients with acute cerebrovascular disease |
Q37863621 | Chlamydia pneumoniae in foci of "early" calcification of the tunica media in arteriosclerotic arteries: an incidental presence? |
Q37881211 | Chlamydia pneumoniae in human abdominal aortic aneurysms |
Q35586029 | Chlamydia pneumoniae in infrequently examined blood vessels |
Q37874332 | Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker |
Q37861614 | Chlamydia pneumoniae in otorhinolaryngological infection |
Q37869930 | Chlamydia pneumoniae in patients undergoing surgery for thoracic aortic disease |
Q37878330 | Chlamydia pneumoniae in patients with acquired pneumonia in the Santiago of Chile community |
Q37868011 | Chlamydia pneumoniae in patients with atherosclerotic ischemia of the lower limbs |
Q42863714 | Chlamydia pneumoniae in peripheral blood mononuclear cells isolated from individuals younger than 20 years or older than 60 years |
Q43428010 | Chlamydia pneumoniae in redo and first-time coronary artery bypass graft surgery |
Q37845113 | Chlamydia pneumoniae in the atherosclerotic plaques of coronary artery disease patients |
Q37868662 | Chlamydia pneumoniae in the atherosclerotic plaques of patients with unstable angina undergoing coronary artery bypass grafting: does it have prognostic implications? |
Q37872756 | Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls |
Q37854537 | Chlamydia pneumoniae in the etiology of the keratoconjunctivitis sicca in adult patients (a pilot study) |
Q43429089 | Chlamydia pneumoniae in the female genital tract |
Q37879489 | Chlamydia pneumoniae in vascular tissue |
Q43429587 | Chlamydia pneumoniae in vascular tissues from heart-transplant donors |
Q35395532 | Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods |
Q41993419 | Chlamydia pneumoniae inclusion membrane protein Cpn0147 interacts with host protein CREB3 |
Q28251473 | Chlamydia pneumoniae inclusion membrane protein Cpn0585 interacts with multiple Rab GTPases |
Q37867591 | Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice |
Q37854176 | Chlamydia pneumoniae induces T cell apoptosis through glutathione redox imbalance and secretion of TNF-alpha |
Q37854249 | Chlamydia pneumoniae induces THP-1-derived foam cell formation by up-regulating the expression of acyl-coenzyme A: cholesterol acyltransferase 1 |
Q37849579 | Chlamydia pneumoniae induces a pro-inflammatory phenotype in murine vascular smooth muscle cells independently of elevating reactive oxygen species |
Q24798576 | Chlamydia pneumoniae induces aponecrosis in human aortic smooth muscle cells |
Q37850586 | Chlamydia pneumoniae induces chemokine expression by platelets in patients with atherosclerosis |
Q37412127 | Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1 |
Q34007947 | Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice |
Q37875553 | Chlamydia pneumoniae induces interleukin-10 production that down-regulates major histocompatibility complex class I expression. |
Q37835221 | Chlamydia pneumoniae induces interleukin-12 responses in peripheral blood mononuclear cells in asthma and the role of toll like receptor 2 versus 4: a pilot study |
Q37856118 | Chlamydia pneumoniae induces interleukin-6 and interleukin-10 in human gingival fibroblasts. |
Q37856080 | Chlamydia pneumoniae induces macrophage-derived foam cell formation by up-regulating acyl-coenzyme A: cholesterol acyltransferase 1. |
Q24311609 | Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways |
Q37869992 | Chlamydia pneumoniae induces neointima formation in coronary arteries of normal pigs |
Q53660409 | Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. |
Q37867963 | Chlamydia pneumoniae induces the expression of inhibitor of apoptosis 2 (c-IAP2) in a human monocytic cell line by an NF-kappaB-dependent pathway |
Q37870068 | Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway |
Q37865222 | Chlamydia pneumoniae infected macrophages exhibit enhanced plasma membrane fluidity and show increased adherence to endothelial cells |
Q37873686 | Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice |
Q37878302 | Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice |
Q36780378 | Chlamydia pneumoniae infection acts as an endothelial stressor with the potential to initiate the earliest heat shock protein 60-dependent inflammatory stage of atherosclerosis |
Q127247439 | Chlamydia pneumoniae infection affects the effect of lipid-lowering drug on carotid atherosclerosis |
Q37865528 | Chlamydia pneumoniae infection after lung transplantation. |
Q37870583 | Chlamydia pneumoniae infection alters the junctional complex proteins of human brain microvascular endothelial cells |
Q37871739 | Chlamydia pneumoniae infection among healthy children and children hospitalised with pneumonia in Greece |
Q37743247 | Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember? |
Q43417606 | Chlamydia pneumoniae infection and MPO-ANCA-associated glomerulonephritis |
Q37877131 | Chlamydia pneumoniae infection and Mycoplasma pneumoniae infection in pediatric patients |
Q43426387 | Chlamydia pneumoniae infection and PFO-associated ischemic stroke |
Q37872931 | Chlamydia pneumoniae infection and accelerated development of coronary artery disease in patients with chronic renal failure |
Q37873250 | Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). |
Q37872256 | Chlamydia pneumoniae infection and arteriosclerosis |
Q43435152 | Chlamydia pneumoniae infection and asthma |
Q37877788 | Chlamydia pneumoniae infection and atherosclerosis |
Q43424105 | Chlamydia pneumoniae infection and atherosclerosis: methodological considerations. |
Q37878342 | Chlamydia pneumoniae infection and atherosclerotic coronary disease |
Q37879253 | Chlamydia pneumoniae infection and cardiac ischemic syndromes |
Q35945225 | Chlamydia pneumoniae infection and cardiac risk factors in patients with myocardial infection. |
Q37844796 | Chlamydia pneumoniae infection and cerebral infarction risk: a meta-analysis |
Q26859186 | Chlamydia pneumoniae infection and cerebrovascular disease: a systematic review and meta-analysis |
Q43427803 | Chlamydia pneumoniae infection and coronary artery disease |
Q42786795 | Chlamydia pneumoniae infection and coronary heart disease. Other infections might have role in South Asians. |
Q42786775 | Chlamydia pneumoniae infection and coronary heart disease. Role of C pneumoniae in pathogenesis of atherosclerosis must be determined |
Q42786761 | Chlamydia pneumoniae infection and coronary heart disease. Trials should assess whether antibiotics eliminate organism from atherosclerotic lesions |
Q37877895 | Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis |
Q37878142 | Chlamydia pneumoniae infection and ethnic origin |
Q37857508 | Chlamydia pneumoniae infection and hyperlipidaemia-induced expression of P50 and c-Fos in the heart of C57BL6J mice |
Q37878104 | Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study |
Q37867540 | Chlamydia pneumoniae infection and inflammation in adults with asthma |
Q37862833 | Chlamydia pneumoniae infection and ischemic heart disease in hemodialysis patients |
Q37873843 | Chlamydia pneumoniae infection and its association with coronary heart disease and cardiovascular risk factors in a sample South Asian population |
Q34951727 | Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease |
Q34157076 | Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis |
Q37876040 | Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study |
Q37871402 | Chlamydia pneumoniae infection and multiple sclerosis |
Q37871996 | Chlamydia pneumoniae infection and nonspecific aortoarteritis: search for a link with a nonatherosclerotic inflammatory arterial disease |
Q37869302 | Chlamydia pneumoniae infection and restenosis in patients with coronary heart disease |
Q37852996 | Chlamydia pneumoniae infection and risk for lung cancer |
Q37866340 | Chlamydia pneumoniae infection and risk of lung cancer. |
Q37859944 | Chlamydia pneumoniae infection and stroke |
Q43421745 | Chlamydia pneumoniae infection and the risk of female early-onset lung cancer |
Q34556018 | Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis |
Q37852381 | Chlamydia pneumoniae infection as a risk factor for accelerated atherosclerosis in hemodialysis patients. |
Q37865525 | Chlamydia pneumoniae infection as a risk factor for subarachnoid hemorrhage |
Q37889936 | Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. |
Q37864797 | Chlamydia pneumoniae infection as a trigger for a Cogan's syndrome |
Q43412034 | Chlamydia pneumoniae infection associated to acute fibrinous and organizing pneumonia |
Q37885115 | Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies |
Q37871138 | Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis |
Q37878919 | Chlamydia pneumoniae infection associated with multi-organ failure and fatal outcome in a previously healthy patient |
Q37848689 | Chlamydia pneumoniae infection associated with uncontrolled asthma: a hospital based cross sectional study |
Q37874064 | Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice |
Q43426027 | Chlamydia pneumoniae infection during an influenza virus A epidemic: preliminary report |
Q34481798 | Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway |
Q37862016 | Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells |
Q37856171 | Chlamydia pneumoniae infection enhances microglial activation in atherosclerotic mice |
Q37865648 | Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile. |
Q37857551 | Chlamydia pneumoniae infection in IL-10 knock out mice: accelerated clearance but severe pulmonary inflammatory response |
Q37887111 | Chlamydia pneumoniae infection in Italian patients |
Q81265970 | Chlamydia pneumoniae infection in Slovenian patients with diffuse coronary artery disease |
Q37886937 | Chlamydia pneumoniae infection in Thai children: serological diagnosis. |
Q37093889 | Chlamydia pneumoniae infection in a breeding colony of African clawed frogs (Xenopus tropicalis). |
Q37881846 | Chlamydia pneumoniae infection in a family |
Q37865326 | Chlamydia pneumoniae infection in abdominal aortic aneurysm (AAA) patients and its clinical impact. |
Q37891841 | Chlamydia pneumoniae infection in acute exacerbations of COPD. |
Q37872934 | Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: analysis of 250 hospitalizations |
Q37848337 | Chlamydia pneumoniae infection in adolescents with type 1 diabetes mellitus. |
Q37869961 | Chlamydia pneumoniae infection in adult patients with persistent cough |
Q37875905 | Chlamydia pneumoniae infection in adults with chronic cough compared with healthy blood donors |
Q37865458 | Chlamydia pneumoniae infection in asthmatic patients |
Q37846181 | Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview |
Q37879993 | Chlamydia pneumoniae infection in children with asthma exacerbation |
Q37887865 | Chlamydia pneumoniae infection in children with lower respiratory tract infections |
Q43102311 | Chlamydia pneumoniae infection in children with persistent cough |
Q31829380 | Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment |
Q37876577 | Chlamydia pneumoniae infection in community-acquired pneumonia in Taiwan |
Q34000720 | Chlamydia pneumoniae infection in human monocytes |
Q35035253 | Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis |
Q37855399 | Chlamydia pneumoniae infection in patients after kidney transplantation treated with spiramycin. |
Q101388462 | Chlamydia pneumoniae infection in patients hospitalised for community-acquired pneumonia in Southern Jordan |
Q37876266 | Chlamydia pneumoniae infection in patients with acute bronchitis and bronchial asthma |
Q37867053 | Chlamydia pneumoniae infection in patients with acute coronary syndrome: a clinical and serological 1-year follow-up. |
Q37865567 | Chlamydia pneumoniae infection in patients with advanced carotid atherosclerosis |
Q37872766 | Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease |
Q24644991 | Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease |
Q37885100 | Chlamydia pneumoniae infection in patients with cystic fibrosis |
Q37879921 | Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. |
Q37880257 | Chlamydia pneumoniae infection in patients with myocardial infarct and angina pectoris |
Q37886945 | Chlamydia pneumoniae infection in patients with pneumonia, bronchitis and acute upper respiratory tract infection in Beijing |
Q33877198 | Chlamydia pneumoniae infection in polarized epithelial cell lines |
Q37852414 | Chlamydia pneumoniae infection in preeclampsia |
Q37867152 | Chlamydia pneumoniae infection in young stroke patients: a case--control study |
Q24641977 | Chlamydia pneumoniae infection increases adherence of mouse macrophages to mouse endothelial cells in vitro and to aortas ex vivo |
Q37865398 | Chlamydia pneumoniae infection increases the risk of coronary artery disease in the patients with dyslipidemia |
Q33939577 | Chlamydia pneumoniae infection induced allergic airway sensitization is controlled by regulatory T-cells and plasmacytoid dendritic cells |
Q37869175 | Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice |
Q37872148 | Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages |
Q35559048 | Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. |
Q37845512 | Chlamydia pneumoniae infection induces vascular smooth muscle cell migration via Rac1 activation |
Q43419797 | Chlamydia pneumoniae infection is an unlikely cause of primary biliary cirrhosis |
Q60699536 | Chlamydia pneumoniae infection is associated with HLA-B⁎35 in patients with coronary artery disease |
Q37867103 | Chlamydia pneumoniae infection is associated with coronary artery disease but not implicated in inducing plaque instability |
Q37853903 | Chlamydia pneumoniae infection is associated with elevated body mass index in young men. |
Q37879407 | Chlamydia pneumoniae infection is frequent but not associated with coronary arteriosclerosis in cardiac transplant recipients |
Q33928612 | Chlamydia pneumoniae infection is not an independent risk factor for arterial disease |
Q37860476 | Chlamydia pneumoniae infection is not associated with chronic transplant dysfunction in a rat aortic allograft model |
Q37871830 | Chlamydia pneumoniae infection is not involved in carotid artery stenosis |
Q37869783 | Chlamydia pneumoniae infection of alveolar macrophages: a model |
Q37859141 | Chlamydia pneumoniae infection of aortic smooth muscle cells reduces platelet-derived growth factor receptor-beta expression |
Q37862494 | Chlamydia pneumoniae infection of brain cells: an in vitro study |
Q37871910 | Chlamydia pneumoniae infection of endothelial cells induces transcriptional activation of platelet-derived growth factor-B: a potential link to intimal thickening in a rabbit model of atherosclerosis |
Q37878378 | Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). |
Q37844344 | Chlamydia pneumoniae infection of lungs and macrophages indirectly stimulates the phenotypic conversion of smooth muscle cells and mesenchymal stem cells: potential roles in vascular calcification and fibrosis |
Q37862086 | Chlamydia pneumoniae infection of microglial cells in vitro: a model of microbial infection for neurological disease |
Q37842499 | Chlamydia pneumoniae infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer's disease |
Q34260373 | Chlamydia pneumoniae infection of the central nervous system |
Q33867663 | Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis |
Q36376620 | Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis |
Q37877720 | Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis |
Q37863853 | Chlamydia pneumoniae infection predicts a reduced risk for subsequent atopic disease |
Q84618381 | Chlamydia pneumoniae infection presenting with angioedema in an adolescent |
Q33927267 | Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo |
Q49808551 | Chlamydia pneumoniae infection promotes monocyte transendothelial migration by increasing vascular endothelial cell permeability via the tyrosine phosphorylation of VE-cadherin |
Q37870146 | Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells |
Q37834498 | Chlamydia pneumoniae infection promotes vascular endothelial cell angiogenesis through an IQGAP1-related signaling pathway |
Q37336070 | Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through a Toll-like receptor 2-related signaling pathway |
Q93169095 | Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration via c-Fos/interleukin-17C signaling |
Q37867366 | Chlamydia pneumoniae infection related atherosclerotic clinical variables on carotid stenosis |
Q37857039 | Chlamydia pneumoniae infection results in generalized bone loss in mice. |
Q37874834 | Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. |
Q37853142 | Chlamydia pneumoniae infection suppresses Staphylococcus enterotoxin B-induced proliferation associated with down-expression of CD25 in lymphocytes |
Q37853504 | Chlamydia pneumoniae infection was associated with risk of mortality from coronary heart disease in Japanese women but not men: the JACC Study. |
Q37353309 | Chlamydia pneumoniae infection, complement factor H variants and age-related macular degeneration |
Q37846128 | Chlamydia pneumoniae infection-associated erythema multiforme |
Q93011416 | Chlamydia pneumoniae infection-induced endoplasmic reticulum stress causes fatty acid-binding protein 4 secretion in murine adipocytes |
Q37851268 | Chlamydia pneumoniae infection-related hemophagocytic lymphohistiocytosis and acute encephalitis and poliomyelitis-like flaccid paralysis |
Q37862830 | Chlamydia pneumoniae infection: an additional factor for chronic allograft rejection |
Q43431103 | Chlamydia pneumoniae infection: an uncommon cause of rhabdomyolysis |
Q43423121 | Chlamydia pneumoniae infection: which role in atherosclerosis? |
Q37861218 | Chlamydia pneumoniae infections |
Q37862759 | Chlamydia pneumoniae infections augment atherosclerotic lesion formation: a role for serum amyloid P. |
Q37882214 | Chlamydia pneumoniae infections in Norway |
Q37895606 | Chlamydia pneumoniae infections in Norway 1981-87 earlier diagnosed as ornithosis |
Q35627745 | Chlamydia pneumoniae infections in asthma: clinical implications. |
Q36003606 | Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research |
Q37871890 | Chlamydia pneumoniae infections in patients with community-acquired pneumonia in Slovenia. |
Q37870988 | Chlamydia pneumoniae infections prevent the programmed cell death on THP-1 cell line |
Q60634822 | Chlamydia pneumoniae infections prevent the programmed cell death on THP-1 cell line |
Q37871406 | Chlamydia pneumoniae infections--diagnostic methods |
Q43434453 | Chlamydia pneumoniae infections. |
Q34009858 | Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro |
Q36108530 | Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways |
Q37872097 | Chlamydia pneumoniae inhibits apoptosis in human epithelial and monocyte cell lines |
Q37876614 | Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. |
Q43423075 | Chlamydia pneumoniae inside the atherosclerotic plaque--does it affect plaque inflammation and plaque progression? |
Q37858986 | Chlamydia pneumoniae is a likely risk factor for ischemic stroke in young patients |
Q37881308 | Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. |
Q37877800 | Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study |
Q37874645 | Chlamydia pneumoniae is associated with graft dysfunction after lung transplantation |
Q43412476 | Chlamydia pneumoniae is frequently detected in the blood after acute lung infection |
Q27314770 | Chlamydia pneumoniae is genetically diverse in animals and appears to have crossed the host barrier to humans on (at least) two occasions |
Q37862257 | Chlamydia pneumoniae is not detectable in subretinal neovascular membranes in the exudative stage of age-related macular degeneration. |
Q34007275 | Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants |
Q37877665 | Chlamydia pneumoniae may be associated with lung cancer. Preliminary report on a seroepidemiological study. |
Q43429477 | Chlamydia pneumoniae may cause respiratory distress syndrome. |
Q37847636 | Chlamydia pneumoniae modulates human monocyte-derived dendritic cells functions driving the induction of a Type 1/Type 17 inflammatory response. |
Q99730797 | Chlamydia pneumoniae mucositis syndrome |
Q37889130 | Chlamydia pneumoniae multiplies in human endothelial cells in vitro |
Q37867863 | Chlamydia pneumoniae multiply in neutrophil granulocytes and delay their spontaneous apoptosis |
Q43432236 | Chlamydia pneumoniae myocarditis |
Q37844121 | Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-Nuclear factor-kappa B and miR-33 pathways in THP-1 macrophage-derived foam cells |
Q37876682 | Chlamydia pneumoniae not detected in temporal artery biopsies from patients with temporal arteritis |
Q37860239 | Chlamydia pneumoniae occurrence in children with adenoid vegetations |
Q43423309 | Chlamydia pneumoniae pathogenesis |
Q37844025 | Chlamydia pneumoniae persistent infection is associated with primary IgA nephropathy |
Q37864218 | Chlamydia pneumoniae pneumonia |
Q37875342 | Chlamydia pneumoniae pneumonia |
Q43428182 | Chlamydia pneumoniae pneumonia |
Q37863960 | Chlamydia pneumoniae pneumonia and Mycoplasma pneumoniae pneumonia: comparison of clinical findings and CT findings |
Q37884686 | Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. |
Q37882840 | Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in bronchoalveolar lavage |
Q43430823 | Chlamydia pneumoniae pneumonia with acute hemorrhagic pericarditis in patient with acute leukemia. |
Q43432507 | Chlamydia pneumoniae pneumonia with endocarditis |
Q37894340 | Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture |
Q37878283 | Chlamydia pneumoniae pneumonia. Radiographic features in a patient with lung transplantation |
Q35892972 | Chlamydia pneumoniae pneumonia: An evolving clinical spectrum |
Q37886212 | Chlamydia pneumoniae pneumonia: role of new macrolides |
Q37876174 | Chlamydia pneumoniae present in the human synovium are viable and metabolically active. |
Q35945524 | Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells |
Q37875071 | Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte- derived macrophages |
Q37878307 | Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms |
Q37861022 | Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection |
Q35014062 | Chlamydia pneumoniae resists antibiotics in lymphocytes |
Q37872245 | Chlamydia pneumoniae respiratory infection after allogeneic stem cell transplantation |
Q37892153 | Chlamydia pneumoniae respiratory infection in a child--a case report |
Q37872121 | Chlamydia pneumoniae respiratory infections |
Q37881880 | Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. |
Q37859568 | Chlamydia pneumoniae respiratory infections in Taiwan |
Q37895602 | Chlamydia pneumoniae respiratory tract infection: the interpretation of high titres in the complement fixation test |
Q37879569 | Chlamydia pneumoniae revisited |
Q34116447 | Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression |
Q90433303 | Chlamydia pneumoniae sero-prevalence in Moroccan patients with cardiovascular diseases |
Q37876545 | Chlamydia pneumoniae serological status is not associated with asthma in children or young adults |
Q37865536 | Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. |
Q37872023 | Chlamydia pneumoniae serology is associated with thrombosis-related but not with plaque-related microembolization during carotid endarterectomy |
Q33889878 | Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. |
Q37869577 | Chlamydia pneumoniae serology: comparing a commercial enzyme immunoassay and microimmunofluorescence test in patients with cardiovascular disease |
Q33972282 | Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals |
Q37876389 | Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results |
Q127739974 | Chlamydia pneumoniae seropositivity and Carotid Atherosclerosis — A Japanese population-based study |
Q37866396 | Chlamydia pneumoniae seropositivity and cardiovascular risk factors: The InCHIANTI Study. |
Q37871330 | Chlamydia pneumoniae seropositivity and early carotid atherosclerosis in a suburban Japanese population |
Q37873964 | Chlamydia pneumoniae seropositivity and hyperhomocysteinemia are linked in patients with atherosclerosis |
Q37863266 | Chlamydia pneumoniae seropositivity and risk of developing coronary heart disease in Western Saudi Arabia |
Q37865328 | Chlamydia pneumoniae seropositivity and risk of ischemic stroke: a nested case-control study |
Q37872233 | Chlamydia pneumoniae seropositivity and systemic and renovascular atherosclerotic disease |
Q43422150 | Chlamydia pneumoniae seropositivity and the risk of NAION. |
Q37872225 | Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy |
Q37850880 | Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study |
Q35121619 | Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: A case-control study |
Q37858958 | Chlamydia pneumoniae seropositivity in aetiological subtypes of brain infarction and carotid atherosclerosis: a case control study. |
Q37867621 | Chlamydia pneumoniae seropositivity in patients with cerebral ischemic attack with or without silent brain infarcts |
Q37863523 | Chlamydia pneumoniae seropositivity in women with pre-eclampsia |
Q37876102 | Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness |
Q37871806 | Chlamydia pneumoniae seropositivity is associated with increased plasma levels of soluble cellular adhesion molecules in community-dwelling subjects: the Shimanami Health Promoting Program (J-SHIPP) study |
Q37871240 | Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty. |
Q37884226 | Chlamydia pneumoniae seroprevalence among HIV-1-infected and uninfected people with known HIV risk factor |
Q36292173 | Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan |
Q45311740 | Chlamydia pneumoniae sp. nov. for Chlamydia sp. Strain TWAR |
Q37866797 | Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release |
Q37868585 | Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. |
Q37860473 | Chlamydia pneumoniae stimulates the proliferation of HUVEC through the induction of VEGF by THP-1. |
Q37894988 | Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease |
Q37889561 | Chlamydia pneumoniae strain TWAR pharyngitis in US Air Force basic trainees. |
Q37896248 | Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population |
Q37869878 | Chlamydia pneumoniae survival in macrophages is regulated by free Ca2+ dependent reactive nitrogen and oxygen species |
Q37867634 | Chlamydia pneumoniae together with collagenase-2 (MMP-8) in periodontal lesions. |
Q37864340 | Chlamydia pneumoniae uses the mannose 6-phosphate/insulin-like growth factor 2 receptor for infection of endothelial cells |
Q43426375 | Chlamydia pneumoniae viability in atherosclerotic tissue: true or false? |
Q37871833 | Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women |
Q37865854 | Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila in elderly patients with stroke (C-PEPS, M-PEPS, L-PEPS): a case-control study on the infectious burden of atypical respiratory pathogens in elderly patients with acute cerebrov |
Q37894217 | Chlamydia pneumoniae, Strain TWAR, Infection in Patients with Chronic Obstructive Pulmonary Disease |
Q37836597 | Chlamydia pneumoniae, and mycoplasma pneumoniae: Are they related to severe asthma in childhood? |
Q43422157 | Chlamydia pneumoniae, antibiotic treatment, and early atherosclerosis |
Q37879825 | Chlamydia pneumoniae, antimicrobial therapy and coronary heart disease: a critical overview |
Q33763030 | Chlamydia pneumoniae, asthma, and COPD: what is the evidence? |
Q37869074 | Chlamydia pneumoniae, atherosclerosis, and coronary disease |
Q37869752 | Chlamydia pneumoniae, but not Bartonella quintana, is associated with coronary heart disease: results of a French case-control study |
Q43424710 | Chlamydia pneumoniae, clarithromycin, and severe asthma |
Q37882074 | Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery |
Q43418992 | Chlamydia pneumoniae, harmful only for peripheral arteries? |
Q28196475 | Chlamydia pneumoniae, heat shock proteins 60 and risk of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes: a prospective study |
Q37863872 | Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Does infection influence plaque stability? |
Q37875347 | Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study |
Q33762172 | Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease |
Q37869080 | Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). |
Q37889932 | Chlamydia pneumoniae, strain TWAR and atherosclerosis. |
Q36086894 | Chlamydia pneumoniae, strain TWAR pneumonia |
Q36473368 | Chlamydia pneumoniae, strain TWAR, as the cause of an outbreak in a boys' school previously called psittacosis |
Q37898682 | Chlamydia pneumoniae, strain TWAR. |
Q43418669 | Chlamydia pneumoniae, stroke, and serological associations: anything learned from the atherosclerosis-cardiovascular literature or do we have to start over again? |
Q37872221 | Chlamydia pneumoniae, systemic inflammation and the risk of venous thrombosis |
Q37875263 | Chlamydia pneumoniae, the Heart, and Coronary Artery Disease: Is There a Cause and Effect Relationship? |
Q33566092 | Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis |
Q37895617 | Chlamydia pneumoniae--a new important respiratory pathogen |
Q37864581 | Chlamydia pneumoniae--a new risk factor for calcific aortic stenosis? |
Q43427691 | Chlamydia pneumoniae--a pathogen with cardiovascular significance |
Q37877819 | Chlamydia pneumoniae--a suspected pathogenetic factor in coronary arteriosclerosis |
Q43424399 | Chlamydia pneumoniae--aetiologic agent of what? |
Q35701591 | Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? |
Q37872685 | Chlamydia pneumoniae--chronic infection and atherosclerosis |
Q37868708 | Chlamydia pneumoniae--etiology of ophthalmia neonatorum |
Q37860795 | Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2. |
Q37891366 | Chlamydia pneumoniae--pathogenesis and perspectives |
Q43431232 | Chlamydia pneumoniae--reactive arthritis and persistent infection |
Q43418252 | Chlamydia pneumoniae--seroprevalance among adults presenting with acute community-acquired pneumonia (CAP). |
Q37868493 | Chlamydia pneumoniae--the etiologic agent of follicular conjunctivitis followed by keratoconjunctivitis sicca in adult patients |
Q26783046 | Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis |
Q37875762 | Chlamydia pneumoniae-associated ADEM. |
Q43423018 | Chlamydia pneumoniae-atherosclerosis link: a sound concept in search for clinical relevance |
Q37063300 | Chlamydia pneumoniae-based atherosclerosis: a smoking gun. |
Q33935073 | Chlamydia pneumoniae-induced atherosclerosis in a rabbit model |
Q37887085 | Chlamydia pneumoniae-induced ciliostasis in ciliated bronchial epithelial cells |
Q37856309 | Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation |
Q33825748 | Chlamydia pneumoniae-induced memory CD4+ T-cell activation in human peripheral blood correlates with distinct antibody response patterns |
Q37413421 | Chlamydia pneumoniae-induced pathological signaling in the vasculature |
Q37877086 | Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis |
Q54963193 | Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma. |
Q37873339 | Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells |
Q37878309 | Chlamydia pneumoniae-reactive T lymphocytes in abdominal aortic aneurysms: the smoking gun? |
Q37839480 | Chlamydia pneumoniae-related hemophagocytic lymphohistiocytosis in an adult patient with clonal karyotype abnormality |
Q21090921 | Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity |
Q37880847 | Chlamydia pneumoniae-specific cell-mediated and humoral immunity in healthy people |
Q37891247 | Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease |
Q43425868 | Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis |
Q37853820 | Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. |
Q37858226 | Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis. |
Q55519882 | Chlamydia pneumoniae. |
Q43431376 | Chlamydia pneumoniae. New diagnostic tools for detection of a common pathogen |
Q73680456 | Chlamydia pneumoniae. Proceedings of a meeting. Gavle, Sweden, 9-10 November 1995 |
Q37883021 | Chlamydia pneumoniae: a new opportunistic infectious agent in AIDS? |
Q37879668 | Chlamydia pneumoniae: an agent involved in the pathogenesis of asthma |
Q37872915 | Chlamydia pneumoniae: an cause of reactive arthritis? |
Q37876610 | Chlamydia pneumoniae: an etiologic of coronary heart disease? |
Q43422370 | Chlamydia pneumoniae: another agent added to the growing list of transfusion-transmitted pathogens? |
Q43429160 | Chlamydia pneumoniae: association with asthma and cardiovascular disease. Therapeutic interventions |
Q43429866 | Chlamydia pneumoniae: can it cause atherosclerosis? |
Q37891331 | Chlamydia pneumoniae: clinical, epidemiological and laboratory aspects |
Q36320102 | Chlamydia pneumoniae: comparison with findings of Mycoplasma pneumoniae and Streptococcus pneumoniae at thin-section CT. |
Q43421089 | Chlamydia pneumoniae: crossing the barriers? |
Q33821294 | Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis |
Q37879482 | Chlamydia pneumoniae: inflammation and instability of the atherosclerotic plaque |
Q37847505 | Chlamydia pneumoniae: modern insights into an ancient pathogen. |
Q43409261 | Chlamydia pneumoniae: possible association with asthma in children |
Q37892016 | Chlamydia pneumoniae: possibly, the third cause of epidemic bacterial pneumopathies? |
Q37882848 | Chlamydia psittaci and Chlamydia pneumoniae infection in Caceres |
Q64888348 | Chlamydia trachomatis and Chlamydia pneumoniae Interaction with the Host: Latest Advances and Future Prospective. |
Q37895235 | Chlamydia trachomatis and Chlamydia pneumoniae bind specifically to phosphatidylethanolamine in HeLa cells and to GalNAc beta 1-4Gal beta 1-4GLC sequences-found in asialo-GM1 and asial-GM2. |
Q35644776 | Chlamydia trachomatis and Chlamydia pneumoniae infections in children and adolescents |
Q37861545 | Chlamydial heat-shock protein 60 : A marker for chronic infection with Chlamydia Pneumoniae in atherosclerosis: Investigation of atherosclerotic coronary arteries by immunocytochemistry |
Q37870954 | Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques |
Q37870991 | Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice |
Q37835017 | Cholesterol uptake in the mouse aorta increases during Chlamydia pneumoniae infection |
Q33555801 | Choroidal neovascularization enhanced by Chlamydia pneumoniae via Toll-like receptor 2 in the retinal pigment epithelium |
Q37867792 | Chronic Chlamydia pneumonia--complications |
Q37893723 | Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study |
Q37881200 | Chronic Chlamydia pneumoniae infection and asthma exacerbations in children |
Q37856331 | Chronic Chlamydia pneumoniae infection and bronchial asthma: is there a link? |
Q37862941 | Chronic Chlamydia pneumoniae infection and stroke in Cameroon: a case-control study |
Q37875613 | Chronic Chlamydia pneumoniae infection in patients with asthma |
Q37870867 | Chronic Chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values |
Q37863343 | Chronic Chlamydia pneumoniae infection in patients with symptomatic atherothrombosis |
Q37868896 | Chronic Chlamydia pneumoniae infection increases the risk of occlusion of lumbar segmental arteries of patients with sciatica: a 3-year follow-up study |
Q37865636 | Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. |
Q37881850 | Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis |
Q37861245 | Chronic Chlamydia pneumoniae infection may promote coronary artery disease in humans through enhancing secretion of interleukin-4. |
Q33873239 | Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome |
Q43406867 | Chronic Chlamydia pneumoniae lung infection: a neglected explanation for macrolide effects in wheezing and asthma? |
Q43406869 | Chronic Chlamydia pneumoniae lung infection: a neglected explanation for macrolide effects in wheezing and asthma? - Authors' reply |
Q37880791 | Chronic follicular conjunctivitis associated with Chlamydia psittaci or Chlamydia pneumoniae |
Q33596962 | Chronic infection in the aetiology of atherosclerosis--focus on Chlamydia pneumoniae |
Q37882065 | Chronic infection in the etiology of atherosclerosis--the case for Chlamydia pneumoniae |
Q35371043 | Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease |
Q37862624 | Chronic peripheral arteriopathy is associated with seropositivity to Chlamydia pneumoniae |
Q101326897 | Chronic wasting associated with Chlamydia pneumoniae in three ex situ breeding facilities for tropical frogs |
Q37861299 | Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease |
Q37877457 | Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease |
Q33971224 | Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography |
Q37864193 | Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice |
Q37887448 | Clinical aspects of Chlamydia pneumoniae infection |
Q37877825 | Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia |
Q37873945 | Clinical comparison of Chlamydia pneumoniae pneumonia, ornithosis, and Mycoplasma pneumoniae pneumonia |
Q37885334 | Clinical features of Chlamydia pneumoniae acute respiratory infection |
Q37885757 | Clinical manifestations of Chlamydia pneumoniae infections |
Q43431997 | Clinical manifestations of Chlamydia pneumoniae infections |
Q37871612 | Clinical manifestations of atherosclerosis in an elderly population are related to plasma neopterin, NGAL and endothelin-1, but not to Chlamydia pneumoniae serology. |
Q36512610 | Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia |
Q37871776 | Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults |
Q37875119 | Clinical relevance of Chlamydia pneumoniae infection--from the respiratory tract to the vascular system |
Q64055332 | Clinical study of chlamydia pneumoniae infection in patients with coronary heart disease |
Q37874312 | Clinical study on acute respiratory infection caused by chlamydia pneumoniae |
Q37874526 | Cloning and characterization of adenylate kinase from Chlamydia pneumoniae |
Q37867510 | Cloning, expression, and characterization of uracil-DNA glycosylase of Chlamydia pneumoniae in Escherichia coli |
Q37864622 | Close association of Chlamydia pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patients |
Q37869204 | Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice |
Q37870157 | Coinfection of laboratory rats with Mycoplasma pulmonis and Chlamydia pneumoniae |
Q37868829 | Coinfection with Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured plaques associated with acute myocardial infarction |
Q37876359 | Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae |
Q37876325 | Collaborative multidisciplinary workshop report: progress toward a Chlamydia pneumoniae vaccine |
Q37876386 | Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases |
Q37876339 | Collaborative multidisciplinary workshop report: what questions regarding the role of Chlamydia pneumoniae in atherosclerosis and cardiovascular disease need to be addressed utilizing animal models? |
Q99607562 | Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China |
Q37870081 | Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina |
Q37878386 | Commentary: Chlamydia pneumoniae infection and ischaemic heart disease |
Q43421679 | Comments on the Failure to Detect Chlamydia pneumoniae in Atherosclerosis |
Q37895663 | Community acquired pneumonia caused by Chlamydia pneumoniae strain TWAR in chronic cardiopulmonary disease in the elderly |
Q42423990 | Community-acquired Chlamydia pneumoniae pneumonia |
Q37870563 | Community-acquired Chlamydia pneumoniae pneumonia in Japan: a prospective multicenter community-acquired pneumonia study. |
Q43427473 | Community-acquired chlamydia pneumoniae pneumonia |
Q43423078 | Community-acquired pneumonia, acute respiratory distress syndrome, and severe sepsis due to Chlamydia pneumoniae |
Q37869639 | Comparative Studies of Glycosaminoglycan Involvement inChlamydia pneumoniaeandC. trachomatisInvasion of Host Cells |
Q36202987 | Comparative analysis of the growth and biological activity of a respiratory and atheroma isolate of Chlamydia pneumoniae reveals strain-dependent differences in inflammatory activity and innate immune evasion. |
Q22122313 | Comparative genomes of Chlamydia pneumoniae and C. trachomatis |
Q37838935 | Comparative genomic analysis of human Chlamydia pneumoniae isolates from respiratory, brain and cardiac tissues |
Q37866691 | Comparative study of community-acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae |
Q87821794 | Comparative study of the effects of acepromazine and structurally related compounds on the TNF-a release by monocytes stimulated by Chlamydia pneumoniae |
Q34174788 | Comparative study of the presence of Chlamydia pneumoniae in cerebrospinal fluid of Patients with clinically definite and monosymptomatic multiple sclerosis |
Q43414282 | Comparative study of the seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae infection in the course of chronic asthma in children |
Q37095262 | Comparison of Chlamydia pneumoniae isolates by western blot (immunoblot) analysis and DNA sequencing of the omp 2 gene. |
Q22066146 | Comparison of Outer Membrane Protein Genes omp and pmp in the Whole Genome Sequences of Chlamydia pneumoniae Isolates from Japan and the United States |
Q37879026 | Comparison of PCR protocols including positive controls for detection of Chlamydia pneumoniae in respiratory specimens |
Q128494403 | Comparison of Th1 and Th2 Immune Responses in Chlamydia pneumoniae-infected Peripheral Blood Mononuclear Cells (PBMC) of Adult and Pediatric Asthmatics |
Q37874634 | Comparison of a new commercial EIA kit and the microimmunofluorescence technique for the determination of IgG and IgA antibodies to Chlamydia pneumoniae |
Q34752011 | Comparison of a new quantitative ompA-based real-Time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays |
Q37871676 | Comparison of an industry-derived LCx Chlamydia pneumoniae PCR research kit to in-house assays performed in five laboratories |
Q37875671 | Comparison of anesthetics for inoculation of mice with Chlamydia pneumoniae |
Q37867281 | Comparison of clinical presentation of mixed pneumonia with Chlamydia pneumoniae and Streptococcus pneumoniae and S. pneumoniae pneumonia |
Q37850352 | Comparison of echocardiographic findings in AVS patients with and without high IgG, IgM, IgA titers against Chlamydia pneumoniae during 12 months' observation of AVS natural course |
Q34203352 | Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals |
Q33998580 | Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae |
Q37870838 | Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome |
Q33636893 | Comparison of koala LPCoLN and human strains of Chlamydia pneumoniae highlights extended genetic diversity in the species |
Q37883766 | Comparison of nasopharyngeal and throat swabs for the detection of Chlamydia pneumoniae and Mycoplasma pneumoniae by polymerase chain reaction |
Q37857956 | Comparison of polymerase chain reaction methods, in situ hybridization, and enzyme immunoassay for detection of Chlamydia pneumoniae in atherosclerotic carotid plaques. |
Q37888291 | Comparison of sample preparation methods for detection of Chlamydia pneumoniae in bronchoalveolar lavage fluid by PCR. |
Q37892730 | Comparison of sensitivity of Hep-2 cells with that of HL cells against Chlamydia pneumoniae |
Q37890053 | Comparison of serological tests for the detection of antibodies against Chlamydia trachomatis and Chlamydia pneumoniae in rheumatological patients. |
Q30327855 | Comparison of the morphology and the reactivity of Chlamydia pneumoniae isolated in north-Kanto Area, Ibaraki Prefecture, Japan |
Q37880640 | Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence |
Q33999140 | Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae |
Q37871437 | Comparison of two microimmunofluorescence tests for detecting antibodies to Chlamydia pneumoniae |
Q37879644 | Comparison of two serological methods and a polymerase chain reaction-enzyme immunoassay for the diagnosis of acute respiratory infections with Chlamydia pneumoniae in adults |
Q37876203 | Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. |
Q36860941 | Complement factor H gene polymorphisms and Chlamydia pneumoniae infection in age-related macular degeneration |
Q37877343 | Computational analysis of the polymorphic membrane protein superfamily of Chlamydia trachomatis and Chlamydia pneumoniae |
Q37880332 | Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis |
Q37848664 | Conformation study of 2-arylbenzimidazoles as inhibitors of Chlamydia pneumoniae growth. |
Q21266688 | Construction of a highly flexible and comprehensive gene collection representing the ORFeome of the human pathogen Chlamydia pneumoniae |
Q37880308 | Construction of an internal control for the detection of Chlamydia pneumoniae by PCR. |
Q37885820 | Continuous isolation and characterization of Chlamydia pneumoniae from a patient with diffuse panbronchiolitis |
Q37849862 | Corn mint (Mentha arvensis) extract diminishes acute Chlamydia pneumoniae infection in vitro and in vivo |
Q33974569 | Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies |
Q74181267 | Coronary heart disease - any likelihood of benefit from the control of Chlamydia pneumoniae? |
Q43426679 | Coronary heart disease and Chlamydia pneumoniae DNA in blood mononuclear cells |
Q37877554 | Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies |
Q94301961 | Correction: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors |
Q60553100 | Correction: Immunization of Chlamydia pneumoniae (Cpn)-Infected Apobtm2SgyLdlrtm1Her/J Mice with a Combined Peptide of Cpn Significantly Reduces Atherosclerotic Lesion Development |
Q43418432 | Correlation between Chlamydia pneumoniae detection from coronary angioplasty balloons and atherosclerosis severity |
Q37847334 | Correlation between Chlamydia pneumoniae infection and chronic obstructive pulmonary disease |
Q37851331 | Correlation between chlamydia pneumoniae IgG positive in lung cancer patients and cytokines related to radiation-induced pulmonary lesion |
Q37874278 | Correlation between detection methods of Chlamydia pneumoniae in atherosclerotic and non-atherosclerotic tissues |
Q37857827 | Correlation between rises in Chlamydia pneumoniae-specific antibodies, platelet activation and lipid peroxidation after percutaneous coronary intervention. |
Q35851191 | Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis |
Q37872297 | Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation |
Q37858820 | Correlation of hyperhomocysteinaemia and Chlamydia pneumoniae IgG seropositivity with coronary artery disease in a general population. |
Q57160270 | Corrigendum to “Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8(+) T cell epitopes recognized by infection-primed T cells” [Vaccine 23 (2005) 5028–5037] |
Q33157589 | Cough syncope caused by a possible Chlamydia pneumoniae pneumonia |
Q37846901 | Could past Chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain? |
Q37898201 | Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981-1983. |
Q37866801 | Cox-2 inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression |
Q37855450 | Cultivation and laboratory maintenance of Chlamydia pneumoniae |
Q37869305 | Culture and immunohistochemical evidence of Chlamydia pneumoniae infection in ulcerative pyoderma gangrenosum |
Q37894592 | Culture-confirmed pneumonia due to Chlamydia pneumoniae |
Q34945146 | Culture-negative endocarditis due to Chlamydia pneumoniae. |
Q37897113 | Culture-negative endocarditis probably due to Chlamydia pneumoniae |
Q32085737 | Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile |
Q43429360 | Current knowledge of Chlamydia pneumoniae and atherosclerosis |
Q37898698 | Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases |
Q37889873 | Current topics of chlamydial respiratory tract infections--special reference to the epidemiology and clinical findings of Chlamydia pneumoniae infections in Japan. |
Q37870502 | Cutaneous vasculitis and reactive arthritis following respiratory infection due to Chlamydia pneumoniae: report of a case. |
Q37864893 | Cytokine response of lymphocytes persistently infected with Chlamydia pneumoniae |
Q128661841 | Cytokine responses in Chlamydia pneumoniae-stimulated PBMC in asthmatic and non-asthmatic subjects. |
Q37866364 | Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention. |
Q35378284 | Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study |
Q37866631 | DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. |
Q37877605 | De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. |
Q37875816 | Decontamination of a Mycoplasma-infected Chlamydia pneumoniae strain by pulmonary passage in SCID mice |
Q33916075 | Decreased expression of liver X receptor-α in macrophages infected with Chlamydia pneumoniae in human atherosclerotic arteries in situ. |
Q33946655 | Degradation of Chlamydia pneumoniae by peripheral blood monocytic cells |
Q37864162 | Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice |
Q37873684 | Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions |
Q37891287 | Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries |
Q37879184 | Demonstration of Chlamydia pneumoniae in cardiovascular tissues from children with Kawasaki disease |
Q37883633 | Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis |
Q37874705 | Demonstration of Chlamydia pneumoniae in the adenoid from children with and without secretory otitis media using immunohistochemistry and PCR. |
Q37883353 | Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms |
Q37877662 | Demonstration of Chlamydia pneumoniae in tissue by immunohistochemistry. |
Q43435469 | Demonstration of Chlamydia pneumoniae in water used for gargling |
Q74006063 | Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease |
Q37865917 | Demonstration of intracellular microorganisms (Rickettsia spp., Chlamydia pneumoniae, Bartonella spp.) in pathological human aortic valves by PCR. |
Q37878157 | Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. |
Q37846612 | Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae |
Q37864721 | Density of Chlamydia pneumoniae is increased in fibrotic and calcified areas of degenerative aortic stenosis |
Q37877956 | Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice |
Q34042489 | Depletion of resident Chlamydia pneumoniae through leukoreduction by filtration of blood for transfusion |
Q37862124 | Description of immunogens of Chlamydia pneumoniae recognized by serum of individuals with peripheral artery disease |
Q37852214 | Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae |
Q33762202 | Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis |
Q37866780 | Detailed protocol for purification of Chlamydia pneumoniae elementary bodies |
Q37896004 | Detection and differentiation of Chlamydia trachomatis, Chlamydia psittaci, and Chlamydia pneumoniae by DNA amplification |
Q37214056 | Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications |
Q43435779 | Detection of Chlamydia pneumoniae |
Q68295810 | Detection of Chlamydia pneumoniae |
Q37869499 | Detection of Chlamydia pneumoniae -Specific Antibodies Binding to the VD2 and VD3 Regions of the Major Outer Membrane Protein |
Q34004325 | Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas |
Q37875345 | Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease |
Q37878712 | Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction |
Q37874394 | Detection of Chlamydia pneumoniae DNA in buffy-coat samples of patients with abdominal aortic aneurysm |
Q43420141 | Detection of Chlamydia pneumoniae DNA in the coronary arteries and bypass in three patients with diffuse coronary artery disease. |
Q37886690 | Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. |
Q37891239 | Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. |
Q33970537 | Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR |
Q37863878 | Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction |
Q37873461 | Detection of Chlamydia pneumoniae antigenin PBMNCs of healthy blood donors |
Q36541516 | Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms |
Q37879001 | Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts |
Q33186908 | Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. |
Q37878481 | Detection of Chlamydia pneumoniae by colorimetric in situ hybridization |
Q37891328 | Detection of Chlamydia pneumoniae by polymerase chain reaction |
Q37893831 | Detection of Chlamydia pneumoniae by polymerase chain reaction |
Q37890224 | Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in an immunocompromised population |
Q37871476 | Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls |
Q37871627 | Detection of Chlamydia pneumoniae deoxyribonucleic acid in blood samples taken from coronary sinus after coronary angioplasty |
Q35915792 | Detection of Chlamydia pneumoniae in a bilateral orbital mucosa-associated lymphoid tissue lymphoma |
Q37840356 | Detection of Chlamydia pneumoniae in a collection of captive snakes and response to treatment with marbofloxacin. |
Q37890285 | Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain |
Q37876382 | Detection of Chlamydia pneumoniae in arterial tissues |
Q43431324 | Detection of Chlamydia pneumoniae in atheroma specimens |
Q37866352 | Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries |
Q37882562 | Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction |
Q37854947 | Detection of Chlamydia pneumoniae in atherosclerotic plaques of patients in Tehran, Iran |
Q37863148 | Detection of Chlamydia pneumoniae in atherosclerotic tissue: a comparative study of PCR and immunocytochemistry |
Q37869219 | Detection of Chlamydia pneumoniae in cholesteatoma tissue: any pathogenetic role? |
Q37888492 | Detection of Chlamydia pneumoniae in clinical specimens by polymerase chain reaction using nested primers |
Q37892518 | Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques |
Q37876046 | Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells |
Q37863062 | Detection of Chlamydia pneumoniae in human aortic tissue: kdtA gene amplification and in vitro hybridization |
Q37883146 | Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves |
Q37889751 | Detection of Chlamydia pneumoniae in intrathoracic abscesses--a case report |
Q37866807 | Detection of Chlamydia pneumoniae in liver transplant patients with chronic allograft rejection. |
Q43418116 | Detection of Chlamydia pneumoniae in patients with peripheral arterial occlusive disease: relationship between infection and disease |
Q37853209 | Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors in Tehran Regional Educational Blood Transfusion Centre. |
Q37869679 | Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: correlation with inflammation and atherosclerosis in haemodialysis patients |
Q37868453 | Detection of Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis by combination of cell culture and PCR: no evidence for possible association |
Q37872587 | Detection of Chlamydia pneumoniae in unexplained pulmonary hypertension |
Q37236613 | Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysema |
Q37876368 | Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction |
Q37876734 | Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery |
Q37855608 | Detection of Chlamydophila pneumoniae (Chlamydia pneumoniae) in endarteroctomy specimens of coronary heart diseases patients. |
Q37864308 | Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation |
Q35662608 | Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma |
Q37892279 | Detection of IgM antibodies to Chlamydia trachomatis, Chlamydia pneumoniae, and Chlamydia psittaci from Japanese infants and children with pneumonia |
Q37875757 | Detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured atherosclerotic plaques. |
Q37851205 | Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay |
Q36087554 | Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection |
Q37886835 | Detection of anti-Chlamydia pneumoniae IgE in children with reactive airway disease |
Q34638664 | Detection of bacterial antigens and Alzheimer's disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae |
Q37865796 | Detection of cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction. |
Q37865729 | Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas. |
Q37867323 | Detection of serum Chlamydia pneumoniae (Cpn) immune complex and Cpn antibody in patients with coronary heart disease. |
Q30826314 | Detection of serum Chlamydia pneumoniae antibodies and analysis of epidemiologic data in 5 years |
Q37884878 | Detection of serum antibodies against Chlamydia pneumoniae by ELISA. |
Q37884866 | Detection of serum antibodies against Chlamydia pneumoniae by in vitro neutralization and microimmunofluorescence assays. |
Q37881977 | Detection of serum antibodies to Chlamydia pneumoniae in patients with endogenous uveitis and acute conjunctivitis |
Q40048610 | Detection of specific Chlamydia pneumoniae and cytomegalovirus antigens in human carotid atherosclerotic plaque in a Chinese population |
Q37876171 | Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms |
Q37877979 | Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children |
Q24798213 | Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae |
Q34946766 | Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae |
Q50124300 | Development of a multiplex TaqMan real-time PCR assay for the detection of Chlamydia psittaci and Chlamydia pneumoniae in human clinical specimens |
Q36269709 | Development of a multiplex real-time PCR assay for detection of Mycoplasma pneumoniae, Chlamydia pneumoniae and mutations associated with macrolide resistance in Mycoplasma pneumoniae from respiratory clinical specimens |
Q37870019 | Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions |
Q37885185 | Development of a simplified polymerase chain reaction-enzyme immunoassay for the detection of Chlamydia pneumoniae |
Q37893420 | Development of an enzyme immunoassay to detect antibody to Chlamydia pneumoniae strain twar and its application in a limited seroepidemiological survey |
Q37862482 | Development of diabetes in non-obese diabetic mice promotes Chlamydia pneumoniae dissemination from lung to peripheral blood |
Q37873371 | Development of enzyme immunoassays to detect salivary sIgA to Chlamydia pneumoniae and Mycoplasma pneumoniae |
Q43425311 | Diabetic foot ulcers and Chlamydia pneumoniae: innocent bystander or opportunistic pathogen? |
Q37881628 | Diagnosis and therapy of Chlamydia pneumoniae and trachomatis |
Q37875971 | Diagnosis of Chlamydia pneumoniae in community-acquired pneumonia in children in Chile |
Q37881958 | Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA. |
Q37888724 | Diagnosis of Chlamydia pneumoniae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay |
Q37872480 | Diagnosis of Chlamydia pneumoniae. |
Q37885769 | Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen |
Q37899046 | Diagnosis of infection caused by Chlamydia pneumoniae (strain TWAR) in patients with "ornithosis" in southern Sweden 1981-1987. |
Q37879274 | Diagnosis of infections with difficulty in isolation and identification of causative organisms. 2) Chlamydia pneumoniae infection |
Q37875910 | Diagnostic procedures in Chlamydia pneumoniae infections |
Q37074513 | Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients |
Q37862421 | Diagnostic value of an ELISA using a recombinant 54-kDa species-specific protein from Chlamydia pneumoniae |
Q37840798 | Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis |
Q37885504 | Differences in the envelope proteins of Chlamydia pneumoniae, Chlamydia trachomatis, and Chlamydia psittaci shown by two-dimensional gel electrophoresis |
Q35261754 | Different presence of Chlamydia pneumoniae, herpes simplex virus type 1, human herpes virus 6, and Toxoplasma gondii in schizophrenia: meta-analysis and analytical study. |
Q37860452 | Differential effects of Chlamydia pneumoniae infection on cytokine levels in human T lymphocyte- and monocyte-derived cell cultures |
Q37873314 | Differential expression of Pmp10 in cell culture infected with Chlamydia pneumoniae CWL029. |
Q37869973 | Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections |
Q37874069 | Differential expression of ompA, ompB, pyk, nlpD and Cpn0585 genes between normal and interferon-gamma treated cultures of Chlamydia pneumoniae |
Q37862553 | Differential involvement of TLR2 and TLR4 in host survival during pulmonary infection with Chlamydia pneumoniae |
Q37855048 | Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for Chlamydia pneumoniae. |
Q35381304 | Dilated cardiomyopathy and Chlamydia pneumoniae infection |
Q37864937 | Discordant detection of Chlamydia pneumoniae in patients with carotid artery disease using polymerase chain reaction, immunofluorescence microscopy and serological methods |
Q37860486 | Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. |
Q37860435 | Disparate innate immune responses to persistent and acute Chlamydia pneumoniae infection in chronic obstructive pulmonary disease |
Q35169118 | Dissemination of Chlamydia pneumoniae to the vessel wall in atherosclerosis |
Q37835990 | Distribution characteristics of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in hospitalized children with acute respiratory tract infection: an analysis of 13 198 cases |
Q37869629 | Distribution of Chlamydia pneumoniae DNA in atherosclerotic carotid arteries: significance for sampling procedures |
Q37874544 | Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual |
Q37881215 | Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery |
Q37852650 | Divergent modulation of Chlamydia pneumoniae infection cycle in human monocytic and endothelial cells by iron, tryptophan availability and interferon gamma |
Q33733197 | Does Chlamydia pneumoniae cause atherosclerosis? |
Q43430155 | Does Chlamydia pneumoniae cause coronary atherosclerosis and should we all take macrolides? |
Q37861249 | Does Chlamydia pneumoniae cause coronary heart disease? |
Q34684124 | Does Chlamydia pneumoniae have a role in atherosclerosis? |
Q37854041 | Does Chlamydia pneumoniae infection trigger to development of asthma in wheezy infants? |
Q43427591 | Does Chlamydia pneumoniae play a role in the pathogenesis of multiple sclerosis? |
Q37870567 | Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes |
Q37871004 | Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans? |
Q43428230 | Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? |
Q43411846 | Does respiratory infection due to Chlamydia pneumoniae still exist? |
Q37884141 | Double infection of Chlamydia pneumoniae and Mycoplasma pneumoniae in children |
Q52609199 | Doxycycline suppresses Chlamydia pneumoniae induced interferon-gamma responses in peripheral blood mononuclear cells in children with allergic asthma. |
Q37846414 | Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma |
Q37844989 | Draft Genome and Plasmid Sequences of Chlamydia pneumoniae Strain B21 from an Australian Endangered Marsupial, the Western Barred Bandicoot |
Q37848290 | Dual-color bioluminescent assay using infected HepG2 cells sheds new light on Chlamydia pneumoniae and human cytomegalovirus effects on human cholesterol 7α-hydroxylase (CYP7A1) transcription |
Q82861062 | EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture |
Q37869614 | Early atherosclerosis and Chlamydia pneumoniae infection in the coronary arteries |
Q37848734 | Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae. |
Q43420636 | Early carotid atherosclerosis and Chlamydia pneumoniae seropositivity: are there arguments to treat with antibiotics? |
Q37863965 | Early detection and successful therapy of fulminant chlamydia pneumoniae myocarditis |
Q37871079 | Early impairment of coronary flow reserve is not associated with Chlamydia pneumoniae antibodies |
Q33935504 | Ectasia and severe atherosclerosis: relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers |
Q37852394 | Ectopic lymphoid tissue formation in the lungs of mice infected with Chlamydia pneumoniae is associated with epithelial macrophage inflammatory protein-2/CXCL2 expression. |
Q37865245 | Effect of Chlamydia pneumoniae infection and hyperlipidaemia on the expression of PPARgamma, P50 and c-Fos in aortic endothelial cells in C57bL/6J mice |
Q37871803 | Effect of Chlamydia pneumoniae infection on carotid atherosclerosis development |
Q37872753 | Effect of Chlamydia pneumoniae infection on coronary flow reserve and intimal hyperplasia after stent implantation in patients with angina pectoris. |
Q33883493 | Effect of Chlamydia pneumoniae on cellular ATP content in mouse macrophages: role of Toll-like receptor 2 |
Q33965613 | Effect of a Mycoplasma hominis-like Mycoplasma on the infection of HEp-2 cells by the TW-183 strain of Chlamydia pneumoniae |
Q37870659 | Effect of acute Chlamydia pneumoniae infection on lipoprotein metabolism in NIH/S mice |
Q36136797 | Effect of age and vaccination on extent and spread of Chlamydia pneumoniae infection in C57BL/6 mice |
Q128451092 | Effect of azithromycin on Chlamydia pneumoniae –mediated Interleukin-4 responses |
Q43423134 | Effect of azithromycin on endothelial function of patients with coronary artery disease and evidence of Chlamydia pneumoniae infection |
Q31713580 | Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae |
Q33979917 | Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice |
Q33976999 | Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis |
Q37872325 | Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection |
Q33752851 | Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial |
Q37873349 | Effect of extended pre-incubation with chlamydia pneumoniae and extended incubation with antimicrobial on the minimum inhibitory concentrations (MICs) of five antimicrobials |
Q43424209 | Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease |
Q37871972 | Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model |
Q36539263 | Effect of hydrocortisone succinate on growth of Chlamydia pneumoniae in vitro. |
Q37866076 | Effect of levofloxacin on the viability of intracellular Chlamydia pneumoniae and modulation of proinflammatory cytokine production by human monocytes |
Q37871907 | Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha |
Q43417045 | Effect of pravastatin treatment on Chlamydia pneumoniae infection, inflammation and serum lipids in NIH/S mice |
Q37875878 | Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction |
Q37872800 | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model |
Q43422848 | Effect of roxithromycin treatment on the endothelial function of Chlamydia pneumoniae seropositive men suffering from peripheral arterial occlusive disease |
Q37869882 | Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function. |
Q33935447 | Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice |
Q37863336 | Effect of therapy with antibiotics on lipid metabolism and antioxidant reserve of patients with ischemic heart disease during Chlamydia pneumoniae infection |
Q37871321 | Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). |
Q37859967 | Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection |
Q37869486 | Effective macrophage redox defense against Chlamydia pneumoniae depends on L-type Ca2+ channel activation |
Q37854835 | Effects of CD14, TLR2, TLR4, LPB, and IL-6 gene polymorphisms on Chlamydia pneumoniae growth in human macrophages in vitro. |
Q37866034 | Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1). |
Q37003254 | Effects of Murine Norovirus on Chlamydia pneumoniae-Accelerated Atherosclerosis in ApoE(-/-) Mice |
Q37859155 | Effects of bradykinin on aortic endothelial function in apoe-knockout mice with chronic Chlamydia pneumoniae infection |
Q37850156 | Effects of coadministration of natural polyphenols with doxycycline or calcium modulators on acute Chlamydia pneumoniae infection in vitro |
Q37864916 | Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells |
Q40968088 | Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells |
Q37873559 | Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection |
Q34033240 | Effects of repeated Chlamydia pneumoniae inoculations on aortic lipid accumulation and inflammatory response in C57BL/6J mice |
Q35110637 | Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis |
Q37857886 | Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection |
Q37122830 | Efficient culture of Chlamydia pneumoniae with cell lines derived from the human respiratory tract |
Q43428517 | Electron microscopy, Chlamydia pneumoniae and atherosclerosis |
Q37882420 | Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction |
Q37867424 | Elevated antibody levels against Chlamydia pneumoniae, human HSP60 and mycobacterial HSP65 are independent risk factors in myocardial infarction and ischaemic heart disease |
Q37872599 | Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity |
Q37859197 | Elevated levels of anti-Chlamydia pneumoniae IgA and IgG antibodies in young adults with ischemic stroke. |
Q37853592 | Elevated serum immunoglobulin G titers against Chlamydia pneumoniae in primary open-angle glaucoma patients without systemic disease |
Q37866956 | Elicitation of reactive oxygen species in Chlamydia pneumoniae-stimulated macrophages: a Ca2+-dependent process involving simultaneous activation of NADPH oxidase and cytochrome oxidase genes |
Q34548131 | Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections |
Q37873974 | Encephalitis associated with Chlamydia pneumoniae |
Q37895599 | Endemic prevalence of Chlamydia pneumoniae in subjectively healthy persons |
Q37867025 | Endothelial Chlamydia pneumoniae infection promotes oxidation of LDL. |
Q37878782 | Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis |
Q37875799 | Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice |
Q37861805 | Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae |
Q37879484 | Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease |
Q37882356 | Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis |
Q37881317 | Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease |
Q37874654 | Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity |
Q43421757 | Enigmatic relationship between Chlamydia pneumoniae and atherosclerosis |
Q30940528 | Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR) |
Q37883750 | Epidemic patterns and carriage of Chlamydia pneumoniae in Norway |
Q33935008 | Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more |
Q37879440 | Epidemiologic study of Chlamydia pneumoniae with ELISA |
Q34283855 | Epidemiological and clinical aspects on infections due to Chlamydia pneumoniae (strain TWAR). |
Q33762140 | Epidemiology of Chlamydia pneumoniae in atherosclerosis |
Q37878762 | Epidemiology of Chlamydia pneumoniae infection in a randomly selected population in a developed country |
Q37872484 | Epidemiology of Chlamydia pneumoniae. |
Q37882014 | Epidemiology of acute lower respiratory tract infections in adults. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae |
Q37858302 | Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand |
Q37836131 | Epigallocatechin gallate suppresses Chlamydia pneumoniae mediated IgE responses in peripheral blood mononuclear cells: a pilot study |
Q37873105 | Epithelial cells infected with Chlamydophila pneumoniae (Chlamydia pneumoniae) are resistant to apoptosis. |
Q43423428 | Eradication of Chlamydia pneumoniae from coronary artery endothelium |
Q57446268 | Erratum - The Progression of Lower Limb Atherosclerosis is Associated with IgA-antibodies Against Chlamydia pneumoniae |
Q94083531 | Erratum: The epidemic cycle of Chlamydia pneumoniae infection in eastern Finland, 1972-1987 |
Q37860685 | Erythema multiforme majus and Chlamydia pneumoniae infection |
Q37895103 | Erythema nodosum in Chlamydia pneumoniae infection |
Q37899042 | Erythema nodosum--a manifestation of Chlamydia pneumoniae (strain TWAR) infection |
Q43423125 | Essential hypertension is associated with Chlamydia pneumoniae but not Epstein-Barr antibodies |
Q37872883 | Establishment and experimental study on mouse model of Chlamydia pneumoniae pneumonitis |
Q98186306 | Etiological analysis of virus, mycoplasma pneumoniae and chlamydia pneumoniae in hospitalized children with acute respiratory infections in Huzhou |
Q37860365 | Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia |
Q37883374 | Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection |
Q33999796 | Evaluation of Chlamydia pneumoniae 43- and 53-kilodalton recombinant proteins for serodiagnosis by Western Blot |
Q34943465 | Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. |
Q33676311 | Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections |
Q37876797 | Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci |
Q37885489 | Evaluation of a direct fluorescent antibody assay for detection of Chlamydia pneumoniae |
Q37882001 | Evaluation of a new commercial microimmunofluorescence test for detection of antibodies to Chlamydia pneumoniae, Chlamydia trachomatis, and Chlamydia psittaci |
Q37862533 | Evaluation of association between an acute attack of childhood bronchial asthma and Chlamydia pneumoniae infection |
Q37887477 | Evaluation of culture conditions used for isolation of Chlamydia pneumoniae |
Q37856450 | Evaluation of direct immunofluorescence test for diagnosis of upper respiratory tract infection by Chlamydia pneumoniae. |
Q24802120 | Evaluation of five DNA extraction methods for purification of DNA from atherosclerotic tissue and estimation of prevalence of Chlamydia pneumoniae in tissue from a Danish population undergoing vascular repair |
Q37873927 | Evaluation of real-time quantitative PCR for identification and quantification of Chlamydia pneumoniae by comparison with immunohistochemistry |
Q37890204 | Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland |
Q37853995 | Evaluation of the combination of the NucliSENS easyMAG and the EasyQ applications for the detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in respiratory tract specimens |
Q37881546 | Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma |
Q37890100 | Evidence for Chlamydia pneumoniae of non-human origin |
Q37876593 | Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis |
Q37858639 | Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas |
Q37878198 | Evidence of 2 waves of Chlamydia pneumoniae infection in Gävle, Sweden, 1990-96. |
Q43430224 | Evidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease |
Q37869154 | Evidence of an association between Chlamydia pneumoniae and cerebrovascular accidents |
Q37866634 | Evidence of chronic Chlamydia pneumoniae infection in patients with Behçet's disease |
Q37881023 | Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse |
Q37873002 | Evidence that Chlamydia pneumoniae affects platelet activity in patients with acute myocardial infarction and ST-segment elevations. |
Q37890130 | Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis |
Q37897937 | Evidence that Chlamydia pneumoniae, strain TWAR, is not sexually transmitted |
Q37451419 | Evidence that human Chlamydia pneumoniae was zoonotically acquired |
Q33570163 | Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae |
Q33756457 | Expansion of a novel pulmonary CD3(-) CD4(+) CD8(+) cell population in mice during Chlamydia pneumoniae infection |
Q37871964 | Experimental Chlamydia pneumoniae infection in NIH/S mice: effect of reinoculation with chlamydial or cell preparation on culture, PCR and histological findings of lung tissue |
Q37887313 | Experimental Chlamydia pneumoniae infection in mice: effect of reinfection and passive immunization |
Q37867617 | Experimental infection by Chlamydia pneumoniae in the hamster |
Q37890203 | Experimental infection of Chlamydia pneumoniae in mice |
Q37898047 | Experimental infection of baboons (Papio cynocephalus anubis) with Chlamydia pneumoniae strain 'TWAR'. |
Q36977911 | Experimental infection with Chlamydia pneumoniae in nonhuman primates |
Q35774105 | Experimental rabbit models of Chlamydia pneumoniae infection |
Q37889605 | Experimental study on the mechanisms of Chlamydia pneumoniae respiratory infection in mice with former chlamydial exposure |
Q37655094 | Exploring the role of Chlamydia pneumoniae in cardiovascular disease: a narrative review. |
Q37859149 | Exposure to Chlamydia pneumoniae infection and age-related macular degeneration: the Blue Mountains Eye Study |
Q37864806 | Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration |
Q37842070 | Exposure to cigarette smoke and Chlamydia pneumoniae infection in mice: Effect on infectious burden, systemic dissemination and cytokine responses: A pilot study |
Q37883033 | Exposures to Legionella pneumophila and Chlamydia pneumoniae in South African Mine Workers |
Q37868333 | Expression and localization of type III secretion-related proteins of Chlamydia pneumoniae |
Q34006871 | Expression of Chlamydia pneumoniae polymorphic membrane protein family genes |
Q37884222 | Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae |
Q37865448 | Expression of both Chlamydia pneumoniae RNase HIIs in Escherichia coli |
Q37870132 | Extraction of Chlamydia pneumoniae DNA from vascular tissue for use in PCR: an evaluation of four procedures |
Q37868688 | Extrarespiratory Chlamydia pneumoniae infection associated with immune disorder, hepatitis and renal disease |
Q37852951 | FDG/PET uptake in asymptomatic multilobar Chlamydia pneumoniae pneumonia |
Q37893037 | Factors influencing the infectivity of Chlamydia pneumoniae elementary bodies on HL cells |
Q63363778 | Faculty of 1000 evaluation for Immunohistostaining assays for detection of Chlamydia pneumoniae in atherosclerotic arteries indicate cross-reactions with nonchlamydial plaque constituents |
Q37874971 | Failure to demonstrate Chlamydia pneumoniae in cardiovascular tissue from children with Kawasaki disease |
Q37881207 | Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). |
Q35130220 | Failure to detect Chlamydia pneumoniae DNA in cerebral aneursymal sac tissue with two different polymerase chain reaction methods |
Q37869472 | Failure to detect Chlamydia pneumoniae by cell culture and polymerase chain reaction in major arteries of 93 patients with atherosclerosis |
Q37871083 | Failure to detect Chlamydia pneumoniae in aortic valves and peripheral blood mononuclear cells from patients undergoing aortic valve replacement in Norway |
Q37880753 | Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. |
Q24551398 | Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients |
Q37877411 | Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease |
Q37880226 | Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. |
Q37885296 | Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy |
Q37886254 | Failure to detect Chlamydia pneumoniae in ear fluids from children with otitis media. |
Q37871128 | Failure to detect Chlamydia pneumoniae in senile calcific aortic stenosis or calcified congenital bicuspid aortic valve by immunofluorescence, polymerase chain reaction and electron microscopy |
Q37877202 | Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. |
Q43424813 | Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. |
Q44029828 | Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. |
Q33968146 | Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain |
Q37881776 | Failure to detect the presence of Chlamydia pneumoniae in sarcoid pathology specimens |
Q37885509 | Familial occurrence of Chlamydia pneumoniae infection |
Q37867096 | Fatal hemorrhagic pneumonia concomitant with Chlamydia pneumoniae and parainfluenza virus 4 infection |
Q37873074 | Field epidemiological investigation on an outbreak of Chlamydia pneumoniae infection--first recognized incidence in a nursing home for elderly in Japan |
Q37867494 | First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae |
Q35805536 | Flotillin-1 (Reggie-2) contributes to Chlamydia pneumoniae growth and is associated with bacterial inclusion |
Q37872007 | Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines |
Q37859729 | Frequency of Chlamydia pneumoniae and Mycoplasma pneumoniae infections in children |
Q37876254 | Frequency of coexistence of cytomegalovirus and Chlamydia pneumoniae in atherosclerotic plaques |
Q37873672 | Frequency of occurrence of cytomegalovirus and Chlamydia pneumoniae in lymphocytes of atherosclerotic patients |
Q37875485 | Frequent contamination of Chlamydia trachomatis and Chlamydia pneumoniae strains with mycoplasma. Biological relevance and selective eradication of mycoplasma from chlamydial cultures with mupirocin |
Q37887875 | Further characterization of Chlamydia pneumoniae specific monoclonal antibodies |
Q37885326 | Future trends in Chlamydia pneumoniae research and the place of macrolides in treatment |
Q37854904 | Gene expression signatures characterizing the development of lymphocyte response during experimental Chlamydia pneumoniae infection. |
Q37866577 | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae |
Q37858513 | Genetic control of susceptibility to pulmonary infection with Chlamydia pneumoniae in the mouse |
Q37836256 | Genome Wide Analysis of Chlamydia pneumoniae for Candidate Vaccine Development |
Q22065998 | Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. |
Q92462206 | Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China |
Q31032708 | Genomic approach for analysis of surface proteins in Chlamydia pneumoniae |
Q35607714 | Genomic factors related to tissue tropism in Chlamydia pneumoniae infection |
Q37866651 | Genomic, serologic, and clinical case-control study of Chlamydia pneumoniae and peripheral artery occlusive disease |
Q37868431 | Genotypic Differences in theChlamydia pneumoniae tyrP Locus Related to Vascular Tropism and Pathogenicity |
Q35078469 | GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, impairs neovascularization by decreasing endothelial progenitor cell function |
Q37851235 | GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, induces lectin-like oxidized low-density lipoprotein receptor 1 expression in endothelial cells and enhances atherogenesis in hypercholesterolemic rabbits |
Q34382599 | GroEL1, from Chlamydia pneumoniae, induces vascular adhesion molecule 1 expression by p37(AUF1) in endothelial cells and hypercholesterolemic rabbit |
Q37866670 | Growth factor production in human endothelial cells after Chlamydia pneumoniae infection |
Q37890113 | Growth in serum-free medium improves isolation of Chlamydia pneumoniae |
Q33935046 | Growth in vascular cells and cytokine production by Chlamydia pneumoniae |
Q47104865 | Growth of Chlamydia pneumoniae Is Enhanced in Cells with Impaired Mitochondrial Function |
Q37884521 | Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response |
Q37884265 | Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line |
Q43435375 | Guillain-Barré syndrome after Chlamydia pneumoniae infection |
Q37866115 | Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection |
Q37866477 | Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo |
Q37869150 | Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction |
Q33821315 | Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease |
Q37877079 | Helicobacter pylori, Chlamydia pneumoniae, reactive C protein, and cerebrovascular diseases |
Q37873984 | Heparan sulfate-like glycosaminoglycan is a cellular receptor for Chlamydia pneumoniae |
Q37881382 | Herd immunity and the role of Chlamydia pneumoniae in the etiology of respiratory diseases in the Czech Republic |
Q115769780 | Heterogeneous expression of Chlamydia pneumoniae antigen candidates and high-level soluble expression of its inclusion membrane proteins in Escherichia coli |
Q127718877 | High Incidence of Chlamydia Pneumoniae in Atherosclerosis of Coronary Arteries With Both Genus and Species Specific Antisera |
Q36262589 | High Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in Children with Acute Respiratory Infections from Lima, Peru. |
Q92765759 | High Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae among Scrub Typhus Patients in South Korea |
Q93043812 | High frequency of Chlamydia pneumoniae and risk factors in children with acute respiratory infection |
Q37856127 | High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker |
Q37883688 | High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement |
Q37880679 | High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. |
Q37865107 | High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia |
Q37869178 | High prevalence of Chlamydia pneumoniae antibodies in white-coat hypertensives |
Q37846411 | High prevalence of Chlamydia pneumoniae infection in an asymptomatic Jordanian population |
Q37892244 | High prevalence of Chlamydia pneumoniae infection in children and young adults in Spain |
Q37867181 | High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin |
Q37866592 | High prevalence of Chlamydia pneumoniae seropositivity in Mexican patients with ischemic heart disease. |
Q36503604 | High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents |
Q37864512 | High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis |
Q37857914 | High sensitivity C-reactive protein and immunoglobulin G against Chlamydia pneumoniae and chlamydial heat shock protein-60 in ischemic heart disease. |
Q33286200 | Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern |
Q37869441 | Higher prevalence of Chlamydia pneumoniae seropositivity in Finnish twins compared with co-twins living in Sweden: relationships with markers of subclinical atherosclerosis |
Q37843935 | Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy: a cross-sectional study |
Q37893957 | Hilar lymphadenopathy associated with Chlamydia pneumoniae infection |
Q74181274 | Histological and ultrastructural findings suggesting an initiating role for Chlamydia pneumoniae in the pathogenesis of atherosclerosis |
Q37866443 | Histopathologic signs for the inflammatory role of Chlamydia pneumoniae in the high-grade atherosclerotic coronary artery wall. |
Q37848046 | Host cell Golgi anti-apoptotic protein (GAAP) and growth of Chlamydia pneumoniae |
Q37856089 | Host cell cytokines induced by Chlamydia pneumoniae decrease the expression of interstitial collagens and fibronectin in fibroblasts |
Q37860251 | Host cell responses to Chlamydia pneumoniae in gamma interferon-induced persistence overlap those of productive infection and are linked to genes involved in apoptosis, cell cycle, and metabolism |
Q37873710 | Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma |
Q37846580 | Host metabolism promotes growth of Chlamydia pneumoniae in a low oxygen environment. |
Q37841986 | Human Chlamydia pneumoniae isolates demonstrate ability to recover infectivity following penicillin treatment whereas animal isolates do not. |
Q35005258 | Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review |
Q37874441 | Human monocyte-derived insulin-like growth factor-2 enhances the infection of human arterial endothelial cells by Chlamydia pneumoniae |
Q37880204 | Humoral immune response to Chlamydia pneumoniae in twin discordant for smoking. |
Q37869027 | Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation |
Q37876716 | Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae |
Q47557566 | Hyperbolic relation between beta-cell function and insulin sensitivity for type 2 diabetes mellitus, malaria, influenza, Helicobacter pylori, Chlamydia pneumoniae, and hepatitis C virus infection-induced inflammation/oxidative stress and temporary i |
Q37872162 | Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease |
Q37875205 | Hyperinsulinemia, lipoprotein (a), and Chlamydia pneumoniae antibodies--are they risk factors or serologic predictors for progression of coronary artery disease? |
Q43422125 | Hypothalamic-pituitary-adrenal (HPA) system activity in depression and infection with Borna disease virus and Chlamydia pneumoniae |
Q35688972 | Hypothetical protein Cpn0308 is localized in the Chlamydia pneumoniae inclusion membrane |
Q37833851 | Hypothetical protein Cpn0423 triggers NOD2 activation and contributes to Chlamydia pneumoniae-mediated inflammation |
Q43433706 | Hypoxemic pneumopathy caused by Chlamydia pneumoniae |
Q37868127 | IFN-gamma induced persistent Chlamydia pneumoniae infection in HL and Mono Mac 6 cells: characterization by real-time quantitative PCR and culture |
Q37852203 | IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice |
Q36539539 | Identification and characterization of Chlamydia pneumoniae-specific proteins that activate tumor necrosis factor alpha production in RAW 264.7 murine macrophages |
Q28283487 | Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain |
Q37869309 | Identification and quantification of Chlamydia pneumoniae in human atherosclerotic plaques by LightCycler real-time-PCR. |
Q37118408 | Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene |
Q88670694 | Identification of Chlamydia pneumoniae candidate genes that interact with human apoptotic factor caspase-9 |
Q37864868 | Identification of Chlamydia pneumoniae in intracranial and extracranial arteries in patients with stroke and in controls: combined immunohistochemical and polymerase chain reaction analyses |
Q37861617 | Identification of Chlamydia pneumoniae proteins in the transition from reticulate to elementary body formation |
Q37864777 | Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. |
Q34125106 | Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes |
Q37889915 | Identification of Chlamydia pneumoniae-specific protein antigens in immunoblots |
Q37871641 | Identification of MEK- and phosphoinositide 3-kinase-dependent signalling as essential events during Chlamydia pneumoniae invasion of HEp2 cells |
Q37844467 | Identification of Sphingomyelinase on the Surface of Chlamydia pneumoniae: Possible Role in the Entry into Its Host Cells |
Q37867654 | Identification of an in vivo CD4+ T cell-mediated response to polymorphic membrane proteins of Chlamydia pneumoniae during experimental infection |
Q37855987 | Identification of high- and low-virulent strains of Chlamydia pneumoniae by their characterization in a mouse pneumonia model |
Q37865826 | Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. |
Q37879463 | Identification of two novel genes encoding 97- to 99-kilodalton outer membrane proteins of Chlamydia pneumoniae |
Q37879806 | IgG subclass-specific antibodies in Chlamydia pneumoniae infections |
Q37868702 | Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients |
Q37886113 | Immune response to Chlamydia trachomatis heat-shock protein in infertile female patients and influence of Chlamydia pneumoniae antibodies |
Q30837656 | Immune response to genital chlamydial infection and influence of Chlamydia pneumoniae (TWAR) antibodies |
Q37879386 | Immune responses to Chlamydia pneumoniae in twins in relation to gender and smoking |
Q37875113 | Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). |
Q35069480 | Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development |
Q37871565 | Immunoblotting analysis of abdominal aortic aneurysms using antibodies against Chlamydia pneumoniae recombinant MOMP. |
Q37870086 | Immunofluorescence in situ and the serologic indices of Chlamydia pneumoniae infection in patients with an abdominal aortic aneurysm. |
Q37862860 | Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae. |
Q37878292 | Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. |
Q37884075 | Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms |
Q37875668 | Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease |
Q33701035 | Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain |
Q37866783 | Immunohistostaining assays for detection of Chlamydia pneumoniae in atherosclerotic arteries indicate cross-reactions with nonchlamydial plaque constituents |
Q37885660 | Immunopathogenesis of Chlamydia pneumoniae Infections in children |
Q37857721 | Immunoproteomic identification and serological responses to novel Chlamydia pneumoniae antigens that are associated with persistent C. pneumoniae infections |
Q37888611 | Immunoreactivity of the 60 kDa cysteine-rich proteins of Chlamydia trachomatis, Chlamydia psittaci and Chlamydia pneumoniae expressed in Escherichia coli |
Q37866555 | Immunoserodiagnosis of acute Streptococcus pneumoniae and Chlamydia pneumoniae infections in the period of epidemic rise of non-hospital pneumonia in children in St. Petersburg, 1998-2001 |
Q37870063 | Impact of Chlamydia pneumoniae infection on survival rate after heart transplantation |
Q37875466 | Impact of Chlamydia pneumoniae infections on asthma |
Q44059306 | Impact of capsaicin, an active component of chili pepper, on pathogenic chlamydial growth (Chlamydia trachomatis and Chlamydia pneumoniae) in immortal human epithelial HeLa cells |
Q37859394 | Impact of chronic Chlamydia pneumoniae infection on left ventricular remodeling after myocardial infarction |
Q37876456 | Impact of chronic infection with chlamydia pneumoniae on incidence of cardiac allograft vasculopathy |
Q35523803 | Impact of serological methodology on assessment of the link between Chlamydia pneumoniae and vascular diseases |
Q34690945 | Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients |
Q37885361 | Importance of Chlamydia pneumoniae as a new respiratory pathogen |
Q37874789 | Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia |
Q37874461 | Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing |
Q37868658 | Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis |
Q37888014 | Importance of smoking for Chlamydia pneumoniae seropositivity |
Q36545356 | Improvement of growth of Chlamydia pneumoniae on HEp-2 cells by pretreatment with polyethylene glycol in combination with additional centrifugation and extension of culture time. |
Q92500148 | In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae |
Q90226068 | In Vitro Activity of Omadacycline against Chlamydia pneumoniae |
Q33565253 | In situ detection of Chlamydia pneumoniae, C. trachomatis, and cytokines among cardiovascular diseased patients from the Amazon region of Brazil |
Q37872796 | In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae |
Q37888833 | In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae |
Q35126064 | In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae |
Q37877849 | In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model |
Q35885610 | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae |
Q37884244 | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae |
Q35121993 | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae |
Q37893696 | In vitro activities of five quinolones against Chlamydia pneumoniae |
Q34141733 | In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. |
Q37877492 | In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. |
Q37870051 | In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae |
Q37876885 | In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae |
Q37843405 | In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae |
Q37874904 | In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis |
Q37881176 | In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. |
Q37869802 | In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae |
Q37880865 | In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. |
Q35818615 | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae |
Q37868805 | In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae |
Q37869288 | In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae |
Q37871838 | In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe |
Q43426019 | In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae |
Q37845251 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae |
Q37873518 | In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae |
Q35138264 | In vitro activity of trovafloxacin against Chlamydia pneumoniae |
Q43422417 | In vitro antibiotic activity against Chlamydia pneumoniae clinical isolates. |
Q37856179 | In vitro characterisation of koala Chlamydia pneumoniae: morphology, inclusion development and doubling time |
Q37872973 | In vitro degradation of aortic elastin by Chlamydia pneumoniae |
Q35824208 | In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae |
Q37878237 | In vitro hyperreactivity to lipopolysaccharide in patients with history of unstable angina is not associated with seropositivity for Cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae |
Q37877535 | In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells |
Q37883558 | In vitro infection of smooth muscle cells by Chlamydia pneumoniae. |
Q37868351 | In vitro inhibitory effects of tea polyphenols on the proliferation of Chlamydia trachomatis and Chlamydia pneumoniae |
Q37855338 | In vitro neutralization of tumor necrosis factor-alpha during Chlamydia pneumoniae infection impairs dendritic cells maturation/function and increases chlamydial progeny |
Q37876245 | In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae |
Q37897794 | In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). |
Q37878178 | In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations |
Q37880155 | In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. |
Q37873067 | In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells |
Q36524413 | In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae |
Q37864023 | In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model |
Q37882878 | In-vitro activity of dirithromycin against Chlamydia pneumoniae |
Q37877336 | In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae |
Q37894473 | In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics |
Q37873507 | Incidence of Chlamydia pneumoniae infection in patients with coronary artery disease subjected to angioplasty or bypass surgery. |
Q37879453 | Incidence of Chlamydia pneumoniae infection in vertically HIV-1 infected children. |
Q37892040 | Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study |
Q37890395 | Incidence of community-acquired pneumonia caused by Chlamydia pneumoniae in Italian patients |
Q37872995 | Incidence of immunoglobulin G antibodies to Chlamydia pneumoniae in acute myocardial infarction patients. |
Q33943276 | Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae |
Q37873486 | Increased CD8(+) T cells associated with Chlamydia pneumoniae in symptomatic carotid plaque |
Q37863199 | Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity |
Q37872208 | Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus |
Q37880979 | Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease |
Q37874359 | Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma |
Q35586809 | Increased incidence of cytomegalovirus but not Chlamydia pneumoniae in atherosclerotic lesions of arteries of lower extremities from patients with diabetes mellitus undergoing amputation |
Q37867086 | Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis |
Q37868606 | Increased production of matrix metalloproteinases 1 and 3 by smooth muscle cells upon infection with Chlamydia pneumoniae |
Q37861838 | Increased prostanoid dependency of arterial relaxation in Chlamydia pneumoniae-infected mice |
Q37844042 | Increased sensitivity to tryptophan bioavailability is a positive adaptation by the human strains of Chlamydia pneumoniae. |
Q43434465 | Increasing prevalence of specific antibodies to Chlamydia pneumoniae in Sweden |
Q37874609 | Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. |
Q37873698 | Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. |
Q64987702 | Indoleamine 2,3-Dioxygenase Activity in Chlamydia muridarum and Chlamydia pneumoniae Infected Mouse Lung Tissues. |
Q37852800 | Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin |
Q37848659 | Induction of VEGF and MMP-9 expression by toll-like receptor 2/4 in human endothelial cells infected with Chlamydia pneumoniae |
Q33553163 | Induction of interferon-stimulated genes by Chlamydia pneumoniae in fibroblasts is mediated by intracellular nucleotide-sensing receptors. |
Q37855545 | Induction of interleukin-18 in atherosclerotic patients: a role for Chlamydia pneumoniae |
Q37867692 | Induction of lipoprotein lipase gene expression in Chlamydia pneumoniae-infected macrophages is dependent on Ca2+ signaling events |
Q37881436 | Induction of macrophage foam cell formation by Chlamydia pneumoniae |
Q37869398 | Induction of oral tolerance as treatment or prevention of chronic diseases associated with Chlamydia pneumoniae infection--hypothesis. |
Q37850249 | Induction of proinflammatory cytokines and cell apoptosis by Chlamydia pneumoniae Cpn0810 |
Q34581245 | Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae infection |
Q37850475 | Induction of proinflammatory cytokines in human osteoblastic cells by Chlamydia pneumoniae. |
Q37862282 | Induction of tissue factor expression and release as microparticles in ECV304 cell line by Chlamydia pneumoniae infection |
Q37875332 | Infection and activation of airway epithelial cells by Chlamydia pneumoniae |
Q37879391 | Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae |
Q37877767 | Infection hypothesis for the pathogenesis of atherosclerosis--caused by Chlamydia pneumoniae? |
Q37883200 | Infection of Acanthamoeba castellanii by Chlamydia pneumoniae |
Q37868327 | Infection of U937 Monocytic Cells withChlamydia pneumoniaeInduces Extensive Changes in Host Cell Gene Expression |
Q37879018 | Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes |
Q35144785 | Infection of human monocytes by Chlamydia pneumoniae and Chlamydia trachomatis: an in vitro comparative study |
Q37881464 | Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model |
Q33729334 | Infection with Chlamydia pneumoniae and atherosclerosis: a review. |
Q34180015 | Infection with Chlamydia pneumoniae and risk of multiple sclerosis |
Q35821202 | Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested |
Q37863230 | Infection with Chlamydia pneumoniae but not Helicobacter pylori is related to elevated apolipoprotein B levels |
Q37895177 | Infection with Chlamydia pneumoniae in Brooklyn |
Q37887510 | Infection with Chlamydia pneumoniae in infants and children with acute lower respiratory tract disease |
Q33216385 | Infection with chlamydia pneumoniae increases oxidative stress and accelerates the development of atherosclerosis in C57BL/6J mice |
Q33706917 | Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides |
Q44058986 | Infections and Chlamydia pneumoniae antibodies influence the functional outcome in thrombolysed strokes |
Q35535575 | Infections caused by Chlamydia pneumoniae strain TWAR |
Q37191198 | Infections with Chlamydia pneumoniae strain TWAR |
Q37876989 | Infections with Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus and atherosclerosis |
Q37875835 | Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis |
Q37851763 | Infectious Chlamydia pneumoniae is associated with elevated interleukin-8 and airway neutrophilia in children with refractory asthma |
Q35079371 | Infectious agents and multiple sclerosis--are Chlamydia pneumoniae and human herpes virus 6 involved? |
Q37866530 | Infectious risk factors for atherosclerotic vascular disease in hemodialysis patients--Chlamydia pneumoniae but not Helicobacter pylori or cytomegalovirus is associated with increased C-reactive protein |
Q37876952 | Infective Chlamydia pneumoniae and coronary disease: where is the truth? |
Q37840502 | Infective endocarditis caused by Chlamydia pneumoniae after liver transplantation. Case report |
Q37863087 | Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease |
Q37862004 | Inflammation and atrial fibrillation: is Chlamydia pneumoniae a candidate pathogen of atrial fibrillation? |
Q35164422 | Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome |
Q43419781 | Inflammatory abdominal aortic aneurysm and Chlamydia pneumoniae infection |
Q37875398 | Inflammatory cells, apoptosis and Chlamydia pneumoniae infection in atherosclerosis. |
Q37860389 | Inflammatory responses following Chlamydia pneumoniae infection of glial cells |
Q37868136 | Influence of Chlamydia pneumoniae infection on aortic stiffness in healthy young men. |
Q37886900 | Influence of centrifugation on the infectivity of Chlamydia pneumoniae IOL-207. |
Q37871579 | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model |
Q32091287 | Influence of iron restriction on Chlamydia pneumoniae and C. trachomatis |
Q37890521 | Influence of temperature and relative humidity on the survival of Chlamydia pneumoniae in aerosols |
Q33829172 | Influence of the Chlamydia pneumoniae AR39 bacteriophage ϕCPAR39 on chlamydial inclusion morphology. |
Q35425745 | Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. |
Q37881021 | Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism. |
Q37875477 | Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity |
Q37866393 | Inhibitory actions of several natural products on proliferation of rat vascular smooth muscle cells induced by Hsp60 from Chlamydia pneumoniae J138. |
Q37869167 | Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae |
Q37863140 | Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. |
Q37862855 | Inhibitory effect of heparan sulfate-like glycosaminoglycans on the infectivity of Chlamydia pneumoniae in HL cells varies between strains |
Q37852736 | Inhibitory effect of the natural product betulin and its derivatives against the intracellular bacterium Chlamydia pneumoniae. |
Q37861426 | Initial empiric antimicrobial treatment of Chlamydia pneumoniae: a study of 54 cases in the Republic of Macedonia |
Q27027451 | Innate immune responses to Chlamydia pneumoniae infection: role of TLRs, NLRs, and the inflammasome |
Q37374326 | Innate immunity and vaccines in chlamydial infection with special emphasis on Chlamydia pneumoniae. |
Q37859349 | Inoculation of Chlamydia pneumoniae or Chlamydia trachomatis with ligands that inhibit attachment to host cells reduces infectivity in the mouse model of lung infection: implication for anti-adhesive therapy |
Q102068539 | Insights Into a Chlamydia pneumoniae-Specific Gene Cluster of Membrane Binding Proteins |
Q37861388 | Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. |
Q37879844 | Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response |
Q37877539 | Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis |
Q37869550 | Interactions between Chlamydia pneumoniae and Trace Elements: A Possible Link to Aortic Valve Sclerosis |
Q33526048 | Interactions between flagellar and type III secretion proteins in Chlamydia pneumoniae |
Q33935050 | Interactions of Chlamydia pneumoniae with human endothelial cells |
Q37073869 | Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test |
Q37872949 | Interferon-beta induction by Chlamydia pneumoniae in human smooth muscle cells |
Q33711781 | Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers |
Q37872553 | Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies |
Q37851321 | Interleukin-6-174 G/C promoter polymorphism is associated with persistence of Chlamydia pneumoniae antibodies in young men. |
Q37865312 | Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection |
Q37856905 | Interrelationship of interleukin 6, C-reactive protein and Chlamydia pneumoniae IgG antibodies in patients with acute coronary syndromes |
Q37857618 | Intragastric primary infection sensitizes to lung reinfection in a Chlamydia pneumoniae mouse model |
Q37861522 | Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model. |
Q90562999 | Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice |
Q34760989 | Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice |
Q24795045 | Intrastrain and interstrain genetic variation within a paralogous gene family in Chlamydia pneumoniae |
Q37874029 | Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response |
Q37867930 | Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. |
Q43424949 | Introducing Chlamydophila pneumoniae: the TWAR agent Chlamydia pneumoniae in a new perspective |
Q37842537 | Invariant Natural Killer T Cells Promote T Cell Immunity by Modulating the Function of Lung Dendritic Cells during Chlamydia pneumoniae Infection. |
Q37865216 | Inverse association between Chlamydia pneumoniae respiratory tract infection and initiation of asthma or allergic rhinitis in children |
Q37874824 | Inverse association of Chlamydia pneumoniae infection with high blood pressure in Japanese adults |
Q37862723 | Investigation of Chlamydia pneumoniae DNA, chlamydial lipopolisaccharide antigens, and Helicobacter pylori DNA in atherosclerotic plaques of patients with aortoiliac occlusive disease |
Q40068224 | Investigation of Chlamydia pneumoniae infection in Moroccan patients suffering from cardiovascular diseases |
Q36370964 | Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas |
Q36000970 | Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence |
Q37869400 | Involvement of nicotinic acetylcholine receptors in controlling Chlamydia pneumoniae growth in epithelial HEp-2 cells |
Q37833858 | Iron Homeostasis in Tissues Is Affected during Persistent Chlamydia pneumoniae Infection in Mice. |
Q43197268 | Iron and the role of Chlamydia pneumoniae in heart disease |
Q37872373 | Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. |
Q37861473 | Iron enhances endothelial cell activation in response to Cytomegalovirus or Chlamydia pneumoniae infection |
Q37860532 | Is Chlamydia pneumoniae a risk factor for peripheral atherosclerosis? |
Q43422245 | Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? |
Q37871479 | Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results |
Q43424830 | Is Chlamydia pneumoniae important in asthma? The first controlled trial of therapy leaves the question unanswered |
Q35590958 | Is Chlamydia pneumoniae infection a risk factor for age related macular degeneration? |
Q37867446 | Is Chlamydia pneumoniae infection associated with stroke in children with sickle cell disease? |
Q33970414 | Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? |
Q42940513 | Is Chlamydia pneumoniae present in cerebrospinal fluid of multiple sclerosis patients? |
Q43426528 | Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients? |
Q43429266 | Is Chlamydia pneumoniae responsible for disease in children? |
Q37855880 | Is Chlamydia pneumoniae seropositivity associated with atherothrombotic cerebrovascular infarction? |
Q43413598 | Is Chlamydia pneumoniae the causative agent of microscopic polyangiitis? |
Q37888501 | Is coronary disease caused by an infection with Chlamydia pneumoniae? |
Q37879915 | Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? |
Q43418862 | Is seropositivity enough to show the association between coronary artery disease and Chlamydia pneumoniae and Helicobacter pylori infection? |
Q37511385 | Is the perceived association between Chlamydia pneumoniae and vascular diseases biased by methodology? |
Q37840151 | Is there a relationship between Parkinson's disease and Chlamydia pneumoniae? |
Q37875235 | Is there a role for Chlamydia pneumoniae in hemodialysis vascular access thrombosis? |
Q37867147 | Is there a role for Chlamydia pneumoniae infection in systemic lupus erythematosus and in the associated atherosclerotic cardiovascular disease? |
Q37876415 | Is there an association between Kawasaki disease and Chlamydia pneumoniae? |
Q37859691 | Is there any relationship between asthma and asthma attack in children and atypical bacterial infections; Chlamydia pneumoniae, Mycoplasma pneumoniae and Helicobacter pylori |
Q43425132 | Isolated 6th nerve palsy in a child associated with asymptomatic Chlamydia pneumoniae infection and elevated anti-GQ1b antibody |
Q43425149 | Isolated pleural effusion as unusual manifestation of Chlamydia pneumoniae infection |
Q35774875 | Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope |
Q37876438 | Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens |
Q36990657 | Isolation and sequence analysis of the Chlamydia pneumoniae GroE operon |
Q37893426 | Isolation of Chlamydia pneumoniae and Antibodies to the Agent in Patients with Acute Bronchitis |
Q34132478 | Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay |
Q37882581 | Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen |
Q37893376 | Isolation of Chlamydia pneumoniae from a patient with acute bronchitis |
Q43436564 | Isolation of Chlamydia pneumoniae from middle ear aspirates of otitis media with effusion: a case report |
Q33949413 | Isolation of Chlamydia pneumoniae from serum samples of the patients with acute coronary syndrome. |
Q37883953 | Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group |
Q37895371 | Isolation of Chlamydia pneumoniae from the lungs of patients infected with the human immunodeficiency virus |
Q43434854 | Isolation of Chlamydia pneumoniae from the maxillary sinus of a patient with purulent sinusitis |
Q37888193 | Isolation of Chlamydia pneumoniae in atypical pneumonia |
Q37868911 | Joint effects of Chlamydia pneumoniae infection and classic coronary risk factors on risk of acute myocardial infarction |
Q37870985 | KN-62 enhances Chlamydia pneumoniae-induced p44/p42 mitogen-activated protein kinase activation in murine fibroblasts and attenuates in vitro infection |
Q88432949 | Kawasaki Disease and Chlamydia Pneumoniae Infection |
Q37850591 | Keratoconjunctivitis sicca during folicular conjunctivitis in adult patients with Chlamydia pneumoniae etiology (summarizing twelve years study) |
Q37873102 | Koala biovar of Chlamydia pneumoniae infects human and koala monocytes and induces increased uptake of lipids in vitro |
Q35892967 | Laboratory diagnosis of Chlamydia pneumoniae infections |
Q42727780 | Labsystems enzyme immunoassay for Chlamydia pneumoniae also detects Chlamydia psittaci infections |
Q43419136 | Lack of PBC-specific antimitochondrial antibodies in patients with Chlamydia pneumoniae infection |
Q24802081 | Lack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteries |
Q37869460 | Lack of association between Chlamydia pneumoniae seropositivity and aortic atherosclerotic plaques: a population-based transesophageal echocardiographic study |
Q37867443 | Lack of association between Chlamydia pneumoniae seropositivity and common carotid intima-media thickness in type 2 diabetic patients |
Q37877152 | Lack of association between Kawasaki syndrome and Chlamydia pneumoniae infection: an investigation of a Kawasaki syndrome cluster in San Diego County. |
Q37876520 | Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpesvirus 8, TT virus, GB virus C/hepatitis G virus or Chlamydia pneumoniae |
Q37878909 | Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease |
Q37877681 | Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. |
Q43415336 | Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer |
Q37870809 | Lack of association between serum immunoreactivity and Chlamydia pneumoniae detection in the human aortic wall |
Q24805877 | Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study |
Q37835396 | Lack of association of Chlamydia pneumoniae with cardiovascular diseases in virologically suppressed HIV patients |
Q37877791 | Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae |
Q37877084 | Lack of correlation between Chlamydia pneumoniae antibody titers and adult-onset asthma |
Q43426520 | Lack of detectable Chlamydia pneumoniae in brain lesions of patients with multiple sclerosis |
Q37880013 | Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation |
Q37890147 | Lack of evidence of Chlamydia pneumoniae infection in infants with acute lower respiratory tract disease |
Q37836191 | Lack of strong association of Chlamydia pneumoniae and atherosclerosis in a Jordanian population |
Q28069433 | Lead Discovery Strategies for Identification of Chlamydia pneumoniae Inhibitors |
Q37877936 | Legionella, Chlamydia pneumoniae and Mycoplasma infection in patients admitted to Christchurch Hospital with pneumonia |
Q37869588 | Levofloxacin kills Chlamydia pneumoniae and modulates interleukin 6 production by HEp-2 cells |
Q37869986 | Limited association of Chlamydia pneumoniae detection with coronary atherosclerosis |
Q37870203 | Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis |
Q33767275 | Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection |
Q35746659 | Localization of the hypothetical protein Cpn0585 in the inclusion membrane of Chlamydia pneumoniae-infected cells |
Q35217607 | Localization of the hypothetical protein Cpn0797 in the cytoplasm of Chlamydia pneumoniae-infected host cells |
Q37873990 | Low iron availability modulates the course of Chlamydia pneumoniae infection |
Q37853983 | Low mannose-binding lectin levels and MBL2 gene polymorphisms associate with Chlamydia pneumoniae antibodies. |
Q37873727 | Low prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae among patients with symptoms of respiratory tract infections in Dutch general practices |
Q37861708 | Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia |
Q37877922 | Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease |
Q98497975 | Low prevalence of Chlamydia pneumoniae infections during the Mycoplasma pneumoniae epidemic season: Results of nationwide surveillance in Japan |
Q90675908 | Low-Dose Aspirin May Prevent Trophoblast Dysfunction in Women With Chlamydia Pneumoniae Infection |
Q37877677 | Lower prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients |
Q37888385 | Lower respiratory tract infection with Chlamydia pneumoniae |
Q37887196 | Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease |
Q37893041 | Lumbosacral meningoradiculitis associated with Chlamydia pneumoniae infection. |
Q37888840 | Lung infections in children. IV. Pneumonia due to Chlamydia pneumoniae |
Q37878373 | Lymphotoxin inhibits Chlamydia pneumoniae growth in HEp-2 cells. |
Q37878697 | Löfgren's syndrome as the first manifestation of acute infection due to Chlamydia pneumoniae: a prospective study |
Q35852332 | M2 Polarization of Human Macrophages Favors Survival of the Intracellular Pathogen Chlamydia pneumoniae |
Q37844674 | MAPK-PPARα/γ signal transduction pathways are involved in Chlamydia pneumoniae-induced macrophage-derived foam cell formation |
Q35709736 | Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. |
Q43423265 | Macrolide treatment does not influence serum homocysteine in Chlamydia pneumoniae-seropositive patients suffering from atherosclerosis. |
Q37868698 | Macrophage L-type Ca2+ channel antagonists alter Chlamydia pneumoniae MOMP and HSP-60 mRNA gene expression, and improve antibiotic susceptibility |
Q37862226 | Macrophage antioxidant enzymes regulate Chlamydia pneumoniae chronicity: evidence of the effect of redox balance on host-pathogen relationship |
Q37867764 | Macrophages, CD4+ or CD8+ cells are each sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-gamma |
Q37858375 | Markers of Chlamydia pneumoniae and human cytomegalovirus infection in patients with chronic peripheral vascular disease and their relation to inflammation, endothelial dysfunction and changes in lipid metabolism |
Q35563186 | Markers of inflammation in induced sputum in acute bronchitis caused by Chlamydia pneumoniae |
Q35329165 | Mast cells play an important role in chlamydia pneumoniae lung infection by facilitating immune cell recruitment into the airway |
Q37857465 | Maternal serum Chlamydia pneumoniae antibodies and CRP levels in women with preeclampsia and gestational hypertension |
Q35583908 | Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques |
Q37883625 | Means of diagnosis of Chlamydia pneumoniae infection |
Q37859577 | Measurement of Chlamydia pneumoniae bacterial load in peripheral blood mononuclear cells may be helpful to assess the state of chlamydial infection in patients with carotid atherosclerotic disease |
Q34579483 | Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one en |
Q35224726 | Measurement of sputum antibodies in the diagnosis of acute and chronic respiratory infections associated with Chlamydia pneumoniae |
Q43424648 | Mechanism of Arterial Infection by Chlamydia pneumoniae. |
Q37840495 | Mechanisms of apoptosis inhibition in Chlamydia pneumoniae-infected neutrophils. |
Q37883684 | Mediastinal lymphadenitis associated with Chlamydia pneumoniae infection |
Q37852001 | Members of the Pmp protein family of Chlamydia pneumoniae mediate adhesion to human cells via short repetitive peptide motifs |
Q43426269 | Meningoencephalitis and Chlamydia pneumoniae infection |
Q37869786 | Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? |
Q37865621 | Methodological aspects affecting the infectivity of Chlamydia pneumoniae in cell cultures in vitro |
Q37833989 | Methods for Real-Time PCR-Based Diagnosis of Chlamydia pneumoniae, Chlamydia psittaci, and Chlamydia abortus Infections in an Opened Molecular Diagnostic Platform |
Q37858349 | Microarray analysis of a Chlamydia pneumoniae-infected human epithelial cell line by use of gene ontology hierarchy. |
Q37881682 | Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. |
Q37876262 | Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae |
Q37869798 | Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae |
Q42729698 | Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae |
Q37868609 | Micromanipulation of the Chlamydia pneumoniae inclusion: implications for cloning and host-pathogen interactions |
Q93366878 | Mint Flavorings from Candies Inhibit the Infectivity of Chlamydia pneumoniae |
Q37857113 | Modulation of cytokine and beta-defensin 2 expressions in human gingival fibroblasts infected with Chlamydia pneumoniae |
Q37858937 | Molecular beacons for isothermal fluorescence enhancement by the cleavage of RNase HII from Chlamydia pneumoniae |
Q37877544 | Molecular biology of Chlamydia pneumoniae surface proteins and their role in immunopathogenicity |
Q37883770 | Molecular biology of the Chlamydia pneumoniae surface |
Q37847213 | Molecular cartography in acute Chlamydia pneumoniae infections--a non-targeted metabolomics approach |
Q37834476 | Molecular characterization of Chlamydia pneumoniae associated to atherosclerosis |
Q37836095 | Molecular characterization of Chlamydia pneumoniae in animals and humans from Argentina: Genetic characterization of Chlamydia pneumoniae. |
Q34391663 | Molecular cloning, sequence analysis, and functional characterization of the lipopolysaccharide biosynthetic gene kdtA encoding 3-deoxy-alpha-D-manno-octulosonic acid transferase of Chlamydia pneumoniae strain TW-183. |
Q37870924 | Molecular detection and seroepidemiology of the Chlamydia pneumoniae bacteriophage (PhiCpn1). |
Q37867485 | Molecular diagnosis of Chlamydia pneumoniae diseases |
Q33775972 | Molecular diagnosis of Chlamydia pneumoniae infection. |
Q37394186 | Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview |
Q37876903 | Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae |
Q37893379 | Morphology and immunotyping of AC-43 strain of Chlamydia pneumoniae isolated from a Japanese child |
Q80403543 | Morphometrical quantification of Chlamydia pneumoniae and Mycoplasma pneumoniae in human atherosclerotic abdominal aortic aneurysms |
Q33232428 | Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates |
Q33762150 | Mouse models of Chlamydia pneumoniae infection and atherosclerosis |
Q43405674 | Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis Concept |
Q90858746 | Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology |
Q33971158 | Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens |
Q37878856 | Multicenter screening of Chlamydia pneumoniae pneumonia by ELISA method |
Q37871365 | Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen |
Q37864464 | Multiple genotypes of Chlamydia pneumoniae identified in human carotid plaque |
Q43427368 | Multiple sclerosis and Chlamydia pneumoniae |
Q37881519 | Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. |
Q37877372 | Multiplex PCR for rapid and differential diagnosis of Mycoplasma pneumoniae and Chlamydia pneumoniae in respiratory infections |
Q37866982 | Multiplex PCR for the simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila in community-acquired pneumonia |
Q37236246 | Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci in respiratory samples |
Q37870429 | Multisystemic severe infection with Chlamydia pneumoniae |
Q37883205 | Murine models of Chlamydia pneumoniae infection and atherosclerosis |
Q37864592 | MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia |
Q37860176 | MyD88-dependent changes in the pulmonary transcriptome after infection with Chlamydia pneumoniae |
Q37861476 | Mycobacterium tuberculosis-susceptible I/St mice develop severe disease following infection with taxonomically distant bacteria, Salmonella enterica and Chlamydia pneumoniae |
Q37880276 | Mycoplasma contamination of Chlamydia pneumoniae isolates |
Q37865844 | Mycoplasma pneumoniae and Chlamydia pneumoniae are associated to inflammation and rupture of the atherosclerotic coronary plaques |
Q34641835 | Mycoplasma pneumoniae and Chlamydia pneumoniae cause lower respiratory tract disease in paediatric patients |
Q43419404 | Mycoplasma pneumoniae and Chlamydia pneumoniae chronic cough in children: efficacy of clarithromycin. |
Q37871773 | Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin |
Q37871282 | Mycoplasma pneumoniae and Chlamydia pneumoniae in calcified nodules of aortic stenotic valves |
Q37886996 | Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. |
Q37874286 | Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Mowgli Study Group |
Q35119852 | Mycoplasma pneumoniae and Chlamydia pneumoniae seropositivity in patients with age-related macular degeneration |
Q37889055 | Mycoplasma pneumoniae and Chlamydia pneumoniae strain TWAR infections in U.S. Marine Corps recruits |
Q74181279 | Myocardial infarction associated with Chlamydia pneumoniae |
Q37878997 | Myocardial infarction, culture-negative endocarditis, and Chlamydia pneumoniae infection: a dilemma? |
Q43434914 | Myocarditis caused by Chlamydia pneumoniae (TWAR) and sudden unexpected death in a Swedish elite orienteer. |
Q54259136 | N-acetyl-cysteine increases the replication of Chlamydia pneumoniae and prolongs the clearance of the pathogen from mice. |
Q90617050 | Naked-Eye Enumeration of Single Chlamydia pneumoniae Based on Light Scattering of Gold Nanoparticle Probe |
Q37851796 | Native properdin binds to Chlamydia pneumoniae and promotes complement activation |
Q54449325 | Neonatal apnea with Chlamydia pneumoniae infection. |
Q37869059 | Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity |
Q36852751 | Neutrophil gelatinase-associated lipocalin and interleukin-10 regulate intramacrophage Chlamydia pneumoniae replication by modulating intracellular iron homeostasis |
Q37884478 | New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses |
Q37865502 | Nicotine modulates cytokine production by Chlamydia pneumoniae infected human peripheral blood cells |
Q37868466 | Nitric oxide synthase plays a role in Chlamydia pneumoniae-induced atherosclerosis |
Q43435454 | No Association of Chronic Chlamydia pneumoniae Infection with Chronic Fatigue Syndrome |
Q37872190 | No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease |
Q37214119 | No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods |
Q37860702 | No detectable Chlamydia pneumoniae and cytomegalovirus DNA in leukocytes in subjects with echolucent and echogenic carotid artery plaques |
Q37869790 | No detection of Chlamydia pneumoniae in normal and atherosclerotic femoral arteries by polymerase chain reaction (PCR)--an autopsy study |
Q43424853 | No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis |
Q58610914 | No evidence of Chlamydia pneumoniae in the synovia of patients with osteoarthritis |
Q37872004 | No evidence of acute Chlamydia pneumoniae infection in patients with Bell's palsy |
Q37857319 | No evidence of involvement of Chlamydia pneumoniae in lung cancer by means of quantitative real-time polymerase chain reaction |
Q37866756 | No evidence of involvement of Chlamydia pneumoniae in severe cerebrovascular atherosclerosis by means of quantitative real-time polymerase chain reaction |
Q37872128 | No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. |
Q37868783 | No evidence of skin infection with Chlamydia pneumoniae in patients with cutaneous T cell lymphoma |
Q37859379 | No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial |
Q37872216 | Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways |
Q24804167 | Non-detection of Chlamydia species in carotid atheroma using generic primers by nested PCR in a population with a high prevalence of Chlamydia pneumoniae antibody |
Q37872512 | Non-specific interstitial pneumonia and Chlamydia pneumoniae infection |
Q33653680 | Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization |
Q37871970 | Novel PCR-EIA method for the detection of Chlamydia pneumoniae in respiratory specimens |
Q37843459 | Novel inflammatory biomarkers and their correlation to Chlamydia pneumoniae titres in acute ischemic stroke |
Q37868428 | Nuclear Factor–κB Activation in Endothelium byChlamydia pneumoniaewithout Active Infection |
Q37875738 | Nucleic acid sequence based amplification (NASBA) of Chlamydia pneumoniae major outer membrane protein (ompA) mRNA with bioluminescent detection |
Q33545301 | Nucleotide sequence and taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae IOL-207. |
Q37856218 | Occurrence of Chlamydia trachomatis and Chlamydia pneumoniae in paediatric respiratory infections |
Q37895800 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections |
Q37847633 | One-year observation of inflammatory markers in patients with aortic valve stenosis who expressed high or low Chlamydia pneumoniae antibody titers |
Q91873242 | Opsonophagocytosis of Chlamydia pneumoniae by human monocytes and neutrophils |
Q37859880 | Optimization of a polymerase chain reaction (PCR) for increasing its sensitivity to detect Chlamydia pneumoniae specific genome. |
Q33963149 | Optimizing culture of Chlamydia pneumoniae by using multiple centrifugations |
Q37848432 | Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial |
Q43436779 | Osler's endocarditis possibly caused by Chlamydia pneumoniae (TWAR stain) |
Q37867663 | Outbreak and persistence of Chlamydia pneumoniae infection in an Italian family |
Q64131400 | Outbreak of Chlamydia pneumoniae Infections and X-ray-Confirmed Pneumonia in Army Trainees at Fort Leonard Wood, Missouri, 2014 |
Q37860970 | Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000. |
Q37889272 | Outbreak of Chlamydia pneumoniae infection in former injection-drug users |
Q37892941 | Outbreak of Chlamydia pneumoniae infection in four farm families |
Q33920289 | Outbreak of pneumonia in the setting of fatal pneumococcal meningitis among US Army trainees: potential role of Chlamydia pneumoniae infection |
Q37861087 | Outbreak of respiratory tract infections on an islet in Korea: possible Chlamydia pneumoniae infection |
Q37849945 | Outcome of Chlamydia pneumoniae associated acute ischemic stroke in elderly patients: a case-control study |
Q37890342 | Outer membrane complex proteins of Chlamydia pneumoniae |
Q37865098 | Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. |
Q43427076 | Oxidation of low-density lipoproteins by acellular components of Chlamydia pneumoniae |
Q37873419 | Oxidative processes in human promonocytic cells (THP-1) after differentiation into macrophages by incubation with Chlamydia pneumoniae extracts. |
Q37849865 | Oxidized LDL promotes the mitogenic actions of Chlamydia pneumoniae in vascular smooth muscle cells. |
Q37892450 | PCR detection and differentiation of Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia trachomatis |
Q37874307 | PCR-based method for isolation and detection of Chlamydia pneumoniae DNA in cerebrospinal fluids |
Q47098892 | PD52 - Role of atypical pathogens mycoplasma pneumoniae and chlamydia pneumoniae in childhood asthma exacerbations |
Q37865286 | Part of Chlamydia pneumoniae in atherosclerosis and exacerbation of chronic obstructive pulmonary disease and asthma |
Q37875783 | Participation of Chlamydia pneumoniae in an epidemic of respiratory infections in Slovakia. |
Q37890128 | Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators |
Q37889940 | Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. |
Q35199820 | Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis: immunohistochemistry study and review of the literature. |
Q37875463 | Percentage of asthmatic patients with acute bronchitis and Chlamydia pneumoniae seropositivity |
Q37888974 | Performance of three commercially available monoclonal reagents for confirmation of Chlamydia pneumoniae in cell culture. |
Q37871661 | Performance of three microimmunofluorescence assays for detection of Chlamydia pneumoniae immunoglobulin M, G, and A antibodies |
Q37856602 | Permanent atrial fibrillation in patients without structural heart disease is not associated with signs of infection by Chlamydia pneumoniae and Helicobacter pylori. |
Q43425629 | Persistence of Chlamydia pneumoniae in coronary plaque tissue |
Q37877292 | Persistence of Chlamydia pneumoniae in coronary plaque tissue. A contribution to infection and immune hypothesis in unstable angina pectoris |
Q37870173 | Persistence of Chlamydia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues. |
Q37880723 | Persistence of Chlamydia pneumoniae in human arteriosclerotic plaque substance. Evidence and consequences |
Q33672332 | Persistent Chlamydia Pneumoniae serology is related to decline in lung function in women but not in men. Effect of persistent Chlamydia pneumoniae infection on lung function |
Q37885849 | Persistent Chlamydia pneumoniae infection in a Swedish family |
Q35570353 | Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction |
Q37874666 | Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection |
Q37893923 | Persistent infection with Chlamydia pneumoniae following acute respiratory illness |
Q37867354 | Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature. |
Q35875539 | Phylogenetic analysis of human Chlamydia pneumoniae strains reveals a distinct Australian indigenous clade that predates European exploration of the continent. |
Q37856808 | Phylogenetic comparison of the known Chlamydia trachomatis sigma(66) promoters across to Chlamydia pneumoniae and Chlamydia caviae identifies seven poorly conserved promoters |
Q37890714 | Phylogenetic relationship of Chlamydia pneumoniae to Chlamydia psittaci and Chlamydia trachomatis as determined by analysis of 16S ribosomal DNA sequences |
Q90307122 | Pivotal Pathogenic and Biomarker Role of Chlamydia Pneumoniae in Neurovascular Diseases |
Q37868469 | Placental infection with Chlamydia pneumoniae and intrauterine growth restriction |
Q35080398 | Plasmacytoid dendritic cells mediate the regulation of inflammatory type T cell response for optimal immunity against respiratory Chlamydia pneumoniae infection |
Q27340476 | Plasmacytoid dendritic cells play a role for effective innate immune responses during Chlamydia pneumoniae infection in mice |
Q28222522 | Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors |
Q37869355 | Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease |
Q35547839 | Pneumonia due to Chlamydia pneumoniae in children: Epidemiology, diagnosis, and treatment |
Q43433820 | Pneumonia due to Chlamydia pneumoniae strain TWAR. |
Q37886087 | Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment |
Q37891807 | Pneumonia, myocarditis and reactive arthritis due to Chlamydia pneumoniae |
Q37877613 | Polymerase chain reaction assay for detecting Chlamydia pneumoniae in middle ear fluid of children with otitis media with effusion |
Q33935030 | Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells |
Q37887506 | Polymerase chain reaction for detection of Chlamydia pneumoniae in gargled-water specimens of children |
Q37869136 | Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. |
Q37865116 | Polymorphonuclear neutrophils improve replication of Chlamydia pneumoniae in vivo upon MyD88-dependent attraction |
Q37890935 | Polypeptide profiles of Chlamydia pneumoniae strains isolated from Japan and western blot analysis using patients' sera |
Q37879706 | Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. |
Q37871590 | Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease |
Q37875191 | Possible role of chronic infection with Chlamydia pneumoniae in Japanese patients with acute myocardial infarction |
Q33935035 | Potential for antimicrobial resistance in Chlamydia pneumoniae |
Q37876334 | Potential relevance of Chlamydia pneumoniae surface proteins to an effective vaccine |
Q37872473 | Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice. |
Q91240713 | Prediction of Chlamydia pneumoniae protein localization in host mitochondria and cytoplasm and possible involvements in lung cancer etiology: a computational approach |
Q37873504 | Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells |
Q37866465 | Preeclampsia and Chlamydia pneumoniae: is there a link? |
Q36758395 | Preliminary data on Chlamydia pneumoniae seroprevalence in HIV-1 infected children. |
Q37877055 | Preliminary study on Chlamydia pneumoniae pneumonia |
Q37841506 | Preparation and evaluation of monoclonal antibodies against chlamydial protease-like activity factor to detect Chlamydia pneumoniae antigen in early pediatric pneumonia |
Q37874596 | Preparation of Chlamydia pneumoniae in roller bottles with high IFUs |
Q37861493 | Presence and severity of Chlamydia pneumoniae and Cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes |
Q37863575 | Presence of Chlamydia pneumoniae DNA in the artery wall--biomarker of coronary artery disease |
Q37874186 | Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis |
Q37874464 | Presence of Chlamydia pneumoniae antibodies in patients with ischemic heart disease and acute myocardial infarct |
Q37871162 | Presence of Chlamydia pneumoniae in abdominal aortic aneurysms is not associated with increased activity of matrix metalloproteinases |
Q34205431 | Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque |
Q37864067 | Presence of Chlamydia pneumoniae in patients with and without atherosclerosis. |
Q37866202 | Presence of Chlamydia pneumoniae in the carotid artery |
Q43431365 | Presence of Chlamydia pneumoniae strain TWAR in bronchial secretions collected from HIV-positive and negative patients: preliminary data. |
Q37864786 | Prevalence and clinical features of Chlamydia pneumoniae pneumonia at Srinagarind Hospital, Khon Kaen, Thailand |
Q37866904 | Prevalence and incidence of Chlamydia pneumoniae antibodies among the healthy elderly and patients with chronic obstructive pulmonary diseases. |
Q33788646 | Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland |
Q37863038 | Prevalence and persistence of antibodies to herpes viruses, Chlamydia pneumoniae and Helicobacter pylori in Alaskan Eskimos: the GOCADAN Study |
Q37868263 | Prevalence of <i>Chlamydia pneumoniae</i> in Japanese Rural Districts; Association of Smoking and Physical Activity awith <i>Chlamydia pneumoniae</i> Seropositivity |
Q43421284 | Prevalence of Chlamydia pneumoniae IgG antibodies in patients with coronary artery disease: a report from an Indian population |
Q58289831 | Prevalence of Chlamydia pneumoniae Infection in Atherosclerotic Plaques of Corpses Referred to Iranian Legal Medicine Organization, Tehran |
Q33998574 | Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays |
Q37854561 | Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae in different forms of coronary disease. |
Q37893843 | Prevalence of Chlamydia pneumoniae antibodies in Hungary |
Q37248184 | Prevalence of Chlamydia pneumoniae antibodies in patients with acute respiratory infections in Israel |
Q43436258 | Prevalence of Chlamydia pneumoniae in Japan |
Q37888837 | Prevalence of Chlamydia pneumoniae in acute lower respiratory infection in the pediatric population in Japan. |
Q37873675 | Prevalence of Chlamydia pneumoniae in acute respiratory tract infection and detection of anti-Chlamydia pneumoniae-specific IgE in Japanese children with reactive airway disease |
Q37882735 | Prevalence of Chlamydia pneumoniae in healthy children and in children with respiratory tract infections |
Q43423000 | Prevalence of Chlamydia pneumoniae in nonrheumatic stenotic aortic valves |
Q37872992 | Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. |
Q37878905 | Prevalence of Chlamydia pneumoniae in respiratory infections in children: an ambulatory diagnostic problem |
Q37869378 | Prevalence of Chlamydia pneumoniae in the atherosclerotic plaque of patients with unstable angina and its relation with serology |
Q37895249 | Prevalence of Chlamydia pneumoniae infection among pneumonias in a sample of Spanish hospital population |
Q37868738 | Prevalence of Chlamydia pneumoniae infection in Thai children with community-acquired pneumonia |
Q37867125 | Prevalence of Chlamydia pneumoniae infection in squamous cell carcinoma of the head and neck |
Q37880214 | Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey |
Q91394513 | Prevalence of Chlamydia psittaci, Chlamydia pneumoniae, and Chlamydia trachomatis Determined by Molecular Testing in Ocular Adnexa Lymphoma Specimens |
Q37884853 | Prevalence of Chlamydia trachomatis, Chlamydia psittaci and Chlamydia pneumoniae antibodies in blood donors and attendees of STD clinics |
Q37391436 | Prevalence of Helicobacter pylori, cytomegalovirus, and Chlamydia pneumoniae immunoglobulin seropositivity in coronary artery disease patients and normal individuals in North Indian population |
Q37876688 | Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community acquired pneumonia |
Q37865747 | Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in pneumonia patients in four major hospitals in Trinidad |
Q127748617 | Prevalence of Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila in LRTI Patients in a Tertiary Care Center, Karimnagar |
Q37859222 | Prevalence of active infection with Chlamydia pneumoniae and human cytomegalovirus in patients with type II diabetes mellitus |
Q43425464 | Prevalence of anti-Chlamydia pneumoniae and anti-Helicobacter pylori antibodies in subjects with acute myocardial infarction |
Q37878594 | Prevalence of anti-Chlamydia pneumoniae antibodies in preadolescent children in Congo |
Q37895455 | Prevalence of antibodies to Chlamydia pneumoniae (strain TWAR) and other Chlamydia in Japan |
Q37890676 | Prevalence of antibodies to Chlamydia pneumoniae TWAR in a group of German medical students |
Q43433288 | Prevalence of antibodies to Chlamydia pneumoniae in Slovenia. |
Q37892833 | Prevalence of antibodies to Chlamydia pneumoniae in a Belgian population |
Q37896623 | Prevalence of antibodies to Chlamydia pneumoniae in a pediatric hospital population in Belgium |
Q35586164 | Prevalence of antibodies to Chlamydia pneumoniae in an Israeli population without clinical evidence of respiratory infection |
Q37233458 | Prevalence of antibody to Chlamydia pneumoniae TWAR in japan. |
Q37871009 | Prevalence of antibody to Chlamydia pneumoniae in residents of Japan, the Solomon Islands, and Nepal. |
Q37874230 | Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults |
Q37887150 | Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture |
Q37872923 | Prevalence of chlamydia pneumoniae antibodies in patients with coronary heart disease |
Q37883379 | Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough |
Q43434779 | Prevalence of specific antibodies to Chlamydia pneumoniae (TWAR) in Swedish orienteers |
Q33688588 | Prevalence of specific antibodies to Chlamydia pneumoniae in Korea |
Q37888150 | Prevalence of specific antibodies to Chlamydia pneumoniae in children with acute respiratory infections |
Q37866868 | Prevalence of viable Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors |
Q37859629 | Prevalence, genetic conservation and transmissibility of the Chlamydia pneumoniae bacteriophage (phiCpn1). |
Q37871372 | Prevalence, rate of persistence and respiratory tract symptoms of Chlamydia pneumoniae infection in 1211 kindergarten and school age children |
Q37873036 | Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. |
Q43429547 | Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty |
Q37874580 | Previous exposure to Chlamydia pneumoniae, Helicobacter pylori and other infections in Canadian patients with ischemic heart disease. |
Q37864816 | Previous infection with Chlamydia pneumoniae and long-term prognosis in patients with acute coronary syndrome with non-ST segment elevation |
Q37867201 | Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? |
Q37876537 | Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty |
Q37861865 | Prior exposure to infection with Chlamydia pneumoniae can influence the T-cell-mediated response to Chlamydia trachomatis |
Q43421621 | Problem of Chlamydia pneumoniae serology today |
Q37856842 | Production and application of Chlamydia pneumoniae-specific monoclonal antibody |
Q34995600 | Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model |
Q37876556 | Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae |
Q37866199 | Prognostic value of antibodies anti-Chlamydia pneumoniae in ischemic heart disease |
Q37867739 | Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity |
Q37865453 | Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment |
Q37871352 | Proinflammatory cytokines, antibodies to Chlamydia pneumoniae and age-associated diseases in Danish centenarians: is there a link? |
Q52596124 | Proliferative stimulation of the vascular Endothelin-1 axis in vitro and ex vivo by infection with Chlamydia pneumoniae. |
Q37869056 | Prolonged febrile syndrome and Chlamydia pneumoniae infection |
Q37878526 | Prolonged respiratory failure in chlamydia pneumoniae pneumonia |
Q33901750 | Promoting effect of Chlamydia pneumoniae infection on human laryngeal carcinoma HEp-2 cell adhesion and migration |
Q30453259 | Properties of the glucose-6-phosphate transporter from Chlamydia pneumoniae (HPTcp) and the glucose-6-phosphate sensor from Escherichia coli (UhpC). |
Q37869279 | Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke. |
Q37878896 | Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction |
Q37876806 | Protective DNA immunization against Chlamydia pneumoniae |
Q33756547 | Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice |
Q37862010 | Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response |
Q37858663 | Proteolytic cleavage of the Chlamydia pneumoniae major outer membrane protein in the absence of Pmp10. |
Q37870594 | Proteome analysis of Chlamydia pneumoniae |
Q30669016 | Proteome analysis of the Chlamydia pneumoniae elementary body |
Q33388890 | Proteomic analysis of Chlamydia pneumoniae-infected HL cells reveals extensive degradation of cytoskeletal proteins |
Q31056127 | Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells |
Q37873916 | Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae |
Q37877156 | Pyoderma gangrenosum and Chlamydia pneumoniae infection in a diabetic man: pathogenic role or coincidence? |
Q37851387 | Quantification and location of Chlamydia pneumoniae-specific antigen in the walls of abdominal aortic aneurysms |
Q37853835 | Quantification of Chlamydia pneumoniae in cultured human macrophages and HL cells: comparison of real-time PCR, immunofluorescence and ELISA methods |
Q37871871 | Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR. |
Q37860138 | RNase HII from Chlamydia pneumoniae discriminates mismatches incorporation into DNA-rN1-DNA/DNA duplexes |
Q37883934 | Rabbit model for Chlamydia pneumoniae infection |
Q37888375 | Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study |
Q37878769 | Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd |
Q33598968 | Rapamycin can inhibit the development of Chlamydia pneumoniae, which might partly contribute to the prevention of in-stent restenosis |
Q37870150 | Rapid and standardized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR. |
Q37871981 | Rapid detection of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells of coronary artery disease patients by real-time fluorescence PCR. |
Q37880695 | Rapid detection of Chlamydia pneumoniae by PCR-enzyme immunoassay. |
Q37882746 | Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. |
Q37863080 | Rapidly progressive glomerulonephritis in a patient with Chlamydia pneumoniae infection: a possibility of superantigenic mechanism of its pathogenesis. |
Q43424592 | Re: Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis |
Q37861896 | Reaching out for the causative agent in inflammatory bowel disease: is there evidence for Chlamydia pneumoniae as a pathogenic factor? |
Q35231913 | Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae |
Q35486096 | Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. |
Q37886683 | Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone |
Q43432666 | Reactive arthritis ascribed to Chlamydia pneumoniae. Report of a case |
Q37890930 | Reactivity of Chlamydia pneumoniae strains in the IDEIA CHLAMYDIA test kit designed for detection of Chlamydia trachomatis |
Q35789698 | Real-time PCR for Chlamydia pneumoniae utilizing the Roche Lightcycler and a 16S rRNA gene target |
Q37851037 | Recent Chlamydia pneumoniae infection is highly associated with active ankylosing spondylitis in a Chinese cohort |
Q37844406 | Recent advances in technologies for developing drugs against Chlamydia pneumoniae. |
Q37895348 | Recovery of Chlamydia pneumoniae and Chlamydia trachomatis in a patient with recurrent tonsillitis, bronchitis and otitis media with effusion |
Q37893027 | Recovery ofChlamydia pneumoniae, in six patients with otitis media with effusion |
Q37869761 | Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice |
Q37861658 | Recurrent optic neuritis associated with Chlamydia pneumoniae infection of the central nervous system |
Q37872604 | Recurrent pneumonia due to persistent Chlamydia pneumoniae infection. |
Q43421538 | Red wine, resveratrol, Chlamydia pneumoniae and the French connection |
Q37870886 | Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity |
Q37893913 | Regional differences of Chlamydia pneumoniae as causative agent of pneumonia in Sweden |
Q37876677 | Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae |
Q37874299 | Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens |
Q37883734 | Reinfection with Chlamydia pneumoniae may induce isolated and systemic vasculitis in small and large vessels. |
Q37872185 | Relation between Chlamydia pneumoniae infection and acute attack of asthma |
Q37878316 | Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque |
Q37873120 | Relation of Chlamydia pneumoniae infection in Taiwan to angiographically demonstrated coronary artery disease and to the presence of acute myocardial infarction or unstable angina pectoris. |
Q37865613 | Relation of Chlamydia pneumoniae infection to documented coronary artery disease in Shiraz, Southern Iran |
Q37878617 | Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study |
Q37866859 | Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes |
Q37868337 | Relationship between Chlamydia pneumoniae and classical risk factors of coronary heart disease |
Q34503313 | Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. |
Q37866358 | Relationship between dyslipidemia, C-reactive protein and serological evidence of Chlamydia pneumoniae in Turkish patients with coronary artery diseases |
Q37873938 | Relationship of Chlamydia pneumoniae infection to severity of coronary atherosclerosis in patients with chronic coronary artery disease and with normal coronary arteries |
Q37876300 | Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis |
Q37848300 | Relationship of cytomegalovirus, Chlamydia pneumoniae and herpes simplex virus type 2 infections with preeclampsia |
Q127324000 | Relative frequency of Chlamydia pneumoniae in patients with respiratory infections using the PCR and ELISA methods in Ahvaz, Iran |
Q43434587 | Relevance of Chlamydia pneumoniae in community-acquired respiratory infections |
Q35118114 | Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents |
Q37854798 | Relevance of the genetic polymorphism of NOD1 in Chlamydia pneumoniae seropositive stroke patients. |
Q37870755 | Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols |
Q43422110 | Reliability of nested PCR for the detection of Chlamydia pneumoniae in carotid artery atherosclerosis |
Q37889465 | Remarkable sequence relatedness in the DNA encoding the major outer membrane protein of Chlamydia psittaci (koala type I) and Chlamydia pneumoniae |
Q37866188 | Repetitive measurements of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in healthy control subjects and dialysis patients: a prospective study |
Q37874322 | Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens |
Q35488540 | Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells |
Q37876249 | Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells |
Q37862545 | Respiratory infection caused by Chlamydia pneumoniae |
Q37888234 | Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients |
Q37871214 | Respiratory symptoms, asthma, atopy and Chlamydia pneumoniae IgG antibodies in a general population sample of young adults |
Q37895268 | Respiratory tract diseases due to Chlamydia pneumoniae |
Q124967643 | Respiratory tract diseases due to Chlamydia pneumoniae. |
Q37883746 | Respiratory tract infection due to Chlamydia pneumoniae in military personnel. |
Q37877330 | Respiratory tract infections triggering bronchial asthma attacks--with special reference to the involvement of Chlamydia pneumoniae |
Q91453136 | Response to "Chronic cerebrospinal venous insufficiency, chlamydia and multiple sclerosis": CCSVI, Chlamydia pneumoniae and multiple sclerosis clarification |
Q37854535 | Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2,3-dioxygenase |
Q37846267 | Resveratrol in Chlamydia pneumoniae-induced foam cell formation and interleukin-17A synthesis |
Q36732330 | Retinoic acid inhibits the infectivity and growth of Chlamydia pneumoniae in epithelial and endothelial cells through different receptors. |
Q37009782 | Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis |
Q37887861 | Reversible acute renal failure associated with Chlamydia pneumoniae infection |
Q34698619 | Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease |
Q37856254 | Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae |
Q37876549 | Risk factors for coronary heart disease and persistent infection with Chlamydia pneumoniae or cytomegalovirus: a population-based study. |
Q37884439 | Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia |
Q37840740 | Role of Chlamydia pneumoniae and Helicobacteria pylori in the development of tympanosclerosis |
Q37868255 | Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as Causative Agents of Community-Acquired Pneumonia in Hospitalised Children and Adolescents |
Q37852585 | Role of Chlamydia pneumoniae and Mycoplasma pneumoniae infections in the course of asthma |
Q37895576 | Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease |
Q37883614 | Role of Chlamydia pneumoniae in asthmatic disease in children |
Q37108634 | Role of Chlamydia pneumoniae in atherosclerosis |
Q37836906 | Role of Chlamydia pneumoniae in community-acquired pneumonia in hospitalized Jordanian adults |
Q37869600 | Role of Chlamydia pneumoniae in the etiology of atherosclerosis |
Q37877163 | Role of Chlamydia pneumoniae in the pathogenesis of coronary disease |
Q37835252 | Role of Chlamydia pneumoniae in the pathogenesis of hypertrophy and adenoid tissue inflammation in children |
Q43415878 | Role of Chlamydia pneumoniae infection in asthma in Northeast of Iran |
Q37851077 | Role of Chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease. |
Q37869530 | Role of Chlamydia pneumoniae‐infected macrophages in atherosclerosis developments of the carotid artery |
Q37860213 | Role of IRAK4 and IRF3 in the control of intracellular infection with Chlamydia pneumoniae |
Q37870576 | Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement |
Q37874412 | Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections |
Q37862475 | Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia in Istanbul, Turkey |
Q77216405 | Role of chlamydia pneumoniae (TWAR) in IgA nephropathy |
Q37871262 | Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae |
Q37878887 | Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. |
Q34590364 | Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae |
Q37871273 | Role of viral infections and Chlamydia pneumoniae and Mycoplasma pneumoniae infections in asthma in infants and young children. Epidemiologic study of 118 children |
Q34004010 | Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection |
Q54309872 | Roquefort cheese proteins inhibit Chlamydia pneumoniae propagation and LPS-induced leukocyte migration. |
Q37871978 | Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial |
Q37871843 | Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial |
Q37860426 | Rupture of the atherosclerotic plaque: is Chlamydia pneumoniae a possible agent? |
Q37857906 | SOCS-1 protects against Chlamydia pneumoniae-induced lethal inflammation but hampers effective bacterial clearance. |
Q37838989 | SPECIFIC SERUM IMMUNOGLOBULIN G AGAINST CHLAMYDIA PNEUMONIAE IN HEALTHY CHILDREN AND ADULTS IN SOUTH-EAST OF IRAN. |
Q37862244 | STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells. |
Q37877691 | Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease |
Q37887299 | Sample preparation for Chlamydia pneumoniae PCR. |
Q35096446 | Scc1 (CP0432) and Scc4 (CP0033) function as a type III secretion chaperone for CopN of Chlamydia pneumoniae |
Q37889144 | Screening for antibody to Chlamydia pneumoniae by the complement fixation test |
Q37874714 | Search for Chlamydia pneumoniae genes and their expression in atherosclerotic plaques of carotid arteries. |
Q37848975 | Searching for Helicobacter pylori and Chlamydia pneumoniae in primary endodontic infections. |
Q37865351 | Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease |
Q33762181 | Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues |
Q37864878 | Secretion of Cpn0796 from Chlamydia pneumoniae into the host cell cytoplasm by an autotransporter mechanism |
Q31907026 | Secretion of predicted Inc proteins of Chlamydia pneumoniae by a heterologous type III machinery |
Q37857356 | Selective cyclooxygenase inhibitors prevent the growth of Chlamydia pneumoniae in HL cells |
Q37863962 | Self-limiting pneumonia due to Chlamydia pneumoniae |
Q36961827 | Sequence analysis of the gene encoding the Chlamydia pneumoniae DnaK protein homolog |
Q37894914 | Sequence analysis of the major outer membrane protein gene of Chlamydia pneumoniae |
Q43413121 | Sequencing of Chlamydia pneumoniae in coronary artery disease patients attending tertiary hospital in India |
Q37865878 | Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae |
Q37853757 | Serodiagnosis of Chlamydia pneumoniae infection using three inclusion membrane proteins. |
Q37889634 | Serodiagnosis of Chlamydia trachomatis and Chlamydia pneumoniae. Evaluation comparing 2 methods: microimmunofluorescence and ELISA. A study of 216 Congolese sera |
Q37888229 | Seroepidemiologic study of Chlamydia pneumoniae and other chlamydial species in a hyperendemic area for trachoma in the Sudan |
Q37879495 | Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis |
Q37863014 | Seroepidemiological studies of Chlamydia pneumoniae infections in 1-36 months old children with respiratory tract infections and other diseases in Poland. |
Q43424116 | Seroepidemiology in Chlamydia pneumoniae-- atherosclerosis association |
Q37892533 | Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979 |
Q35585961 | Seroepidemiology of Chlamydia pneumoniae in Japan between 1991 and 2000. |
Q126791029 | Seroepidemiology of chlamydia pneumoniae infections in the city of Utrecht, the Netherlands |
Q37875823 | Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae |
Q37866810 | Serologic evidence of Chlamydia pneumoniae infection as a long-term predictor of cardiovascular death in renal transplant recipients. |
Q37876906 | Serologic markers for Chlamydia pneumoniae in asthma |
Q43433982 | Serologic tests for Chlamydia pneumoniae |
Q44059118 | Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China. |
Q37869645 | Serological Association Between Chlamydia pneumoniae Infection and Age-Related Macular Degeneration |
Q37859518 | Serological Evidence of Chronic Chlamydia pneumoniae Infection in Coronary Artery Disease |
Q37875894 | Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration |
Q37861895 | Serological and DNA-based evaluation of Chlamydia pneumoniae infection in inflammatory bowel disease |
Q27006867 | Serological association of Chlamydia pneumoniae infection with age-related macular degeneration: a systematic review and meta-analysis |
Q37873980 | Serological cross-reaction among Bartonella henselae, Chlamydia pneumoniae and Coxiella burnetii by indirect fluorescence antibody method |
Q37781228 | Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. |
Q37877275 | Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions |
Q37883417 | Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer |
Q37876946 | Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma |
Q37849329 | Serological findings of Chlamydial pneumoniae in the Czech Republic--control group of patients examined in the study: Chlamydia pneumoniae in the aetiology of keratoconjunctivitis sicca |
Q37872711 | Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events; the Scottish Heart Health Study Cohort |
Q37868948 | Serological markers of Chlamydia pneumoniae, cytomegalovirus and Helicobacter pylori infection in diabetic and non-diabetic patients with unstable angina pectoris. |
Q37858396 | Serological markers of chronic Chlamydia pneumoniae and cytomegalovirus (CMV) infection in patients with peripheral occlusive artery disease--an initial report |
Q37132394 | Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. |
Q37884209 | Serological response to Chlamydia pneumoniae in patients with sarcoidosis |
Q37184543 | Serological response to Chlamydia pneumoniae infection |
Q37876727 | Serological screening examinations of atypical pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae) in respiratory tract infection |
Q37861143 | Serology of Chlamydia pneumoniae in patients with chronic cough |
Q129144231 | Seropositivity Rates of Mycoplasma pneumoniae and Chlamydia pneumoniae in Cases with Community-Acquired Childhood Pneumonia |
Q37876599 | Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis |
Q37862797 | Seropositivity for Chlamydia pneumoniae in patients with primary biliary cirrhosis |
Q43421467 | Seropositivity of Chlamydia pneumoniae and Helicobacter pylori among coronary heart disease patients and normal individuals in a South Indian population. |
Q37863096 | Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke |
Q43419456 | Seropositivity to Chlamydia pneumoniae or Helicobacter pylori and coronary artery disease |
Q37877198 | Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study |
Q37876969 | Seroprevalence of Chlamydia pneumoniae antibodies in a young adult population sample living in Verona. European Community Respiratory Health Survey (ECRHS) Verona |
Q37853986 | Seroprevalence of Chlamydia pneumoniae antibodies in stroke in young. |
Q37878194 | Seroprevalence of Chlamydia pneumoniae in Chile |
Q37891923 | Seroprevalence of Chlamydia pneumoniae in Taiwan |
Q37860260 | Seroprevalence of Chlamydia pneumoniae in asthmatic children from Northern India |
Q43435230 | Seroprevalence of Chlamydia pneumoniae in the normal population |
Q37868059 | Seroprevalence of Chlamydia pneumoniae infection in Taiwan |
Q37874882 | Seroprevalence of Chlamydia pneumoniae infection in Thailand. |
Q37893633 | Seroprevalence of Chlamydia pneumoniae infections in otolaryngeal diseases |
Q57253017 | Seroprevalence of Helicobacter pylori and Chlamydia pneumoniae among Patients with Coronary Artery Diseases at Mansoura University Hospital, Egypt |
Q37870815 | Seroprevalence of IgG antibodies against Chlamydia pneumoniae in Chinese, Malays and Asian Indians in Singapore |
Q37863546 | Seroprevalence of IgG antibodies to Chlamydia pneumoniae and Helicobacter pylori among coronary heart disease patients and normal individuals in South Indian population |
Q33599500 | Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in stable asthma and chronic obstructive pulmonary disease |
Q37876475 | Seroprevalence of antibodies to Chlamydia pneumoniae in elderly people: a two-decade longitudinal and cohort difference study |
Q37870192 | Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia |
Q43422044 | Seroprevalence of antibodies to chlamydia pneumoniae in women with preeclampsia |
Q37871695 | Seroprevalence of chronic Chlamydia pneumoniae infection in patients affected by chronic stable asthma |
Q37863634 | Serum IgG and IgA antibodies to Chlamydia pneumoniae and severity of emphysema |
Q37867220 | Serum antibodies against Chlamydia pneumoniae outer membrane protein cross-react with the heavy chain of immunoglobulin in the wall of abdominal aortic aneurysms |
Q37885579 | Serum gamma-interferon in patients with pneumonia caused by Chlamydia pneumoniae |
Q37855525 | Serum levels of antibodies to Chlamydia pneumoniae and human HSP60 in giant cell arteritis patients |
Q37865564 | Serum lipid profiles poorly correlate with Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus seropositivity in prospectively followed-up healthy children |
Q37868195 | Severe Chlamydia pneumoniae infection in a patient with mild neutropenia during treatment of Hodgkin's disease |
Q33982905 | Severe Chlamydia pneumoniae infection in patients with neutropenia: case reports and literature review |
Q37866174 | Severe chlamydia pneumoniae pneumonia requiring mechanical ventilation and steroid therapy in an elderly patient |
Q37869236 | Severe community-acquired pneumonia with acute hypoxemic respiratory failure due to primary infection with Chlamydia pneumoniae in a previously healthy adult |
Q37882885 | Severe community-acquired pneumonia, shock and multiorgan dysfunction syndrome caused by Chlamydia pneumoniae |
Q37885786 | Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae |
Q37877234 | Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection |
Q37881612 | Severe pneumonia caused by Chlamydia pneumoniae in a patient treated with steroids for bronchial asthma |
Q37123769 | Severity of allergic airway disease due to house dust mite allergen is not increased after clinical recovery of lung infection with Chlamydia pneumoniae in mice. |
Q37858208 | Severity of carotid atherosclerosis unrelated to Chlamydia pneumoniae infection in acute ischemic stroke patients: a clinicopathological study |
Q37844983 | Shear Stress Enhances Chemokine Secretion from Chlamydia pneumoniae-infected Monocytes |
Q37843237 | Shear stress upregulates IL-1β secretion by Chlamydia pneumoniae- infected monocytes |
Q37878639 | Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. |
Q43432055 | Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions |
Q37865400 | Signs of active infection with Chlamydia pneumoniae in patients with coronary heart disease |
Q37864413 | Silencing or permanent activation: host-cell responses in models of persistent Chlamydia pneumoniae infection |
Q36973222 | Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene |
Q37876764 | Simplified preparation of human arterial sections for PCR analysis of Chlamydia pneumoniae and human DNA |
Q37878900 | Single channel analysis of recombinant major outer membrane protein porins from Chlamydia psittaci and Chlamydia pneumoniae |
Q37862359 | Single-nucleotide-polymorphism-specific PCR for quantification and discrimination of Chlamydia pneumoniae genotypes by use of a "locked" nucleic acid |
Q37860515 | Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle |
Q37866388 | Smoking increases the risk of coronary artery disease in Chinese with Chlamydia pneumoniae infection |
Q37892687 | Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association |
Q24797351 | Smoking, season, and detection of Chlamydia pneumoniae DNA in clinically stable COPD patients |
Q37888681 | Species-specific monoclonal antibodies against Chlamydia pneumoniae |
Q37876372 | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma |
Q35764383 | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis |
Q37892198 | Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections |
Q37874605 | Sphingomyelin trafficking in Chlamydia pneumoniae-infected cells. |
Q37886696 | Spontaneous Cure of Pneumonia Caused by Chlamydia pneumoniae |
Q37890387 | Spontaneous cure of acute bronchitis caused by Chlamydia pneumoniae in a 15-year-old boy. |
Q37893998 | Spread of subclinical Chlamydia pneumoniae infection in a closed community |
Q34312881 | Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). |
Q37853780 | Stevens-Johnson syndrome/erythema multiforme major and Chlamydia pneumoniae infection in young patients |
Q35558055 | Strong correlation between Helicobacter pylori seropositivity and Chlamydia pneumoniae IgG concentrations |
Q43414066 | Strong correlation in the serum levels of IgM rheumatoid factor and IgM anti-Chlamydia pneumoniae antibody |
Q36975448 | Structural and antigenic analysis of Chlamydia pneumoniae |
Q28732757 | Structural characterization of a novel Chlamydia pneumoniae type III secretion-associated protein, Cpn0803 |
Q37896267 | Studies on Chlamydia pneumoniae, strain TWAR infection. 2. Seroepidemiology of TWAR on healthy controls and patients with acute respiratory infections |
Q37897302 | Studies on Chlamydia pneumoniae, strain TWAR, infection. I. Experimental infection of C. pneumoniae in mice and serum antibodies against TWAR by MFA |
Q37871867 | Submitral annular aneurysm, postpartum cardiomyopathy, and anti-Chlamydia pneumoniae antibodies in Niamey (Niger) |
Q37888330 | Successful culture of Chlamydia pneumoniae in 2 asymptomatic patients |
Q37862635 | Successful removal of Chlamydia pneumoniae from plateletpheresis products collected using automated leukoreduction hemapheresis techniques |
Q43431545 | Sudden cardiac death in young athletes: orienteering on Chlamydia pneumoniae? |
Q24816884 | Sudden psychotic episode probably due to meningoencephalitis and Chlamydia pneumoniae acute infection |
Q100942032 | Super-Resolution Fluorescence Microscopy Reveals Clustering Behaviour of Chlamydia pneumoniae's Major Outer Membrane Protein |
Q37846456 | Supra-additive expression of interleukin-6, interleukin-8 and basic fibroblast growth factor in vascular smooth muscle cells following coinfection with Chlamydia pneumoniae and cytomegalovirus as a novel link between infection and atherosclerosis |
Q37887457 | Survival of Chlamydia pneumoniae following contact with various surfaces |
Q37873270 | Survival of Chlamydia pneumoniae-infected Mono Mac 6 cells is dependent on NF-kappaB binding activity |
Q37888689 | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia |
Q37883672 | Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations |
Q43432916 | Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection |
Q37858280 | Susceptibility of human monocyte-macrophages to Chlamydia pneumoniae infection in vitro is highly variable and associated with levels of soluble CD14 and C. pneumoniae IgA and human HSP-IgG antibodies in serum. |
Q37874367 | Sweet's syndrome and Chlamydia pneumoniae infection. |
Q37840819 | Synergistic Costimulatory Effect of Chlamydia pneumoniae with Carbon Nanoparticles on NLRP3 Inflammasome-Mediated Interleukin-1β Secretion in Macrophages |
Q37869454 | Synergistic Effect of Persistent Chlamydia pneumoniae Infection, Autoimmunity, and Inflammation on Coronary Risk |
Q37861538 | Systemic and mucosal antibody response in experimental Chlamydia pneumoniae infection of mice. |
Q37887366 | Systemic dissemination of Chlamydia pneumoniae following intranasal inoculation in mice |
Q37871681 | Systemic inflammation, Chlamydia pneumoniae DNA in circulating leukocytes and coronary atherosclerosis |
Q35922115 | Systems Biology Approaches for the Prediction of Possible Role of Chlamydia pneumoniae Proteins in the Etiology of Lung Cancer |
Q37877466 | Sézary T-cell activating factor is a Chlamydia pneumoniae-associated protein. |
Q126658004 | T cell lines and clones from unstable human atherosclerotic plaques respond to chlamydia pneumoniae |
Q37196471 | TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis |
Q93206750 | TLR2/CXCR4 co-association facilitates Chlamydia pneumoniae infection-induced atherosclerosis |
Q37568474 | Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice |
Q37841231 | Temperature and host cell-dependent changes in virulence of Chlamydia pneumoniae CWL029 in an optimized mouse infection model. |
Q34935390 | Temporal Expression of Type III Secretion Genes of Chlamydia pneumoniae |
Q34601757 | Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls |
Q74254691 | Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen |
Q37875269 | Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. |
Q36950013 | Temporal delay of peak T-cell immunity determines Chlamydia pneumoniae pulmonary disease in mice |
Q102978124 | The Association Between Mycoplasma pneumoniae and Chlamydia pneumoniae, a Life-Threatening Condition in Small Children-A Case Report and a Review of the Literature |
Q37835815 | The Chlamydia pneumoniae Adhesin Pmp21 Forms Oligomers with Adhesive Properties |
Q35633956 | The Chlamydia pneumoniae Inclusion Membrane Protein Cpn1027 Interacts with Host Cell Wnt Signaling Pathway Regulator Cytoplasmic Activation/Proliferation-Associated Protein 2 (Caprin2). |
Q49268348 | The Chlamydia pneumoniae Tarp Ortholog CPn0572 Stabilizes Host F-Actin by Displacement of Cofilin |
Q27334989 | The Chlamydia pneumoniae invasin protein Pmp21 recruits the EGF receptor for host cell entry |
Q37863637 | The Chlamydia pneumoniae type III secretion-related lcrH gene clusters are developmentally expressed operons |
Q37886395 | The CrP operon of Chlamydia psittaci and Chlamydia pneumoniae |
Q37886297 | The Etiology of Community-Acquired Pneumonia among Hospitalized Patients during a Chlamydia pneumoniae Epidemic in Finland |
Q57285394 | The Genetic Transformation of Chlamydia pneumoniae |
Q128079263 | The Impact of Chlamydia Pneumoniae Infection on the Immune Status of Children |
Q93002037 | The Important Role of Dendritic Cell (DC) in iNKT-Mediated Modulation of NK Cell Function in Chlamydia pneumoniae Lung Infection |
Q37864227 | The Relationship between chlamydia trachomatis and chlamydia pneumoniae as the cause of neonatal conjunctivitis (ophthalmia neonatorum). |
Q37868392 | The Role of Chlamydia pneumoniae Infection in Children With Chronic Sinusitis |
Q35928664 | The Type III Secretion System-Related CPn0809 from Chlamydia pneumoniae |
Q34140532 | The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis |
Q37873971 | The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae |
Q37854139 | The association between Chlamydia pneumoniae DNA in arherosclerotic plaque and major risk factors in patients undergoing coronary artery bypass grafting |
Q34088551 | The association between Chlamydia pneumoniae and metabolic syndrome in Taiwanese adults |
Q37858277 | The association between past Chlamydia pneumoniae infection and markers of chronic inflammation in obese women |
Q44059163 | The association between serological features of chronic Chlamydia pneumoniae infection and markers of systemic inflammation and nutrition in COPD patients |
Q37881687 | The association between serum sialic acid and asymptomatic carotid atherosclerosis is not related to antibodies to herpes type viruses or Chlamydia pneumoniae. The Atherosclerosis Risk in Communities (ARIC) Study Investigators |
Q37856609 | The association of C (-260)-->T polymorphism in CD14 promoter and Chlamydia pneumoniae infection in ischemic stroke patients |
Q37888656 | The association of Chlamydia pneumoniae infection and reactive airway disease in children |
Q37851226 | The association of body mass index, waist and hip circumference, and waist-hip ratio with Chlamydia pneumoniae IgG antibodies and high-sensitive C-reactive protein at 31 years of age in Northern Finland Birth Cohort 1966. |
Q37860798 | The association of carotid plaque inflammation and Chlamydia pneumoniae infection with cerebrovascular symptomatology. |
Q61798413 | The association of mannose binding lectin genotype and immune response to Chlamydia pneumoniae: The Strong Heart Study |
Q24673197 | The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study |
Q37870997 | The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study |
Q33843538 | The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae |
Q37852294 | The clinical and morphological features of Chlamydia pneumoniae-induced chorioretinitis in an experiment |
Q37867236 | The detection of Chlamydia pneumoniae in aneurysm of abdominal aorta and in normal aortic wall of organ donors |
Q37871621 | The detection of Chlamydia pneumoniae in atherosclerotic plaques of Australian subjects |
Q37868399 | The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin. |
Q37859023 | The development of asthma in wheezing infants with Chlamydia pneumoniae infection |
Q37847297 | The dynamics of detection of antibodies class G against Chlamydia pneumoniae and Chlamydia psittaci in blood serum of patients of different age groups |
Q37857559 | The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells |
Q37881386 | The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production |
Q37869647 | The effect of viable Chlamydia pneumoniae on serum cytokines and adhesion molecules in hemodialysis patients |
Q90736099 | The endogenous antiseptic N-chlorotaurine irreversibly inactivates Chlamydia pneumoniae and Chlamydia trachomatis |
Q36506125 | The epidemic cycle of Chlamydia pneumoniae infection in eastern Finland, 1972-1987. |
Q35820707 | The epidemiology and significance of Chlamydia pneumoniae |
Q37856476 | The essential role of the CopN protein in Chlamydia pneumoniae intracellular growth |
Q37872119 | The evolving relationship between Chlamydia pneumoniae and atherosclerosis. |
Q24795016 | The expression, processing and localization of polymorphic membrane proteins in Chlamydia pneumoniae strain CWL029 |
Q101469980 | The global prevalence of Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus and Herpes simplex virus in patients with coronary artery disease: A systematic review and meta-analysis |
Q37852535 | The implication of Chlamydia pneumoniae in damage to human aortic endotheliocytes in atherosclerosis |
Q43420849 | The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae |
Q37895406 | The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR) |
Q37895842 | The in-vitro antibiotic susceptibility of Chlamydia pneumoniae |
Q33559443 | The incidence of Chlamydia pneumoniae lower respiratory tract infections among university students in northern California |
Q37655083 | The inflammatory aspects of Chlamydia pneumoniae-induced brain infection. |
Q37868324 | The influence of Chlamydia pneumoniae infection on acute coronary syndromes |
Q37862621 | The inhibitory effect of antihyperlipidemic drugs on the growth of Chlamydia pneumoniae in vitro |
Q37864470 | The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype |
Q37876392 | The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation |
Q37890807 | The morphology of Chlamydia pneumoniae |
Q37884214 | The nPCR detection of Chlamydia pneumoniae and Chlamydia trachomatis in children hospitalized for bronchiolitis |
Q37837847 | The novel chlamydial adhesin CPn0473 mediates the lipid raft-dependent uptake of Chlamydia pneumoniae |
Q37896091 | The nucleotide sequence of the 60 kDa cysteine rich outer membrane protein of Chlamydia pneumoniae strain IOL-207. |
Q37867714 | The occurrence of Chlamydia pneumoniae, Mycoplasma pneumoniae, and herpesviruses in otitis media with effusion |
Q43416608 | The ongoing debate over the association between Chlamydia pneumoniae infection and coronary artery disease: antibiotic dilemma |
Q37869346 | The pathogenesis of Chlamydia pneumoniae-type pneumonitis in mice. |
Q43425861 | The pathology of Chlamydia pneumoniae lesions in humans and animal models |
Q37861669 | The possible association of Chlamydia pneumoniae infection with nasal polyps |
Q74197029 | The potential etiologic role of Chlamydia pneumoniae in atherosclerosis. Proceedings of a meeting. Seattle, Washington, USA. 22-25 September 1999 |
Q37877801 | The presence of Chlamydia pneumoniae in atherosclerotic plaques--a report of three cases of ischaemic heart disease |
Q37874213 | The presence of anti-Chlamydia pneumoniae antibodies in peripheral vascular and neurological disorders |
Q37841749 | The presence of some cytokines and Chlamydia pneumoniae in the atherosclerotic carotid plaque in patients with carotid artery stenosis |
Q37893513 | The prevalence and regional distribution of antibodies against Chlamydia pneumoniae (strain TWAR) in Finland in 1958 |
Q37877687 | The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease. |
Q37879200 | The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery |
Q43424431 | The prevalence of Chlamydia pneumoniae in respiratory infections in the lower respiratory tracts in children under two |
Q37836053 | The prevalence of Chlamydia pneumoniae in the aortic wall and in peripheral blood of patients scheduled for coronary artery bypass grafting |
Q37889630 | The prevalence of anti-Chlamydia trachomatis and anti-Chlamydia pneumoniae antibodies in Brazzaville |
Q37879934 | The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischaemic heart disease |
Q37876824 | The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. |
Q37877179 | The progression of lower limb atherosclerosis is associated with IgA antibodies against Chlamydia pneumoniae |
Q37274217 | The prospective association of Chlamydia pneumoniae and four other pathogens with development of coronary artery calcium: the multi-ethnic study of atherosclerosis (MESA). |
Q42390881 | The relation between Chlamydia pneumoniae and atherosclerosis |
Q37872328 | The relation between Chlamydia pneumoniae infection and abdominal aortic aneurysm |
Q37876114 | The relation between Chlamydia pneumoniae infection and abdominal aortic aneurysm: case-control study |
Q37874658 | The relation between carotid ultrasound changes and seropositivity to Chlamydia pneumoniae in patients with acute stroke |
Q37872878 | The relationship between Chlamydia pneumoniae and atherosclerosis |
Q37883789 | The relationship between Chlamydia pneumoniae and atherosclerotic lesions of the aorta |
Q100696461 | The relationship between Chlamydia pneumoniae infection and CD4/CD8 ratio, lymphocyte subsets in middle-aged and elderly individuals |
Q37866409 | The relationship between Chlamydia pneumoniae infection and primary biliary cirrhosis |
Q43421710 | The relationship between Chlamydia pneumoniae seropositivity and peripheral vascular diseases, acute myocardial infarction and late-onset asthma |
Q37849268 | The relationship between seropositivity against Chlamydia pneumoniae and stroke and its subtypes in a Latvian population |
Q37867778 | The reproducibility of an enzyme-linked immunosorbent assay for detection of Chlamydia pneumoniae-specific antibodies |
Q37876793 | The resistance of human monocyte-derived macrophages to Chlamydia pneumoniae infection is enhanced by interferon-gamma |
Q37862246 | The role of Chlamydia pneumoniae in acute respiratory tract infections in young children in The Gambia, West Africa |
Q37875691 | The role of Chlamydia pneumoniae in atherogenesis |
Q43428087 | The role of Chlamydia pneumoniae in atherosclerosis |
Q33934178 | The role of Chlamydia pneumoniae in atherosclerosis--recent evidence from animal models |
Q33817488 | The role of Chlamydia pneumoniae in cardiovascular disease |
Q37873386 | The role of Chlamydia pneumoniae in etiology of acute bronchitis in children |
Q37866349 | The role of Chlamydia pneumoniae in human aortic disease-a hypothesis revisited |
Q43419200 | The role of Chlamydia pneumoniae in multiple sclerosis: real or fictitious? |
Q37889412 | The role of Chlamydia pneumoniae in severe acute tonsillitis. |
Q37860157 | The role of Chlamydia pneumoniae in the etiology of acne rosacea: response to the use of oral azithromycin. |
Q37843000 | The role of Chlamydia pneumoniae in the etiology of keratoconjunctivitis sicca (KCS). |
Q37864473 | The role of Chlamydia pneumoniae in the pathogenesis of abdominal aortic aneurysm |
Q43428884 | The role of Chlamydia pneumoniae in the pathogenesis of atherosclerosis |
Q37870107 | The role of Chlamydia pneumoniae infection in the pathology of respiratory organs |
Q37870210 | The role of atypical pathogen: Mycoplasma pneumoniae and Chlamydia pneumoniae in the acute respiratory infection in childhood |
Q37880009 | The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection |
Q37876418 | The role of chlamydia pneumoniae in atherosclerosis - recent evidence from animal models: response |
Q37842253 | The role of endoplasmic reticulum-related BiP/GRP78 in interferon gamma-induced persistent Chlamydia pneumoniae infection |
Q37859699 | The role of endothelial dysfunction and Chlamydia pneumoniae infection in patients with ischemic stroke |
Q37862874 | The significance of Chlamydia pneumoniae in selected neurologic disorders |
Q37873368 | The significance of Chlamydia pneumoniae in symptomatic carotid stenosis |
Q37230432 | The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae |
Q27333845 | The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism |
Q37877192 | The studying of Chlamydia pneumoniae in atherosclerosis |
Q90918083 | The therapeutic role of inhibition of miR-328 on pulmonary carcinoma induced by chlamydia pneumoniae through targeting histone H2AX |
Q27825840 | The transcriptional landscape of Chlamydia pneumoniae |
Q30885714 | The ultrastructure of a new species of Chlamydia--Chlamydia pneumoniae |
Q37876877 | Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections |
Q30682022 | Time-dependent expression and processing of a hypothetical protein of possible importance for regulation of the Chlamydia pneumoniae developmental cycle |
Q37835597 | To study the association between anti-Chlamydia pneumoniae antibodies (IgG), anti-Mycoplasma pneumoniae antibodies (IgG) and coronary artery disease (CAD). |
Q37863624 | Tobacco smoke induces a persistent, but recoverable state in Chlamydia pneumoniae infection of human endothelial cells |
Q37863888 | Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells |
Q37854329 | Toll-like receptor-4 (TLR4) mediates human beta-defensin-2 (HBD-2) induction in response to Chlamydia pneumoniae in mononuclear cells. |
Q34077643 | Toll-like receptors 2 and 4 regulate the frequency of IFNγ-producing CD4+ T-cells during pulmonary infection with Chlamydia pneumoniae |
Q37864028 | Total hip arthroplasty infection with Chlamydia pneumoniae and Mycobacterium chelonae. |
Q37885691 | Towards Chlamydia Pneumoniae vaccination |
Q36673413 | Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection. |
Q37838929 | Transforming activities of Chlamydia pneumoniae in human mesothelial cells |
Q37890551 | Transmission of Chlamydia pneumoniae |
Q37895809 | Transmission of Chlamydia pneumoniae in young children in a Japanese family |
Q37865867 | Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model |
Q37886846 | Transport and storage conditions for cultural recovery of Chlamydia pneumoniae |
Q43423013 | Treating Chlamydia pneumoniae in patients with early atherosclerosis |
Q43426684 | Treatment of Chlamydia pneumoniae |
Q34974820 | Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease |
Q34295748 | Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial |
Q37873906 | Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial |
Q37878785 | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease |
Q37867216 | Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice |
Q37873600 | Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae |
Q37881246 | Tricuspid endocarditis caused by Chlamydia pneumoniae. Apropos of a case |
Q33431609 | Trophoblast infection with Chlamydia pneumoniae and adverse pregnancy outcomes associated with placental dysfunction |
Q37199823 | Tryptophan Codon-Dependent Transcription in Chlamydia pneumoniae during Gamma Interferon-Mediated Tryptophan Limitation |
Q33769133 | Tumor necrosis factor alpha plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice |
Q57187454 | Tumor necrosis factor receptor superfamily members 1a and 1b contribute to exacerbation of atherosclerosis by Chlamydia pneumoniae in mice |
Q37850119 | Two cases of erythema exsudativum multiforme associated with Chlamydia pneumoniae infection |
Q37889579 | Two family outbreaks of Chlamydia pneumoniae infection |
Q37872509 | Typing strains of Chlamydia pneumoniae by amplified fragment length polymorphism typing |
Q37879427 | Ultrastructural Analysis of Chlamydia Pneumoniae in the Alzheimer's Brain |
Q34004081 | Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells |
Q37888544 | Ultrastructural lung pathology of experimental Chlamydia pneumoniae pneumonitis in mice |
Q37873353 | Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model |
Q37894232 | Ultrastructure of Chlamydia pneumoniae in cell culture |
Q33320687 | Under the microscope: focus on Chlamydia pneumoniae infection and multiple sclerosis |
Q37875278 | Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae |
Q37860674 | Up-regulation of host cell genes during interferon-gamma-induced persistent Chlamydia pneumoniae infection in HL cells |
Q37870410 | Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis |
Q37892713 | Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae |
Q37182583 | Use of HL cells for improved isolation and passage of Chlamydia pneumoniae |
Q37876328 | Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection |
Q33672291 | Use of lambda phage DNA as a hybrid internal control in a PCR-enzyme immunoassay to detect Chlamydia pneumoniae |
Q37867461 | Use of quantitative and objective enzyme immunoassays to investigate the possible association between Chlamydia pneumoniae and Mycoplasma pneumoniae antibodies and asthma |
Q37863292 | Usefulness of sparfloxacin against Chlamydia pneumoniae infection in patients with bronchial asthma |
Q43431172 | Uveitis and joint pain without pulmonary involvement disclosing Chlamydia pneumoniae infection |
Q73382390 | Vaccination against infections by Chlamydia pneumoniae |
Q43426598 | Validation of the use of an ELISA test in the detection of Chlamydia pneumoniae antibodies |
Q37877532 | Value of animal models for Chlamydia pneumoniae-related atherosclerosis |
Q37878273 | Vascular surgical society of great britain and ireland: immunoglobulin A antibodies against chlamydia pneumoniae are associated with expansion of small abdominal aortic aneurysms and declining ankle blood pressure |
Q37876304 | What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis? |
Q37865213 | Why Chlamydia pneumoniae is associated with asthma and other chronic conditions? Suggestions from a survey in unselected 9 yr old schoolchildren |
Q43414862 | Why first degree relatives of coronary artery disease patient's have Chlamydia pneumoniae infection |
Q37882965 | Widely used, commercially available Chlamydia pneumoniae antigen contaminated with mycoplasma |
Q128852287 | Yersinia enterocolitica and Chlamydia pneumoniae possible triggering agents of Guillain-Barre syndrome: a case report |
Q37844072 | Zoledronic acid affects the cytotoxic effects of Chlamydia pneumoniae and the modulation of cytokine production in human osteosarcoma cells |
Q44025531 | [Chlamydia pneumoniae and atherosclerosis] |
Q77317950 | [Chlamydia pneumoniae pneumonia] |
Q36763581 | [Chlamydia pneumoniae] |
Q43436048 | [Chlamydia pneumoniae] |
Q37872743 | [Clinical significance of interaction between Chlamydia infection (Chlamydia pneumoniae) and free radical processes during ischemic heart disease] |
Q74406210 | [Diseases from Chlamydia psittaci and Chlamydia pneumoniae] |
Q74374927 | [Influence of Chlamydia pneumoniae and cytomegalovirus infections on prevalence and the course of coronary artery disease] |
Q74194114 | [Is Chlamydia pneumoniae infection the risk factor of unstable angina pectoris?] |
Q84407997 | [Morphological factors of productive and persistent developmental cycles of Chlamydia pneumoniae in human coronary and aortic endothelium] |
Q74505785 | [Presence of Chlamydia pneumoniae antibodies in patients with ischemic heart disease and acute myocardial infarct] |
Q75186812 | [The response to the letter of Dr. Jerzy Durkalec regarding literature review by Przemyslaw Kotyla, Bogna Sliwińska-Kotyla and Eugeniusz J. Kucharz "The Significance of Chlamydia pneumoniae Infection in the Development of Sclerosis] |
Q73250338 | [The role of Chlamydia pneumoniae infection in the development of atherosclerosis in humans] |
Q91905173 | [Viral identification, Chlamydia pneumoniae and Mycoplasma pneumoniae during asthma exacerbation: comparative epidemiology between infants and children.] |
Q37874954 | cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection |
Q129424231 | chlamydia pneumoniae unfection in - patients with community acquired pneumonia in Iraq |
Q126338711 | Infections respiratoires à Chlamydia pneumoniae, sur 5 ans, au centre hospitalier d'Aix (1991–1995) |